

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 561 175 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 93102668.6

(22) Date of filing: 19.02.93

(51) Int. Cl.⁵: C07D 239/48, C07D 239/58,
C07D 239/46, C07D 239/50,
C07D 239/52, C07D 239/56,
C07D 239/42, C07D 401/14,
A61K 31/505

(30) Priority: 18.03.92 JP 62380/92

(43) Date of publication of application:
22.09.93 Bulletin 93/38

(94) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

(71) Applicant: MOCHIDA PHARMACEUTICAL CO.,
LTD.
7, Yotsuya 1-chome
Shinjuku-ku Tokyo 160(JP)

(72) Inventor: Yanagibashi, Kazutoshi
c/o MOCHIDA PHARMA. CO., LTD., 7, Yotsuya
1-chome
Shinjuku-ku, Tokyo(JP)
Inventor: Mizuguchi, Kiyoshi
c/o MOCHIDA PHARMA. CO., LTD., 7, Yotsuya
1-chome
Shinjuku-ku, Tokyo(JP)
Inventor: Onishi, Shuhei
c/o MOCHIDA PHARMA. CO., LTD., 7, Yotsuya
1-chome
Shinjuku-ku, Tokyo(JP)
Inventor: Murakami, Kimihiro
c/o MOCHIDA PHARMA. CO., LTD., 7, Yotsuya
1-chome
Shinjuku-ku, Tokyo(JP)

(74) Representative: Patentanwälte Grünecker,
Kinkeldey, Stockmair & Partner
Maximilianstrasse 58
D-80538 München (DE)

EP 0 561 175 A1

(54) Pyrimidine derivatives and pharmaceutical compositions containing them.

(57) The present invention relates to novel 5-(ω -substituted amino-alkanoyl amino)pyrimidine derivatives, processes for producing the derivatives, and pharmaceutical compositions containing said derivatives.

The compounds of the present invention have potent effects of inhibiting ACAT activity and lowering serum cholesterol. The compounds of the present invention are extremely useful for the treatment and/or prevention of arteriosclerosis or hyperlipidemia.

BACKGROUND OF THE PRESENT INVENTION

The present invention relates to novel substituted pyrimidine derivatives which have an amide bond in 5-position, processes for producing the derivatives, and pharmaceutical compositions containing the pyrimidine derivatives for the treatment and/or prevention of arteriosclerosis or hyperlipidemia.

In recent years, arteriosclerosis has been recognized as one of rapidly increasing diseases in circulatory disorder, and is also given much attention as a basal lesion for serious disease. Arteriosclerosis causes various ischemic diseases or bleeding, for example, the ischemic heart disease due to coronary atherosclerosis such as angina pectoris and myocardial infarction etc., the cerebrovascular disease due to cerebrovascular arteriosclerosis such as cerebral infarction and cerebral apoplexy, the optic nerve atrophy and hydrocephalia due to compression by cerebral arteriosclerosis, nephrosclerosis due to kidney arteriosclerosis, aneurysm and arteriosclerosis obliterans due to stenosis in lumen of aorta and peripheral artery, and so on. Such diseases occasionally cause fatal symptoms. It is generally said that hypertension, hyperlipidemia, smoking, obesity, diabetes and the like are concerned in the crisis of arteriosclerosis, especially of pultaceous atherosclerosis. It is also known that cholesterinosis, calcinosis and foam cells derived from macrophages or vascular smooth muscle cells appear in sclerosis lesions. However, clear mechanism in the crisis of arteriosclerosis is not elucidated, hence the sufficient treatment and/or prophylactic for arteriosclerosis have not been established yet.

In order to treat these diseases, as one direction, the investigation of the drugs which can decrease serum cholesterol has been developed. Colestyramine and melinamide which are the inhibitors of cholesterol absorption from intestine, and clofibrate which partially facilitates cholesterol metabolism are typical examples. As the mechanism of transport of serum cholesterol is gradually comprehended, the drugs which regulate the balance of serum cholesterol level have also been developed. However, these drugs have not been effective enough to direct positive prevention or treatment of the crisis or progress of arteriosclerosis. The development of the drugs which lower the serum cholesterol level by the inhibition of cholesterol biosynthesis (HMG-CoA reductase inhibitors, squalene epoxidase inhibitors) has been progressed, too. On the other hand, the antagonistic drugs to platelet derived growth factor (PDGF) which inhibit the proliferation of vascular smooth muscle cells, and the drugs which prevent macrophage infiltration to the arterial wall and the formation of foam cell, are also given much attention as the remedy for arteriosclerosis. Especially, in the progress of the arteriosclerosis lesions, macrophage which transform into foam cell after scavenging degenerated lipids has been recognized as an essential factor which links hyperlipidemia to arteriosclerosis. It has also been said that the acyl-CoA cholesterol acyltransferase (ACAT) plays an important role on the onset of arteriosclerosis. That is to say, ACAT participates to facilitate dietary cholesterol absorption from intestine by esterifying of free cholesterol at the site of intestinal mucosa. Furthermore, it is indicated that ACAT contributes to the formation of deposit of cholesterol esters derived from above macrophage in the arterial wall. Therefore, ACAT inhibitors have been expected for the lowering action to serum lipids, and for the treatment and/or prevention of arteriosclerosis.

Until now, various kinds of drugs for the treatment of arteriosclerosis have been developed, and some compounds directing to ACAT inhibition are exhibited in JP-A-60 41655 and JP-A-2 117651. However, the development of all these compounds has been discontinued for the reasons that some of the compounds did not exert significant efficiency in the later clinical studies or others were concerned about adverse effects on liver etc. despite of good effects on lowering serum cholesterol in the animal models in the specifications.

Although JP-A-62 258366 and JP-A-3 120243 exhibit pyrimidineamide compounds as anti-arteriosclerotic agents with an inhibitory effect on ACAT, the structures of such compounds is able to distinguish from those of the present invention, and only a part of inhibitory activities on ACAT in a variety of animal cells in vitro can be seen. And there is no disclosure about the result of toxicological study in connection with these compounds.

Under these circumstances, anti-arteriosclerotic agents which possess beneficial effects directly on the arterial wall with good clinical efficiency and high safety at Homo sapiens.

SUMMARY OF THE INVENTION

An object of the present invention is to provide novel 5-(ω -substituted amino-alkanoyl amino)-pyrimidine derivatives, or salts or solvates or solvates of said salts thereof.

Another object of the present invention is to provide process for producing the novel pyrimidine derivatives.


A further object of the present invention is to provide pharmaceutical compositions for the treatment and/or the prevention of arteriosclerosis or hyperlipidemia which comprise the novel pyrimidine derivatives as active components.

Since the compounds of the present invention significantly prevent the accumulation of cholesteryl esters in macrophages and potentially inhibit the microsomal ACAT activity from a variety of organs in vitro, these compounds are expected to exert beneficial effects directly on the atherosclerotic lesion. Further, the compounds of the present invention not only show significant hypolipidemic effect on high cholesterol diet feeding animals, but also have inhibitory activities on ACAT in microsomal fraction of human hepatoma cell line. In addition, The compounds of the present invention have little toxicity and side effect on a liver and other organs apprehended with the former hypolipidemic drugs and/or ACAT inhibitor. It is therefore indicated that the compounds of the present invention are safe and beneficial drugs for the treatment of arteriosclerosis itself and various morbid states and maladies derived from arteriosclerosis, as follows: ischemic heart diseases caused by coronary atherosclerosis such as angina pectoris and myocardial infarction etc., the cerebrovascular diseases caused by cerebrovascular arteriosclerosis such as cerebral infarction and cerebral apoplexy, optic nerve atrophy and hydrocephalia caused by increased mechanical pressure in the region of cerebral arteriosclerosis, nephrosclerosis caused by arteriosclerosis of kidney, aneurysm and arteriosclerosis obliterans caused by stenosis of aorta and peripheral artery, sthenia of platelet aggregation, deep venous thrombosis, and others; hyperlipidemia, hypercholesterolemia, diabetes, variety of thrombosis, xanthoma and so on.

DETAILED DESCRIPTION OF THE INVENTION

As a result of extensive investigations, the present inventors have found novel pyrimidine derivatives and their salts which can effect directly on the arterial wall, strongly prevent the accumulation of cholesteryl esters in macrophages, and potentially inhibits ACAT activity, and have accomplished the present invention.

The present invention is directed to the pyrimidine derivatives represented by the formula(I):



wherein R¹ represents a hydrogen atom, an alkyl group of straight or branched chain having 1 to 4 carbon atoms, NR⁶R⁷, SR⁸ or OR⁸,

R² represents hydrogen atom, NR⁹R¹⁰, SR¹¹, OR¹¹, an alkyl group of straight or branched chain having 1 to 6 carbon atoms, or a halogen atom,

R³ represents a hydrogen atom, NR¹²R¹³, SR¹⁴, OR¹⁴, an alkyl group of straight or branched chain having 1 to 6 carbon atoms, or a halogen atom,

R⁴ and R⁵ are identical or different and each represents a group selected from the group consisting of hydrogen atom, an alkyl group of straight or branched chain having 1 to 12 carbon atoms, a benzyl group, a cycloalkyl group having 3 to 10 carbon atoms and a phenyl group which may be substituted with 1 to 5 substituents selected optionally from the group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxyl group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, a hydroxyl group and an alkylenedioxy group having 1 or 2 carbon atoms,

or R⁴ and R⁵, together with the nitrogen atom to which they are bonded, form a piperazine ring substituted with a phenyl group, or a tetrahydroquinoline ring,

R⁶, R⁷ and R⁸ are identical or different and each represents a group selected from the group consisting of hydrogen atom, and an alkyl group of straight or branched chain having 1 to 4 carbon atoms,

R⁹, R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ are identical or different and each represents a group selected from the group consisting of hydrogen atom, a phenyl group, a benzyl group, and an alkyl group of straight or branched chain having 1 to 10 carbon atoms,

or R⁹ and R¹⁰, or R¹² and R¹³, together with the nitrogen atom to which they are bonded, each form a morpholine ring, or a piperazine ring which may be substituted with an alkyl group of straight or branched chain having 1 to 4 carbon atoms, and

n represents an integer from 1 to 6, provided that when n represents an integer of 1 and R² and R³ represent methyl groups, R¹ does not represent a methyl group or an amino group,

or a salt or a solvate or a solvate of said salt thereof, processes for producing above compounds, or the antiarteriosclerosis agent or antihyperlipidemia which comprises at least one of the present compounds and pharmaceutically acceptable carries. The present invention substituted pyrimidine derivatives and their salts potentially inhibit the accumulation of cholesterol ester in macrophages and act on arterial wall directly, moreover they also have the ability of the ACAT inhibition. Therefore they can be used for prevention, reduction or treatment of arteriosclerosis and hyperlipidemia.

In the compounds of the present invention represented by the formula (I), as regards group R¹, above-mentioned groups are preferable, hydrogen atom, methyl group, methoxy group, methylthio group or dimethylamino group are specially preferable, as regards group R², NR⁹R¹⁰ or an alkyl group of straight or branched chain having 1 to 6 carbon atoms are preferable, NR⁹R¹⁰ or isopropyl group are specially preferable, as regards group R³, SR¹⁴, OR¹⁴ or an alkyl group of straight or branched chain having 1 to 6 carbon atoms are preferable, SR¹⁴ or OR¹⁴ are specially preferable. As regards groups R⁴ and R⁵, an alkyl group of straight or branched chain having 1 to 12 carbon atoms, a benzyl group, cycloalkyl group having 3 to 10 carbon atoms, and phenyl group which may be substituted with 1 or 2 substituents selected from a group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxyl group and an alkylenedioxy group having 1 or 2 carbon atoms are preferable; or R⁴ and R⁵, together with the nitrogen atom to which they are bonded, preferably form a piperazine ring substituted with a phenyl group, or a tetrahydroquinoline ring; as regards group R⁴, an alkyl group of straight or branched chain having 3 to 10 carbon atoms or a cycloalkyl group having 3 to 10 carbon atoms are specially preferable; as regards group R⁵, a phenyl group which may be substituted with 1 or 2 substituents selected from a group consisting of an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, a hydroxyl group and an alkylenedioxy group having 1 or 2 carbon atoms are specially preferable. As regards groups R⁹ and R¹⁰, alkyl groups of straight chain having 1 to 7 carbon atoms, phenyl groups or benzyl groups are preferable, or R⁹ and R¹⁰, together with the nitrogen atom to which they are bonded, preferably form a morpholine ring. As regards group R¹⁴, a hydrogen atom, an alkyl group of straight chain having 1 to 6 carbon atoms or a benzyl group are preferable. As regards n, 2 to 5 are preferable, 3 or 4 are specially preferable.

From the view point of combination of these substituents, the preferable examples in the compounds of the present invention are, the compounds of the formula (I), wherein R¹ represents hydrogen atom or an alkyl group of straight or branched chain having 1 to 4 carbon atoms, R² represents NR⁹R¹⁰ or an alkyl group of straight or branched chain having 1 to 6 carbon atoms, R³ represents SR¹⁴, OR¹⁴ or an alkyl group of straight or branched chain having 1 to 6 carbon atoms, R⁴ and R⁵ are identical or different and represent groups selected from the group consisting of an alkyl group of straight or branched chain having 1 to 12 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms, a benzyl group and a phenyl group which may be substituted with 1 or 2 substituents selected from the group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxyl group and an alkylenedioxy group having 1 to 2 carbon atoms; or R⁴ and R⁵, together with the nitrogen atom to which they are bonded, form a piperazine ring substituted with a phenyl group, or a tetrahydroquinoline ring. Furthermore, other preferable examples are the compounds wherein R¹ represents NR⁶R⁷, SR⁸ or OR⁸, R² represents NR⁹R¹⁰ or an alkyl group of straight or branched chain having 1 to 6 carbon atoms, R³ represents SR¹⁴, OR¹⁴ or an alkyl group of straight or branched chain having 1 to 6 carbon atoms, R⁴ and R⁵ are identical or different and represent groups selected from the group consisting of an alkyl group of straight or branched chain having 1 to 12 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms, a benzyl group and a phenyl group which may be substituted with 1 or 2 substituents selected from a group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxyl group and an alkylenedioxy group having 1 or 2 carbon atoms; or R⁴ and R⁵, together with the nitrogen atom to which they are bonded, form a piperazine ring substituted with a phenyl group, or a tetrahydroquinoline ring.

More preferable compounds in the above preferable compounds are the compounds of the formula (I), wherein R¹ represents hydrogen atom or an alkyl group of straight or branched chain having 1 to 4 carbon atoms, R² represents NR⁹R¹⁰ or an alkyl group of straight or branched chain having 1 to 6 carbon atoms, R³ represents SR¹⁴, R⁴ represents an alkyl group of straight or branched chain having 3 to 10 carbon atoms or a cycloalkyl group having 3 to 10 carbon atoms, R⁵ represents a benzyl group, or a phenyl group which may be substituted with 1 or 2 substituents selected from the group consisting of: an alkyl group of


straight or branched chain having 1 to 6 carbon atoms, an alkoxyl group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxyl group and an alkylenedioxy group having 1 or 2 carbon atoms; R^9 and R^{10} are identical or different and represent alkyl groups of straight chain having 1 to 7 carbon atoms, phenyl groups or benzyl groups, or R^9 and R^{10} , together with the nitrogen atom to which they are bonded, form a morpholine ring, R^{14} represents hydrogen atom, an alkyl group of straight chain having 1 to 6 carbon atoms or a benzyl group and n represents an integer of 3 or 4. And some of more preferable examples are the compounds of the formula (I), wherein R^1 represents hydrogen atom, an alkyl group of straight or branched chain having 1 to 4 carbon atoms, R^2 represents NR^9R^{10} , R^3 represents OR^{14} , R^4 represents an alkyl group of straight or branched chain having 3 to 10 carbons atoms, R^5 represents a phenyl group which may be substituted with 1 or 2 substituents selected from a group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxyl group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxyl group and an alkylenedioxy group having 1 to 2 carbon atoms; R^9 , R^{10} and R^{14} are identical or different and represent alkyl groups of straight or branched chain having 1 to 4 carbon atoms, and n represents an integer of 3 or 4. Further, others of more preferable examples are the compounds of the formula (I), wherein R^1 represents NR^6R^7 , SR^8 or OR^8 , R^2 represents NR^9R^{10} , R^3 represents SR^{14} or OR^{14} , R^4 represents an alkyl group of straight or branched chain having 3 to 10 carbon atoms, R^5 represents a phenyl group which may be substituted with 1 or 2 substituents selected from a group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxyl group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, a hydroxyl group and an alkylenedioxy group having 1 or 2 carbon atoms; R^6 , R^7 , R^8 , R^9 , R^{10} and R^{14} are identical or different and represent alkyl groups of straight or branched chain having 1 to 4 carbon atoms, and n represents an integer of 3 or 4.

The invention compounds of the present invention represented by the formula (I) can be obtained for example by the following Process 1, shown in (reaction scheme 1). In the intermediates represented by the formula (II)-(VI) in reaction schemes 1- 3, descriptions and other reaction schemes, substituents R^1 - R^5 and n have the same significance as defined in the formula (I), X and Z each represent halogen atoms, R and R' each represent lower alkyl groups, and Ph represents a phenyl group.


Further in these intermediates, R^1 - R^3 can also represent hydroxyl, mercapto or amino groups protected with a suitable conventional protecting group mentioned later.

(reaction scheme 1)

process 1



process 2



Process 1

Compounds of the formula (I) can be obtained by the reaction of intermediates of the formula (II) and intermediates of the formula (III) in the presence of condensing reagents in organic solvents. As a

condensing reagent, dicyclohexylcarbodiimide (DCC), 2-halogeno-1-methylpyridinium iodide (Mukaiyama reagent), diethyl phosphorocyanidate (DEPC) or 1,1'-carbonyl diimidazole (CDI) can be used, preferably DCC or Mukaiyama reagent.

Moreover, instead of condensing reagents, the mixed anhydride method by using chloroformic ester and triethylamine, pyridine or N-methylmorpholine is useful for condensation.

In case of using DCC, DCC is added to the mixture of intermediates of the formula (II) and intermediates of the formula (III) at a temperature from approximately -20 °C to room temperature, preferably under ice-cooling, in the halogenated hydrocarbon type solvent such as methylene chloride, chloroform and dichloroethane. And then the reaction mixture is warmed up to room temperature, and stirred for a suitable hour from 1 hr to 24 hrs to obtain compounds of the formula (I).

Moreover, Mukaiyama reagent is useful as a condensing reagent, described in Chemistry Letters, p1163 (1975). After addition of Mukaiyama reagent according to arrangements of above DCC method, the reaction is carried out at a suitable temperature from ice-cooling condition to gentle reflux condition.

15 Process 2

Intermediates of the formula (V) are obtained by the condensation of intermediates of the formula (II) and intermediates of the formula (IV) according to Process 1 or by the reaction of intermediates of the formula (II) with activated acid derivatives, prepared from intermediates of the formula (IV), such as acid halides or acid anhydrides.

The reaction using an acid halide is carried out in organic solvents at a suitable temperature below boiling point of the mixture, in the presence of a suitable acid scavenger.

A tertiary amine such as triethylamine, pyridine, diisopropylethylamine or dimethylaminopyridine is employed as an acid scavenger, and an inert solvent such as a halogenated hydrocarbon, for example methylene chloride, such as an ether-type solvent, for example tetrahydrofuran or dioxane, such as an aromatic hydrocarbon, for example toluene, preferably methylene chloride, is employed as a solvent.

And then intermediates of the formula (V) can be converted to compounds of the formula (I) by the reaction with amine derivatives of the formula (VI) in the presence of an organic base such as diethylaniline.

In the case of the formula (I) pyrimidine derivatives, having mercapto groups, obtained above, the mercapto groups can be converted to substituted mercapto groups by the reaction with a suitable alkyl halide, aryl halide and/or aralkyl halide in the presence of an acid scavenger such as above-mentioned tertiary amine.

Further, hydroxyl groups of pyrimidine derivatives can be converted to several substituent groups according to the preparation shown in the following Process (i) of pyrimidine derivatives.

Furthermore, the protecting groups of reactive functional groups such as hydroxyl, mercapto or amino group can be removed by described methods in "Protective Groups in Organic Synthesis, second edition" T.W.Greene and P.G.M.Wuts ed., published by John Wiley and Sons, 1991. And these reactive groups also can be subsequently converted to several functional groups by above-mentioned methods.

Intermediates of the formula (III) are known compounds, or can be synthesized from known or commercially available intermediates and can be synthesized from halogenocarboxylic acid derivatives, preferably halogenocarboxylic acid esters, or acrylic acid derivatives, with amine derivatives of the formula (VI).

In the case of the synthesis from halogenocarboxylic acid esters, the intermediates of the formula (III) can be obtained by the reaction of amine derivatives of the formula (VI) with halogenocarboxylic acid esters with or without the inert solvents described in Process 2, using an organic base such as pyridine, triethylamine, dimethylaminopyridine, diethylaniline, dimethylaniline, diazabicycloundecene (DBU), etc., or an inorganic base such as potassium carbonate etc. and then by the hydrolysis with an alkali hydroxide such as sodium hydroxide.

In the case of the synthesis from acrylic acid, the intermediates of the formula (III) can be obtained by the reaction of acrylic acid and amine derivatives of the formula (VI) in an aqueous solution at a temperature from room temperature to the reflux temperature of the reaction mixture, preferably reflux condition.

Compounds of the formula (II) are also known compounds, or can be synthesized from known or commercially available intermediates. The synthetic methods about many pyrimidine intermediates are described in the review of "The Pyrimidines" D.J.Brown ed., published by John Wiley and Sons, 1962.

The detailed synthetic methods are described below.

Process (i)

4,6-Dihydroxypyrimidine derivatives, as starting materials, can be synthesized from amidine derivatives, such as formamidine or acetamidine, urea or its O-alkyl derivatives, thiourea or its S-alkyl derivatives and guanidine or its alkyl derivatives and malonic acid diesters by well-known method. The obtained 4,6-Dihydroxypyrimidine derivatives with reactive functional groups, such as hydroxyl, mercapto and amino, at 2-position can be protected suitable protecting group, such as benzyl or acetyl, if necessary. Further pyrimidine derivatives with protected the reactive functional group at 2-position, can be synthesized directly using the derivatives such as S-benzylisothiurea, O-benzylisourea, or 1-acetylguanidine.


Thus obtained 4,6-dihydroxypyrimidine derivatives are converted to the corresponding 4,6-dihydroxy-5-nitropyrimidine derivatives by the reaction with suitable nitrating reagents such as concentrated nitric acid, fuming nitric acid, alkyl nitrate, nitric oxide, nitronium tetrafluoroborate and nitronium trifluoromethanesulfonate, preferably with fuming nitric acid in acetic acid. Furthermore, 5-nitropyrimidine derivatives can be synthesized directly from 2-nitromalonic esters.

hydroxyl groups at 4- and 6-positions of the obtained 5-nitropyrimidine derivatives can be converted to 4,6-dichloro- or 4,6-dibromo-pyrimidine. As chlorinating or brominating reagents, oxalyl chloride, thionyl chloride, phosphorus trichloride, phosphorus pentachloride, phosphorus oxychloride, or corresponding bromide can be used.

Various kind of substituents can be introduced into the positions 4 and 6 of 4,6-disubstitued-5-nitropyrimidine derivatives by the reaction with nucleophilic reagents, shown (reaction scheme 2) below.

Same substituent groups are introduced at 4- and 6-positions using over two equivalents of nucleophilic reagents, and a different substituent group is introduced at 4- position from that at 6-position using an equivalent of different nucleophilic reagents one by one. As nucleophilic reagents, substituted amine, alcohol, phenol, or mercapto etc. can be used. In (reaction scheme 2), X represents a halogen atom, and R^1 , R^2 and R^3 of each compounds have the same significance as defined in the formula (I).

(reaction scheme 2)



The introduction of amino groups can be carried out with desired mono- and/or di-substituted amines in the presence of the acid scavengers described above. The reactions are carried out conventionally in non-solvent or in suitable inert solvents such as above-mentioned ether-type solvents or halogenated hydrocarbons at a suitable temperature, preferably from $-20^\circ C$ to room temperature, for 10 min. to 5 hrs.

The introduction of mercapto groups are carried out with sodium hydrosulfide in polar solvents such as ethanol, methanol and dimethylformamide at a suitable temperature, preferably room temperature, for 1 hr to 10 hrs.

If necessary, the conversion from mercapto to alkylthio, arylthio or aralkylthio is carried out with alkyl halide, aryl halide or aralkyl halide using alkaline metal compounds such as sodium hydride and alkoxide, or the acid scavengers such as the above-mentioned tertiary amines.

The substituted mercapto groups can directly be introduced by the reaction with sodium methylthiolate solution in an alcohol solvent, or with an alkyl mercaptane, an aryl mercaptane, an aralkyl mercaptane in inert an ether solvent such as cyclic- and dialkyl-ether in the presence of base such as sodium hydride or alkoxide.

The synthesis of pyrimidine derivatives having an alkoxyl and/or phenoxy group can be carried out with an alkaline metal hydroxide in an alcohol, or a metal alkoxide or phenoxide such as sodium alkoxide or phenoxide in an alcoholic solvent.

Organometal reagents represented typically by Grignard reagents or lithium reagents, can be used as nucleophilic reagents to introduce alkyl and/or aryl groups. In the case of Grignard reagents, the reactions

are carried out in above mentioned inert solvents or dimethylformamide, preferably in an ether-type solvent such as cyclic- or dialkyl-ether, without a catalyst or with metal catalysts such as 1,3-bis-(diphenylphosphino)propane nickel chloride(Nidppp), 1,2-bis(diphenylphosphino)ethane nickel chloride-(Nidppe), bis(triphenylphosphine)palladium chloride, palladium acetate, preferably Nidppp or Nidppe, at a suitable temperature, generally reflux condition with heat, for 1 hr to 24 hrs.

The corresponding 5-aminopyrimidine intermediates of the formula(II) can be prepared by the reduction of 5-nitropyrimidine derivatives obtained above, using zinc in acetic acid, or tin chloride, tin powder or iron powder in hydro chloric acid, or a reductant such as hydrogen gas with suitable catalysts such as Raney nickel or palladium-carbon in an alcohol, preferably zinc in acetic acid. Namely, 5-nitropyrimidine derivatives are dissolved with acetic acid, and zinc powder is added to the mixture under ice-cooling. And then the mixture is reacted at the temperature from - 20 °C to the reflux temperature of the reaction mixture, preferably room temperature, for 1 hr to 48 hrs., with stirring to convert to the 5-aminopyrimidine intermediates of the formula (II).

Thus in the obtained intermediates of the formula (II), the compounds having halogeno groups at 4(6)-position, if necessary, can be reacted with the above-mentioned nucleophilic reagents. The compounds having a mercapto group of the pyrimidine derivatives can be converted to the compound having a substituted mercapto group same as before.


If necessary, the protecting group of reactive functional group such as hydroxyl, mercapto and amino can be removed by the method of already described publication at an arbitrary step in above process.

Process (ii)

According to the following (reaction scheme 3), 5-phenylazopyrimidine can be synthesized by reacting phenylazo-β-keto esters prepared from β-keto esters, typically malonate or acetoacetate, and diazonium salts prepared from aniline and sodium nitrite, and amidine derivatives, such as formamidine and acetamidine, urea and its O-alkyl derivatives, thiourea and its S-alkyl derivatives, and guanidine and its alkyl derivatives in organic solvents such as an alcohol in the presence of bases such as sodium alkoxide at a suitable temperature from room temperature to the boiling temperature of the reaction mixture for 1 hr to 10 hrs.

4,6-Dihydroxypyrimidine derivatives can be obtained using malonic acid diesters as starting materials.

(reaction scheme 3)



In the case of 4,6-dihydroxypyrimidine derivatives with reactive functional groups, such as hydroxyl, mercapto and amino at 2-position, the reactive functional groups can be protected by a suitable protecting group such as benzyl and acetyl etc., if necessary.

Further pyrimidine derivatives with protected reactive functional group at the 2-position, can be synthesized directly using the derivatives of S-benzylisothiurea, O-benzylisourea, or 1-acetylguanidine.

5-Phenylazopyrimidine intermediates can be converted to 5-aminopyrimidine intermediates by reduction in the conditions of an electrolytic reduction in an acid solution, metal reduction using e.g. zinc, tin, nickel, or inorganic salts reduction such as sodium hydrosulfite, preferably by the reduction of using sodium hydrosulfite. Hydroxyl groups at 4(6)-position of 5-aminopyrimidine, obtained above, can be converted to other several substituent groups by the method shown in Process (i).

Process (iii)

The synthesis of pyrimidine having 6-alkyl, 6-aryl or 6-aralkyl group can be carried out directly by condensing β -diketones, typically acetoacetic acid ester, with amidine derivatives, such as formamidine or acetamidine, urea and its O-alkyl derivatives, thiourea and its S-alkyl derivatives, and guanidine and its alkyl derivatives. This method is well-known as Pinner's pyrimidine synthesis, namely the reaction is carried out under a basic condition, for example, sodium alkoxide etc. in an alcohol at a suitable temperature, preferably in a reflux condition, at a suitable hour from 1 hr to 24 hrs.

β -diketone equivalents such as an acyl Meldrum's acid, diketene, diketene-acetone adduct(2,2,6-trimethyl-1,3-dioxin-4-one) can be used for pyrimidine synthesis under a neutral condition. In the case of pyrimidine derivatives with reactive functional groups, such as hydroxyl, mercapto, and amino at 2-position, the reactive functional groups can be protected by a suitable protecting group, such as benzyl or acetyl, if necessary. Further pyrimidine derivatives with a protected reactive functional group at 2-position, can be synthesized directly, using a derivative of S-benzylisothiurea, O-benzylisourea, 1-acetylguanidine etc.

The obtained 2,6-disubstituted-4-pyrimidone derivatives can be converted to substituted amino derivatives after halogenation according to the above-mentioned process. And then the nitration and reduction at 5-position can convert the derivative to 5-aminopyrimidine intermediates of the formula (II).

Since the compounds of the present invention significantly prevent the ability of macrophages from accumulating cholesteryl esters, these compounds are expected to show an inhibitory effect against atherogenesis and/or the development of atherosclerotic lesion. Furthermore, the compounds potentially inhibit the microsomal ACAT activity from a variety of organs in vitro. Indeed, these compounds are effective in reducing the intestinal absorption of dietary cholesterol and in inhibiting the synthesis and secretion of lipoproteins in liver, resulting in hypolipidemic effect in experimental animals. Therefore, obvious reduction of a risk factor for atherosclerosis can be expected. Not only pyrimidine derivatives and their salts of the present invention exert much potent inhibition on the ACAT activity in microsomal fractions prepared from either animal organs but also do the derivatives possess much potent inhibition on the ACAT activity in those from human hepatoma cell line, HepG2, as compared with previous ACAT inhibitors. In addition, the compounds of the present invention possess quite low toxicity and side effect on liver and other organs that is apprehended with the former hypolipidemic drugs and/or ACAT inhibitor.

Experimental Example will be illustrated by the pharmacological effects, toxicities, doses and directions for use of the compounds of the present invention.

Pharmacological effects of the compounds of the present invention are shown in more detail as follows.

Experimental Example 1

Inhibitory effect on cholesteryl ester accumulation in macrophages.

Mouse peritoneal macrophages were isolated from ddY-family male mice and cultured by the method of MS Brown et al. (MS Brown et al., J. Biol. Chem., 255, 9344 (1980)) with partial modification. Namely resident peritoneal cells suspended in phosphate-buffered saline (PBS) were plated in plastic Petri dishes (35 mm x 10 mm) at a density of 2×10^6 cells. The adherent macrophages were cultured overnight at 37°C in Dalbecco's modified Eagle medium (DME) containing 10% fetal bovine serum (FCS) under humidified 5% CO₂. And then, the compounds of the present invention and the reference compound at the concentrations of 0.01-10 μ M were applied to macrophages in DME containing 30 μ g/ml rabbit β -very low density lipoproteins, 0.2 mM [³H]oleic acid (185 kBq/ml) and 2.4 mg/ml bovine serum albumin, and incubated for additional 3 hrs. After discarding the medium, each macrophage monolayer was washed with PBS and lipids were extracted with hexane/isopropyl alcohol (3:2). Cholesteryl esters in the extract were separated by thin-layer chromatography and the radioactivity was measured by liquid scintillation counter. As the reference compound, CL277082 ((N'-2,4-difluorophenyl)-N-[[4-(2,2-dimethylpropyl)phenyl]methyl]-N-heptyl urea; synthesized by the method of VG DeVries et al.; VG DeVries et al. J. Med. Chem., 29, 1131 (1986)), which is a representative compound developed as an anti-atherosclerotic agent with selective inhibitory effect on ACAT, was used.

The inhibitory effect of the compounds of the present invention on cholesteryl ester accumulation in macrophages was shown in Fig. 1. The evaluation of the activity was defined in 3 grades as follows according to the concentration inducing 50% inhibition (IC₅₀).

- A: $0.01 \mu\text{M} \leq \text{IC}_{50} < 0.1 \mu\text{M}$
- B: $0.1 \mu\text{M} \leq \text{IC}_{50} < 1.0 \mu\text{M}$
- C: $1.0 \mu\text{M} \leq \text{IC}_{50} < 10 \mu\text{M}$

Table 1

Example No.	Inhibition activity on cholesteryl ester accumulation
143	C
148	A
219	B
220	B
221	A
223	A
225	A
238	B
247	A
249	B
CL277082	C

Each compound of the present invention exerted obvious inhibitory activity on the cholesteryl ester accumulation in macrophages.

Experimental Example 2

Hypocholesterolemic effect on cholesterol feeding rats.

Male Wistar rats aged 7 weeks old were fed a diet (CE-2®) supplemented with 2%(w/w) cholesterol, 0.5%(w/w) sodium cholate, 10%(w/w) lard, 0.2%(w/w) propylthiouracyl and 5%(w/w) sucrose, for 3 days. Following 3 days, the compounds of the present invention were administered orally, and the animals were maintained with the high cholesterol diet. On the next day of final drug administration, blood was drawn and serum total cholesterol levels were measured enzymatically by autoanalyzer. CL277082 was used as a reference compound. The daily dose of the present compounds and % reduction of serum total cholesterol are shown in table 2.

Table 2

Example No.	Dose (mg/kg/day)	% reduction of serum total cholesterol
143	30	20
149	30	21
155	10	66
196	10	48
216	100	33
220	30	23
223	10	70
225	10	64
232	10	65
233	10	76
238	10	65
247	10	76
260	10	70
262	10	53
CL277082	30	52

Each of the compounds of the present invention significantly improved hypercholesterolemia in the rats fed with the high cholesterol diet.

Experimental Example 3

Inhibitory effect on microsomal ACAT activity in rabbit aorta.

Microsomal fraction of rabbit aorta was isolated by the method of Aram V Chobanian et al. (Aram V. Chobanian et al., Circulation Res., 56, 755 (1985)) with partial modifications. Namely, male New Zealand white rabbits aged 8 weeks old were fed on a diet supplemented with 1%(w/w) cholesterol for 2 months, and then the thoracic aorta was removed from the animals with serum total cholesterol levels from 2600 mg/dl to 4200 mg/dl. After removing the adventitia of the aorta, the intima and media were homogenized by teflon homogenizer in 40 mM 2-amino-2-hydroxymethyl-1,3-propanediol (Tris)-HCl (pH 7.2) containing 0.25 M sucrose, 0.3 mM EDTA and 2 mM dithiothreitol. The obtained homogenate was centrifuged at 10,000 × g for 15 minutes, and the supernatant was centrifuged twice at 100,000 × g for 60 minutes. The resulting microsomal fraction was washed once and used for the experiment after resuspension in the same buffer.

The inhibitory effect of the compounds of the present invention on the microsomal ACAT activity were assayed by the method of AC Rustan et al. (AC Rustan et al., J. Biol. Chem., 263, 8126 (1988)) with partial modifications. In the incubation mixture of 0.1 M potassium phosphate buffer (pH 7.4) containing 30 μM [¹⁴C]oleyl-CoA (0.25 kBq/nmol) and 1 mg/ml bovine serum albumin, the enzymatic reaction was started by adding microsomes at the final concentration of 0.4 mg protein/ml. The incubation was carried out at 37 °C for 5 minutes, and stopped by the addition of acetone. After the extraction of lipids with hexane, cholesteryl esters were separated from other lipids by thin layer chromatography and the radioactivity was measured as described in experimental example 1. CL277082 was used as a reference compound.

Table 3 shows the concentration of the present compounds required to produce 50% inhibition of cholesterol esterification (IC₅₀).

Table 3 (I)

Example No.	IC ₅₀ (μM)
81	0.11
83	0.17
84	0.11
86	0.15
103	0.22
104	0.072
125	0.022
126	0.019

Table 3 (II)

Example No.	IC ₅₀ (μM)
128	0.11
130	0.017
135	0.031
140	0.024
145	0.12
148	0.069
153	0.048
CL277082	0.21

Each compound of the present invention showed remarkable inhibitory activity on ACAT in the rabbit aorta microsomes.

Experimental Example 4

Inhibitory effect on microsomal ACAT activity in rat liver.

Liver microsomes as an enzyme sample of ACAT were prepared from overnight-fasted male rats aged 6 weeks old according to the method of GN Anderson et al. (GN Anderson et al., Biochim. Biochem. Acta, 512, 539 (1978)) with partial modifications. ACAT activity was measured by the same procedure as described in Experimental Example 3. CL277082 was used as a reference compound.

Table 4 shows the concentration of the present compounds required to produce 50% inhibition of cholesterol esterification (IC_{50}).

Table 4 (I)

Example No.	IC_{50} (μM)
133	0.26
143	0.080
145	0.080
146	0.11
148	0.055
149	0.14
155	0.088
156	0.038
166	0.081
167	0.043
168	0.087
173	0.17
180	0.20
182	0.22
183	0.28
185	0.079
187	0.047
188	0.035
195	0.047
197	0.0088
205	0.28
210	0.47
216	0.12

Table 4 (II)

Example No.	IC_{50} (μM)
218	0.43
219	0.13
220	0.052
221	0.029
223	0.064
224	0.22
225	0.019
226	0.016
227	0.11
234	0.025
235	0.026
236	0.032
237	0.083
238	0.11
239	0.12
240	0.073
241	0.076
242	0.22
243	0.095
244	0.19
245	0.064
246	0.014
247	0.016

Table 4 (III)

Example No.	IC ₅₀ (μ M)
248	0.032
249	0.16
250	0.0096
252	0.033
256	0.10
257	0.22
258	0.23

Table 4 (IV)

Example No.	IC ₅₀ (μ M)
259	0.076
261	0.023
263	0.10
266	0.17
268	0.056
272	0.037
CL277082	0.62

Each compound of the present invention exhibited remarkable inhibitory activity on ACAT in the rat liver microsomes.

Experimental Example 5

Inhibitory effect on microsomal ACAT activity in human hepatoma cell line, HepG2.

The human hepatoma cell, HepG2, was cultured with DME containing 10% FCS. The cells were suspended in 40 mM Tris-HCl buffer (pH 7.4) containing 25 mM sucrose at a density of 4.5×10^8 cells and the membrane fraction of the cell was prepared by the method of Field F J et al. (Lipids, Vol.26, 1, (1991)) with partial modifications. Namely, a homogenate of the fraction was prepared by a sonication. The homogenate was centrifuged at $10,000 \times g$ for 20 minutes and the supernatant was centrifuged at $100,000 \times g$ for 60 minutes. The resulting microsomal fraction was washed once by centrifuging at $100,000 \times g$ for 60 minutes and used for the experiment after resuspension in the same buffer.

The measurement of ACAT activity was performed by the same procedure as described in Experimental Example 3, wherein the enzyme sample was 0.8 mg/ml of the membrane fraction of HepG2, the reaction was carried out for 15 min. CL277082 was used as a reference compound.

Table 5 shows the concentration of the present compounds required to produce 50% inhibition of cholesterol esterification (IC₅₀).

Table 5

Example No.	IC ₅₀ (μ M)
81	0.21
120	1.0
121	0.85
CL277082	1.4

Each compound of the present invention showed potent inhibitory activity on ACAT in HepG2 microsomes.

Experimental Examination 6

Acute toxicity.

5 The pyrimidine derivatives of the present invention were examined for acute toxicity by using male Wistar rats fasted over night aged 7 weeks old. After given orally the compounds of the Example 143 of the present invention at the single dose of 2 g/kg or the compounds of the Example 155, 196, 231, 232, 233, 240, 247, 260 and 262 of the present invention at the single dose of 1 g/kg, no lethal incident was observed over 7 days after the administration.

10 As mentioned above, it is clear that the compounds of the present invention possess a potent inhibitory effect on the accumulation of cholesteryl ester in macrophages in vitro and on ACAT in microsomal fractions of arterial wall and liver. These inhibitory activities on ACAT were more potent than a representative ACAT inhibitor, CL277082. Therefore, the compounds of the present invention are expected to exert beneficial effects directly on the atherosclerotic lesion. The compounds also show remarkable hypolipidemic effect on a high cholesterol diet feeding rats and have inhibitory activity on ACAT in microsomal fraction of the human hepatoma cell line, HepG2. These compounds are accordingly expected to have a beneficial effect on the human hyperlipidemia and atherosclerosis. In addition, The compounds of the present invention have little toxicities and side effect on liver and other organs apprehended with the former hypolipidemic drugs and/or ACAT inhibitor. It is therefore indicated that the compounds of the present invention are safe and beneficial drugs for the prevention and treatment of arteriosclerosis itself and various morbid states and maladies derived from arteriosclerosis as follows; (1) ischemic heart diseases caused by coronary atherosclerosis such as angina pectoris and myocardial infarction etc., (2) the cerebrovascular diseases caused by cerebrovascular arteriosclerosis such as cerebral infarction, cerebral apoplexy, cerebral thrombosis, transient ischemic attack and subarachnoid hemorrhage etc., (3) optic nerve atrophy and hydrocephalia caused by increased mechanical pressure in the region of cerebral arteriosclerosis, (4) nephrosclerosis caused by arteriosclerosis of kidney, (5) aneurysm and arteriosclerosis obliterans caused by stenosis of aorta and peripheral artery, (6) sthenia of platelet aggregation, (7) deep venous thrombosis, and (8) others; hyperlipidemia, diabetes, variety of thrombosis, xanthoma and so on.

20 The compounds of the present invention may be formed pharmaceutically acceptable salts. Typical examples of such salts of the compounds include pharmaceutically acceptable salts with organic or inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, p-toluenesulfonic acid, methanesulfonic acid, salicylic acid, citric acid, fumaric acid, succinic acid, tartaric acid, oxalic acid, lactic acid and mandelic acid, or with acidic amino acids such as aspartic acid and glutamic acid.

30 The compounds of the present invention can be administered independently or can be mixed with appropriate pharmaceutically acceptable carriers or medium such as excipients, binders, lubricants, coloring agents, flavors, and optionally sterilized water, edible oils, non-toxic organic solvents or non-toxic solubilizers (for example, glycerin or propylene glycol), emulsifying agents, suspending agents (for example, Tween 80 or arabic gum), etc. and can be prepared into the appropriate pharmaceutical compositions by appropriate selection and combination of the above compounds and carriers according to a conventional process.

40 The compounds of the present invention can be administered to the patient either orally or parenterally, in the form of tablets, capsules, powders, granules, subilized granules, orally administrative liquid compositions, suppositories, syrups, inhalants, ointments or injections of aqueous or oily solutions, emulsions, suspensions or solidities or lyophilized formulations. The amount of the administration of the compounds may be in the range of 0.1 mg to 2.5 g/day, preferably 1 mg to 1.5 g/day. And the amount of the administration may also be adjusted according to patients conditions or to the route of the administration, and the whole amount of daily dose can be administered at a time or at 2 to 6 times separately.

Hereafter the present invention will be described with references to the examples below but is not deemed to be limited thereof.

EXAMPLE 1

Preparation of 4,6-dihydroxy-2-methylpyrimidine

55 To a solution of sodium ethoxide, prepared from sodium (36.2g) and ethanol (1000ml), diethyl malonate (114ml) and acetamidine hydrochloride (71g) were added at room temperature, and the mixture was stirred for 5 hours under reflux. After cooling to room temperature, the resulting solid was collected by filtration and washed with ethanol and then dissolved in water. The aqueous solution was acidified to pH Ca.2 with

concentrated hydrochloric acid (Ca. 170 ml) under ice-cooling. The formed precipitate was separated by filtration and washed with water, ethanol and ether to give 153g (81%) of the objective compound.

Melting point: $>300^{\circ}\text{C}$

IR(KBr) ν cm^{-1} :

5 1687, 1641, 1577, 1456, 1329, 533, 525

NMR(90MHz, DMSO- d_6) δ ppm:

4.95(1H, s), 2.21(3H, s)

The following compounds were prepared in a similar manner as EXAMPLE 1.

10 EXAMPLE 2

4,6-dihydroxy-2-(N,N-dimethylamino)pyrimidine

Yield: 68%

15 Melting point: 185.0°C (decomposition)

IR(KBr) ν cm^{-1} :

1616, 1520, 1377, 1325, 789, 523

NMR(90MHz, DMSO- d_6) δ ppm:

10.55(2H, br.s), 4.66(1H, s), 3.01(6H, s)

20

EXAMPLE 3

4,6-dihydroxy-2-methoxypyrimidine

25 Yield: 70%

IR(KBr) ν cm^{-1} :

1678, 1664, 1641, 1606, 1446, 1338, 1281

NMR(90MHz, DMSO- d_6) δ ppm:

11.50(2H, br.s), 4.98(1H, s), 3.84(3H, s)

30

EXAMPLE 4

Preparation of 4,6-dihydroxy-2-methyl-5-nitropyrimidine

35 To a mixture of fuming nitric acid (160ml) and acetic acid (260ml) the product obtained in EXAMPLE 1 (100g) was added portionwise, keeping inside at $10-15^{\circ}\text{C}$. After stirring for 75 minutes at room temperature, the reaction mixture was poured into ice-water (1000ml). The formed precipitate was separated by filtration and washed with water, ethanol and ether to give 107g (79%) of the objective compound.

Melting point: $>300^{\circ}\text{C}$

40 IR(KBr) ν cm^{-1} :

2297, 1713, 1646, 1364, 1308

NMR(90MHz, CDCl_3) δ ppm:

13.98(2H, br.s), 2.31(3H, s)

The following compounds were prepared in a similar manner as EXAMPLE 4.

45

EXAMPLE 5

4,6-dihydroxy-2-(N,N-dimethylamino)-5-nitropyrimidine

50 Yield: 82%

Melting point: 285.3°C (decomposition)

IR(KBr) ν cm^{-1} :

2997, 1647, 1406, 1387, 1321, 538

NMR(90MHz, DMSO- d_6) δ ppm:

55 11.3(2H, br.s), 3.10(6H, s)

EXAMPLE 6

4,6-dihydroxy-2-methoxy-5-nitropyrimidine

5 Yield: 69%

Melting point: 168.8-170.0 °C

IR(KBr) ν cm^{-1} :

1664, 1630, 1595, 1560, 1435, 1315

NMR(90MHz, DMSO- d_6) δ ppm:

10 6.12(2H, br.s), 3.95(3H, s)

EXAMPLE 7

4,6-dihydroxy-2-methylthio-5-nitropyrimidine

15

Yield: 56.5%

Melting point: 214.3-214.8 °C

IR(KBr) ν cm^{-1} :

1697, 1635, 1566, 1362, 1302, 1205, 530

20 NMR(90MHz, DMSO- d_6) δ ppm:

7.50(2H, br.s), 2.56(3H, s)

EXAMPLE 8

25 Preparation of 4,6-dichloro-2-methyl-5-nitropyrimidine

To a suspension of the product obtained in EXAMPLE 4 (154g) and phosphorus oxychloride (696ml), diethylaniline (286ml) was added dropwise under ice cooling. After refluxing for 3 hours, the reaction mixture was concentrated under reduced pressure. The residue was poured into ice-water (2000ml) and extracted three times with ether. The organic layer was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methylene chloride : hexane = 1:1 to methylene chloride) to give 160.4g (86%) of the objective compound.

Melting point: 42-44 °C

35 IR(KBr) ν cm^{-1} :

1546, 1516, 1425, 1405, 1373, 1345, 834

NMR(90MHz, CDCl_3) δ ppm:

2.73(3H, s)

The following compounds were prepared in a similar manner as EXAMPLE 8.

40

EXAMPLE 9

4,6-dichloro-2-(N,N-dimethylamino)-5-nitropyrimidine

45 Yield: 50%

Melting point: 123.1-123.9 °C

IR(KBr) ν cm^{-1} :

1593, 1525, 1414, 1336, 1284, 829

NMR(90MHz, CDCl_3) δ ppm:

50 3.25(6H, s)

EXAMPLE 10

4,6-dichloro-2-methoxy-5-nitropyrimidine

55

Yield: 18%

Melting point: 72.1-73.8 °C

IR(KBr) ν cm^{-1} :

1566, 1543, 1525, 1479, 1389, 1358, 1300
 NMR(90MHz, CDCl₃) δ ppm:
 4.12(3H, s)

5 EXAMPLE 11

4,6-dichloro-2-methylthio-5-nitropyrimidine

Yield: 95.3%

10 Melting point: 59.4-60.0 °C
 IR(KBr) ν cm⁻¹:
 1537, 1500, 1292, 1238, 872, 845, 831
 NMR(90MHz, DMSO-d₆) δ ppm:
 2.61(3H, s)

15 EXAMPLE 12

Preparation of 4-chloro-6-hydroxy-2-methyl-5-nitropyrimidine

20 To a suspension of the product obtained in EXAMPLE 4 (50g) and phosphorus oxychloride (200ml), diethylaniline (84ml) was added dropwise under ice cooling. After stirring for 3 hours at 80 °C, the reaction mixture was concentrated under reduced pressure. The residue was poured into ice-water (1000ml) and extracted five times with ethyl acetate. The organic layer was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was
 25 purified by silica gel column chromatography (methanol : methylene chloride = 2:98-5:95) to give 6.4g (11.5%) of the objective compound.

Melting point: 193.5-196.5 °C
 IR(KBr) ν cm⁻¹:
 1687, 1584, 1542, 1359, 1187
 30 NMR(90MHz, DMSO-d₆) δ ppm:
 2.38(3H, s)

EXAMPLE 13

35 Preparation of 4-chloro-2-methyl-5-nitro-6-(N-phenyl-N-propylamino)pyrimidine

To a solution of the product obtained in EXAMPLE 8 (160g) and triethylamine (128.6ml) in THF (400ml), a solution of N-propylaniline (109.5ml) in THF (100ml) was added dropwise. After stirring for 2 hours at room temperature, the formed insoluble material was removed by filtration and the filtrate was concentrated
 40 under reduced pressure. The residue was crystallized from ether and the crystal was separated by filtration and then washed with hexane/ether (9:1) to give 201g (85%) of the objective compound.

Melting point: 99.8-100.2 °C
 IR(KBr) ν cm⁻¹:
 1561, 1541, 1519, 1498, 1407, 1354, 1054
 45 NMR(90MHz, CDCl₃) δ ppm:
 7.41-6.93(5H, m), 3.97(2H, t, J = 7.6Hz), 2.59(3H, s),
 1.89-1.37(2H, m), 0.92(3H, t, J = 7.0Hz)

The following compounds were prepared in a similar manner as EXAMPLE 13.

50 EXAMPLE 14

4-chloro-6-(N,N-dimethylamino)-2-methyl-5-nitropyrimidine

Yield: 85%
 55 Melting point: 96.9-98.4 °C
 IR(KBr) ν cm⁻¹:
 1580, 1534, 1485, 1404, 1357, 1196, 835
 NMR(90MHz, CDCl₃) δ ppm:

3.12(6H, s), 2.51(3H, s)

EXAMPLE 15

5 4-chloro-6-(N,N-diethylamino)-2-methyl-5-nitropyrimidine

Yield: 84%

IR(neat) ν cm^{-1} :

2981, 2938, 1576, 1531, 1483, 1352, 834

10 NMR(90MHz, CDCl_3) δ ppm:

3.46(4H, q, $J = 7.0\text{Hz}$), 2.50(3H, s), 1.21(6H, t, $J = 7.0\text{Hz}$)

EXAMPLE 16

15 4-chloro-6-(N,N-dipropylamino)-2-methyl-5-nitropyrimidine

Yield: 99%

IR(neat) ν cm^{-1} :

2968, 1574, 1533, 1481, 1352, 833

NMR(90MHz) CDCl_3 δ ppm:

20 3.35(4H, t, $J = 7.8\text{Hz}$), 2.50(3H, s), 1.86-1.32(4H, m), 0.89(6H, t, $J = 7.8\text{Hz}$)

EXAMPLE 17

25 4-chloro-6-(N,N-dibutylamino)-2-methyl-5-nitropyrimidine

Yield: 97%

IR(neat) ν cm^{-1} :

2962, 1571, 1533, 1478, 1353, 834

NMR(90MHz, CDCl_3) δ ppm:

30 3.39(4H, t, $J = 7.4\text{Hz}$), 2.49(3H, s), 1.80-1.05(8H, m), 0.94(6H, t, $J = 5.9\text{Hz}$)

EXAMPLE 18

35 4-chloro-6-(N,N-dihexylamino)-2-methyl-5-nitropyrimidine

Yield: 100%

IR(neat) ν cm^{-1} :

2957, 2929, 1576, 1533, 1477, 1353, 834

NMR(90MHz, CDCl_3) δ ppm:

40 3.38(4H, t, $J = 8.2\text{Hz}$), 2.49(3H, s), 1.74-1.62(16H, m), 0.89(6H, t, $J = 5.6\text{Hz}$)

EXAMPLE 19

45 4-(N-benzyl-N-ethylamino)-6-chloro-2-methyl-5-nitropyrimidine

Yield: 86%

IR(neat) ν cm^{-1} :

1570, 1531, 1481, 1412, 1350, 1043, 1043

NMR(90MHz, CDCl_3) δ ppm:

50 7.44-7.11(5H, m), 4.81(2H, s), 3.36(2H, q, $J = 7.1\text{Hz}$), 2.51(3H, s), 1.16(3H, t, $J = 7.1\text{Hz}$)

EXAMPLE 20

55 4-(N-benzyl-N-heptylamino)-6-chloro-2-methyl-5-nitropyrimidine

Yield: 99%

IR(neat) ν cm^{-1} :

2929, 1569, 1533, 1351, 834

NMR(90MHz, CDCl₃) δ ppm:

7.56-7.08(5H, m), 4.80(2H, s), 3.27(2H, t, J = 7.6Hz), 2.51(3H, s), 1.68-0.99(10H, m), 0.87(3H, t, J = 5.6Hz)

EXAMPLE 21

4-(N-butylamino)-6-chloro-2-methyl-5-nitropyrimidine

Yield: 100%

IR(neat) ν cm⁻¹:

2960, 2934, 1590, 1561, 1542, 1341

NMR(90MHz, CDCl₃) δ ppm:

7.70(1H, br.s), 3.61(2H, q, J = 6.3Hz), 2.54(3H, s), 1.83-1.20(4H, m), 0.97(3H, t, J = 6.9Hz)

EXAMPLE 22

4-chloro-2-methyl-6-morpholino-5-nitropyrimidine

Yield: 63%

Melting point: 96.7-98.1 °C

IR(KBr) ν cm⁻¹:

2855, 1571, 1522, 1451, 1346, 1114, 832

NMR(90MHz, CDCl₃) δ ppm:

3.84-3.48(8H, m), 2.53(3H, s)

EXAMPLE 23

4-chloro-2-methyl-6-(4-methylpiperazinyl)-5-nitropyrimidine

Yield: 83%

Melting point: 80.4-81.0 °C

IR(KBr) ν cm⁻¹:

2936, 1575, 1540, 1518, 1438, 1339, 989

NMR(90MHz, CDCl₃) δ ppm:

3.61(4H, t, J = 5.0Hz), 2.51(3H, s), 2.46(4H, t, J = 4.6Hz), 2.32(3H, s)

EXAMPLE 24

4-chloro-5-nitro-6-(N-phenyl-N-propylamino)pyrimidine

Yield: 90%

Melting point: 136.8-139.0 °C

IR(KBr) ν cm⁻¹:

1556, 1538, 1496, 1431, 1055

NMR(90MHz, CDCl₃) δ ppm:

8.48(1H, s), 7.44-6.96(5H, m), 3.98(2H, t, J = 7.8Hz), 1.90-1.38(2H, m), 0.93(3H, t, J = 7.3Hz)

EXAMPLE 25

4-chloro-6-(N,N-dimethylamino)-5-nitropyrimidine

Yield: 57%

Melting point: 99.7-102.0 °C

IR(KBr) ν cm⁻¹:

1590, 1526, 1481, 1425, 1003

NMR(90MHz, CDCl₃) δ ppm:

8.36(1H, s), 3.15(6H, s)

EXAMPLE 26

4-chloro-6-(N,N-diethylamino)-5-nitropyrimidine

5 Yield: 82%

Melting point: 31.5-31.7 °C

IR(KBr) ν cm⁻¹:

1578, 1524, 1483, 1354, 1022

NMR(90MHz, CDCl₃) δ ppm:

10 8.34(1H, s), 3.48(4H, q, J = 7.1Hz), 1.30(6H, t, J = 7.1Hz)

EXAMPLE 27

4-chloro-6-(N,N-dibutylamino)-5-nitropyrimidine

15

Yield: 98%

IR(neat) ν cm⁻¹:

2962, 2873, 1572, 1533, 1485, 1352, 1030

NMR(90MHz, CDCl₃) δ ppm:

20 8.33(1H, s), 3.40(4H, t, J = 7.4Hz), 1.80-1.05(8H, m), 0.94(6H, t, J = 5.9Hz)

EXAMPLE 28

4-chloro-6-(N,N-diethylamino)-2-methoxy-5-nitropyrimidine

25

Yield: 91%

IR(neat) ν cm⁻¹:

1576, 1525, 1500, 1462, 1385, 1344, 1254, 1030

NMR(90MHz, CDCl₃) δ ppm:

30 3.96(3H, s), 3.46(4H, q, J = 7.0Hz), 1.24(6H, t, J = 7.0Hz)

EXAMPLE 29

4-chloro-6-(N,N-diethylamino)-2-methylthio-5-nitropyrimidine

35

Yield: 83%

Melting point: 69.5-70.7 °C

IR(KBr) ν cm⁻¹:

1564, 1522, 1477, 1354, 1182

40 NMR(90MHz, CDCl₃) δ ppm:

3.46(4H, q, J = 7.1Hz), 2.50(3H, s), 1.23(6H, t, J = 7.1Hz)

EXAMPLE 30

45 4-hydroxy-2-methyl-5-nitro-6-(N-phenyl-N-propylamino)pyrimidine

Yield: 90%

Melting point: 267.6-268.6 °C

IR(KBr) ν cm⁻¹:

50 1639, 1616, 1552, 1532, 1494, 1482, 1421

NMR(90MHz, CDCl₃) δ ppm:

12.96(1H, s), 7.56-7.02(5H, m), 4.01(2H, t, J = 7.6Hz), 2.41(3H, s), 1.83-1.35(2H, m), 0.89(3H, t, J = 7.1Hz)

55

EXAMPLE 31

Preparation of 4-chloro-6-(N,N-diphenylamino)-2-methyl-5-nitropyrimidine

A mixture of the product obtained in EXAMPLE 8 (15g), diphenylamine (12.2g) and potassium carbonate (11.46g) was stirred for 7 hours at 150 °C. After cooling to room temperature, the reaction mixture was dissolved in hot ethyl acetate and the insoluble material was filtered off. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (methylene chloride : hexane = 1:1-3:1) followed by crystallization from ether-hexane to give 4.9g (20%) of the objective compound.

Melting point: 128.0-129.9 °C

IR(KBr) ν cm⁻¹:

1548, 1541, 1508, 1490, 1436, 1397, 1347, 701

NMR(90MHz, CDCl₃) δ ppm:

7.47-7.05(10H, m), 2.48(3H, s)

EXAMPLE 32

Preparation of 4,6-bis(N,N-diethylamino)-2-methyl-5-nitropyrimidine

To a solution of the product obtained in EXAMPLE 8 (5g) and triethylamine (10ml) in THF (50ml), a solution of diethylamine (7.5ml) in THF (20ml) was added dropwise. After stirring for 6 hours at room temperature, diethylamine (5.0ml) and triethylamine (8.4ml) was added and the reaction mixture was stirred for another 17 hours at room temperature. The formed insoluble material was filtered off and the filtrate was concentrated under reduced pressure. The residue was dissolved in ether and washed with water and saturated sodium chloride. After drying over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure to give 6.7g (99%) of the objective compound.

IR(neat) ν cm⁻¹:

2979, 1549, 1507, 1498, 1492, 1459, 1250, 1100

NMR(90MHz, CDCl₃) δ ppm:

3.63(8H, q, J = 7.0Hz), 2.29(3H, s), 1.26(12H, t, J = 7.0Hz)

The following compound was prepared in a similar manner as EXAMPLE 32

EXAMPLE 33

4,6-bis(hexylamino)-2-methyl-5-nitropyrimidine

Yield: 94%

Melting point: 48.2-48.7 °C

IR(KBr) ν cm⁻¹:

3338, 2929, 2855, 1571, 1536, 1263, 1172

NMR(90MHz, CDCl₃) δ ppm:

9.33(2H, br.s), 3.59(4H, dt, J = 5.6 and 6.6Hz), 2.35(3H, s), 1.83-1.08(16H, m), 0.89(6H, t, J = 5.6Hz)

EXAMPLE 34

Preparation of 4-mercapto-2-methyl-5-nitro-6-(N-phenyl-N-propylamino)pyrimidine

To a suspension of sodium hydrosulfide n- hydrate (65.3g) in ethanol (300ml), a solution of the product obtained in EXAMPLE 13 (100g) in ethanol (200ml) was added. After refluxing for 40 minutes, the solvent was evaporated under reduced pressure and the residue was dissolved in water (1500ml). The aqueous solution was acidified to pH 4 with 3N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to give 96.9g (97%) of the objective compound.

IR(neat) ν cm⁻¹:

1605, 1564, 1556, 1539, 1509, 1423, 1335

NMR(90MHz, CDCl₃) δ ppm:

12.56(1H, s), 7.39-6.99(5H, m), 3.96(2H, t, J = 7.6Hz), 2.47(3H, s), 1.87-1.36(2H, m), 0.89(3H, t, J = 7.6Hz)

The following compounds were prepared in a similar manner as EXAMPLE 34.

EXAMPLE 35

5 4-(N,N-dimethylamino)-6-mercapto-2-methyl-5-nitropyrimidine

Yield: 99%

Melting point: 192.5 °C (decomposition)

IR(KBr) ν cm⁻¹:

10 1611, 1579, 1516, 1417, 1401, 1350

NMR(90MHz, CDCl₃) δ ppm:

3.16(6H, s), 2.42(3H, s)

EXAMPLE 36

15

4-(N,N-diethylamino)-6-mercapto-2-methyl-5-nitropyrimidine

yield: 85%

Melting point: 185.6-186.3 °C

20 IR(KBr) ν cm⁻¹:

1617, 1576, 1523, 1482

NMR(90MHz, CDCl₃) δ ppm:

12.47(1H, s), 3.49(4H, q, J = 7.1Hz), 2.42(3H, s), 1.22(6H, t, J = 7.1Hz)

25 EXAMPLE 37

4-(N,N-dipropylamino)-6-mercapto-2-methyl-5-nitropyrimidine

Yield: 80.4%

30 Melting point: 165.5-167.0 °C

IR(KBr) ν cm⁻¹:

2972, 1614, 1570, 1525, 1477, 1333

NMR(90MHz, CDCl₃) δ ppm:

12.53(1H, s), 3.39(4H, t, J = 7.6Hz), 2.41(3H, s), 1.84-1.38(4H, m), 0.89(6H, t, J = 7.3Hz)

35

EXAMPLE 38

4-(N,N-dibutylamino)-6-mercapto-2-methyl-5-nitropyrimidine

40 Yield: 97%

Melting point: 139.5-141.0 °C

IR(KBr) ν cm⁻¹:

2960, 2932, 1619, 1560, 1527

NMR(90MHz, CDCl₃) δ ppm:

45 12.09(1H, s), 3.42(4H, t, J = 7.4Hz), 2.40(3H, s), 1.80-1.05(8H, m), 0.92(6H, t, J = 6.3Hz)

EXAMPLE 39

4-(N,N-dihexylamino)-6-mercapto-2-methyl-5-nitropyrimidine

50

Yield: 96%

Melting point: 81.8-83.6 °C

IR(KBr) ν cm⁻¹:

2956, 2928, 2857, 1611, 1568, 1531

55 NMR(90MHz, CDCl₃) δ ppm:

12.37(1H, s), 3.42(4H, t, J = 7.3Hz), 2.40(3H, s), 1.80-1.08(16H, m), 0.88(6H, t, J = 5.8Hz)

EXAMPLE 40

4-(N,N-diphenylamino)-6-mercapto-2-methyl-5-nitropyrimidine

5 Yield: 90%

Melting point: 205.5-207.9 °C

IR(KBr) ν cm^{-1} :

1604, 1552, 1532, 1488, 1465, 1423, 1195

NMR(90MHz, DMSO- d_6) δ ppm:

10 13.74(1H, s), 7.46-7.06(10H, m), 2.23(3H, s)

EXAMPLE 41

4-(N-benzyl-N-ethylamino)-6-mercapto-2-methyl-5-nitropyrimidine

15 Yield: 93%

Melting point: 136.7-137.6 °C

IR(KBr) ν cm^{-1} :

1605, 1558, 1525, 1477, 1452, 1329

NMR(90MHz, CDCl_3) δ ppm:

20 12.40(1H, br.s), 7.56-7.08(5H, m), 4.82(2H, s), 3.37(2H, q, J = 7.1Hz), 2.40(3H, s), 1.16(3H, t, J = 7.1Hz)

EXAMPLE 42

4-(N-benzyl-N-heptylamino)-6-mercapto-2-methyl-5-nitropyrimidine

25

Yield: 87%

Melting point: 116.2-117.5 °C

IR(KBr) ν cm^{-1} :

2968, 2928, 1635, 1570, 1499

30 NMR(90MHz, CDCl_3) δ ppm:

12.27(1H, s), 7.44-6.96(5H, m), 4.80(2H, s), 3.29(2H, t, J = 7.8Hz), 2.41(3H, s), 1.74-1.02(10H, m), 0.86(3H, t, J = 5.8Hz)

EXAMPLE 43

35

4-(N-butylamino)-6-mercapto-2-methyl-5-nitropyrimidine

Yield: 60%

Melting point: 209.8-212.4 °C

40 IR(KBr) ν cm^{-1} :

3315, 2958, 1598, 1546, 1542, 1140

NMR(90MHz, DMSO- d_6) δ ppm:

13.07(1H, br.s), 8.39(1H, t, J = 5.3Hz), 3.43(2H, q, J = 6.3Hz), 2.31(3H, s), 1.68-1.02(4H, m), 0.95(3H, t, J = 6.6Hz)

45

EXAMPLE 44

4-mercapto-2-methyl-6-morpholino-5-nitropyrimidine

50 Yield: 97%

Melting point: 213.2-216.9 °C

IR(KBr) ν cm^{-1} :

3190, 1607, 1571, 1517, 1423, 1320

NMR(90MHz, DMSO- d_6) δ ppm:

55 13.31(1H, br.s), 3.72-3.36(8H, m), 2.32(3H, s)

EXAMPLE 45

4-mercapto-2-methyl-6-(4-methyl-piperazinyl)-5-nitropyrimidine

- 5 Yield: 100%
 Melting point: 234.2-243.2 °C
 IR(KBr) ν cm^{-1} :
 3384, 1615, 1595, 1561, 1522, 978
 NMR(90MHz, DMSO- d_6) δ ppm:
 10 3.51-3.06(8H, m), 2.75(3H, s), 2.36(3H, s)

EXAMPLE 46

4-mercapto-5-nitro-6-(N-phenyl-N-propylamino)pyrimidine

- 15 Yield: 92%
 Melting point: 136.7-139.2 °C
 IR(KBr) ν cm^{-1} :
 1610, 1555, 1530, 1509
 20 NMR(90MHz, CDCl_3) δ ppm:
 7.88(1H, s), 7.44-7.00(5H, m), 3.96(2H, t, J = 7.6Hz), 1.80-1.32(2H, m), 0.90(3H, t, J = 7.3Hz)

EXAMPLE 47

- 25 4-(N,N-diethylamino)-6-mercapto-5-nitropyrimidine

- Yield: 88%
 Melting point: 146.1-148.2 °C
 IR(KBr) ν cm^{-1} :
 30 1618, 1566, 1520, 1423, 1335, 1032
 NMR(90MHz, DMSO- d_6) δ ppm:
 13.45(1H, br.s), 8.08(1H, s), 3.43(4H, q, J = 6.9Hz), 1.13(6H, t, J = 6.9Hz)

EXAMPLE 48

- 35 4-(N,N-dibutylamino)-6-mercapto-5-nitropyrimidine

- Yield: 86%
 Melting point: 97.3-99.4 °C
 40 IR(KBr) ν cm^{-1} :
 2958, 1616, 1562, 1533, 1479, 1335, 1038
 NMR(90MHz, CDCl_3) δ ppm:
 12.61(1H, br.s), 7.80(1H, s), 3.43(4H, t, J = 7.4Hz), 1.83-1.08(8H, m), 0.92(6H, t, J = 6.3Hz)

45 EXAMPLE 49

4-(N,N-diethylamino)-6-mercapto-2-methoxy-5-nitropyrimidine

- Yield: 93%
 50 Melting point: 145.5-145.8 °C
 IR(KBr) ν cm^{-1} :
 1612, 1566, 1524, 1342, 1327, 1032
 NMR(90MHz, DMSO- d_6) δ ppm:
 13.20(1H, br.s), 3.93(3H, s), 3.42(4H q, J = 7.0Hz), 1.15(6H, t, J = 7.0Hz)
 55

EXAMPLE 50

4-(N,N-diethylamino)-6-mercapto-2-methylthio-5-nitropyrimidine

- 5 Yield: 95%
 Melting point: 143.9-144.3 °C
 IR(KBr) ν cm^{-1} :
 1566, 1527, 1438, 1412, 1333, 1230
 NMR(90MHz, DMSO- d_6) δ ppm:
 10 13.61(1H, s), 3.44(4H, q, J = 7.0Hz), 2.51(3H, s), 1.15(6H, t, J = 7.0Hz)

EXAMPLE 51

Preparation of 4,6-dimercapto-2-methyl-5-nitropyrimidine

- 15 Starting from the product obtained in EXAMPLE 8, the objective compound was prepared in a similar manner as EXAMPLE 34.
 Yield: 99%
 Melting point: >300 °C
 20 IR(KBr) ν cm^{-1} :
 1624, 1618, 1601, 1579, 1542, 1535, 1353, 1158
 NMR(90MHz, DMSO- d_6) δ ppm:
 2.39(3H, s)

25 EXAMPLE 52

Preparation of 4-(N,N-diethylamino)-2-(N,N-dimethylamino)-6-mercapto-5-nitropyrimidine

- Starting from 4-chloro-6-(N,N-diethylamino)-2-(N,N-dimethylamino)-5-nitropyrimidine (prepared in a similar manner as EXAMPLE 13 by using the product obtained in EXAMPLE 9 as a starting substrate), the objective compound was prepared in a similar manner as EXAMPLE 34.
 Yield: 52%
 Melting point: 152.3 °C (decomposition)
 IR(KBr) ν cm^{-1} :
 35 2933, 1608, 1562, 1514, 1444, 1327
 NMR(90MHz, CDCl_3) δ ppm:
 3.42(4H, q, J = 6.9Hz), 3.17(6H, s), 1.22(6H, t, J = 6.9Hz)
 The following compound was prepared in a similar manner as EXAMPLE 52

40 EXAMPLE 53

4-(N,N-dibutylamino)-2-(N,N-dimethylamino)-6-mercapto-5-nitropyrimidine

- Yield: 43%
 45 Melting point: 153.0-153.6 °C
 IR(KBr) ν cm^{-1} :
 2960, 1614, 1556, 1512, 1454
 NMR(90MHz, DMSO- d_6) δ ppm:
 11.2(1H, s), 3.48-3.12(4H, m), 3.10(6H, s), 1.74-0.84(8H, m), 0.87(6H, t, J = 5.9Hz)

50 EXAMPLE 54

Preparation of 2-methyl-4-methylthio-5-nitro-6-(N-phenyl-N-propylamino)pyrimidine

- 55 To a solution of the product obtained in EXAMPLE 13 (1.0g) in methanol (100ml), 15% aqueous sodium methanethiolate (15ml) was added. After stirring for 1 hour at room temperature, the solvent was evaporated under reduced pressure and the residue was dissolved in ethyl acetate. The solution was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced

pressure to give 0.98g (95%) of the objective compound.

Melting point: 116.9-118.9 °C

IR(KBr) ν cm^{-1} :

1542, 1510, 1491, 1424, 1340, 1214, 1061, 836, 700

5 NMR(90MHz, CDCl_3) δ ppm:

7.46-6.94(5H, m), 4.04(2H, t, $J=7.4\text{Hz}$), 2.57(3H, s), 2.49(3H, s), 1.67-1.44(2H, m), 0.92(3H, t, $J=7.3\text{Hz}$)

EXAMPLE 55

10 Preparation of 4,6-dimethoxy-2-methyl-5-nitropyrimidine

To a solution of potassium hydroxide (9.5g) in ethanol (95ml), the product obtained in EXAMPLE 8 (10g) was added under ice-cooling and the mixture was stirred for 15 minutes. The solvent was evaporated under reduced pressure and the residue was dissolved in water. The aqueous solution was neutralized with
15 2N hydrochloric acid and extracted with ethyl acetate. The organic layers were collected to wash with water and saturated sodium chloride. After drying over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and the residue was crystallized from ether to give 7.5g (78%) of the objective compound.

Melting point: 113.5-115.2 °C

20 IR(KBr) ν cm^{-1} :

1578, 1568, 1530, 1392, 1375, 1341, 1252, 1141

NMR(90MHz, CDCl_3) δ ppm:

4.05(6H, s), 2.55(3H, s)

The following compounds were prepared in a similar manner as EXAMPLE 55.

25

EXAMPLE 56

4-methoxy-2-methyl-5-nitro-6-(N-phenyl-N-propylamino)pyrimidine

30 Yield: 93%

Melting point: 133.3-135.0 °C

IR(KBr) ν cm^{-1} :

1574, 1543, 1496, 1377, 1336, 1192

NMR(90MHz, CDCl_3) δ ppm:

35 7.46-6.99(5H, m), 3.97(2H, t, $J=7.6\text{Hz}$), 3.95(3H, s), 2.51(3H, s), 1.89-1.39(2H, m), 0.91(3H, t, $J=7.3\text{Hz}$)

EXAMPLE 57

4-(N,N-diethylamino)-6-methoxy-2-methyl-5-nitropyrimidine

40

Yield: 100%

IR(neat) ν cm^{-1} :

2975, 2934, 1583, 1552, 1523

NMR(90MHz, CDCl_3) δ ppm:

45 3.96(3H, s), 3.43(4H, q, $J=6.9\text{Hz}$), 2.42(3H, s), 1.18(6H, t, $J=6.9\text{Hz}$)

EXAMPLE 58

4-(N,N-dipropylamino)-6-methoxy-2-methyl-5-nitropyrimidine

50

Yield: 97%

IR(neat) ν cm^{-1} :

1585, 1551, 1524, 1377, 1119

NMR(90MHz, CDCl_3) δ ppm:

55 3.96(3H, s), 3.33(4H, t, $J=7.4\text{Hz}$), 2.41(3H, s), 1.83-1.38(4H, m), 0.87(6H, t, $J=7.3\text{Hz}$)

EXAMPLE 59

4-(N,N-dibutylamino)-6-methoxy-2-methyl-5-nitropyrimidine

5 Yield: 98%

IR(neat) ν cm^{-1} :

3410, 2960, 1597, 1375, 1120, 839, 787

NMR(90MHz, CDCl_3) δ ppm:

3.96(3H, s), 3.37(4H, t, J = 7.3Hz), 2.41(3H, s), 1.74-1.02(8H, m), 0.92(6H, t, J = 6.3Hz)

10

EXAMPLE 60

4-(N,N-dibutylamino)-6-ethoxy-2-methyl-5-nitropyrimidine

15 Yield: 96%

IR(neat) ν cm^{-1} :

2960, 2873, 1581, 1549, 1524, 1379, 1344, 1120

NMR(90MHz, CDCl_3) δ ppm:

4.42(2H, q, J = 7.1Hz), 3.37(4H, t, J = 7.3Hz), 2.40(3H, s), 1.34(3H, t, J = 7.1Hz), 1.75-0.96(8H, m), 0.92(6H, t,

20 J = 6.3Hz)

EXAMPLE 61

4-(N,N-dibutylamino)-6-ethoxy-5-nitropyrimidine

25

Yield: 87%

IR(neat) ν cm^{-1} :

2960, 1587, 1537, 1506, 1470, 1444, 1101

NMR(270MHz, CDCl_3) δ ppm:

30 8.19(1H, s), 4.44(2H, q, J = 7.1Hz), 3.37(4H, t, J = 7.8Hz), 1.62-1.49(4H, m), 1.37(3H, t, J = 7.1Hz), 1.38-1.20-(4H, m), 0.92(6H, t, J = 7.3Hz)

EXAMPLE 62

35 4-(N,N-diethylamino)-6-methoxy-2-methylthio-5-nitropyrimidine

Yield: 98%

IR(neat) ν cm^{-1} :

1572, 1518, 1435, 1379, 1327, 1304, 1254, 1109

40 NMR(90MHz, CDCl_3) δ ppm:

3.97(3H, s), 3.43(4H, q, J = 7.1Hz), 2.49(3H, s), 1.20(6H, t, J = 7.1Hz)

EXAMPLE 63

45 4-(N,N-diethylamino)-2,6-dimethoxy-5-nitropyrimidine

Yield: 84%

IR(neat) ν cm^{-1} :

1591, 1560, 1524, 1456, 1385, 1352, 1209, 1109

50 NMR(90MHz, CDCl_3) δ ppm:

3.99(3H, s), 3.94(3H, s), 3.43(4H, q, J = 7.1Hz), 1.22(6H, t, J = 7.1Hz)

EXAMPLE 64

55 Preparation of 2-methyl-4-methylthio-5-nitro-6-(N-phenyl-N-propylamino)pyrimidine

Methyl iodide (4.6ml) was added slowly to a solution of the product obtained in EXAMPLE 34 (15g) and triethylamine (8.1ml) in methylene chloride (200ml) and the mixture was stirred for 1 hour at room

temperature. The solution was washed with water and saturated sodium chloride. After drying over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and the residual crystal was washed with ether to give 13.5g (86%) of the objective compound.

Melting point: 116.9-118.9 °C

5 IR(KBr) ν cm^{-1} :

1542, 1510, 1491, 1424, 1340, 1214, 1061, 836, 700

NMR(90MHz, CDCl_3) δ ppm:

7.46-6.94(5H, m), 4.04(2H, t, J = 7.4Hz), 2.57(3H, s), 2.49(3H, s), 1.67-1.44(2H, m), 0.92(3H, t, J = 7.3Hz)

The following compounds were prepared in a similar manner as EXAMPLE 64.

10

EXAMPLE 65

2-methyl-4,6-bis(methylthio)-5-nitropyrimidine

15 Yield: 73%

Melting point: 181.8-184.7 °C

IR(KBr) ν cm^{-1} :

1525, 1519, 1507, 1329, 1311, 1202, 826

NMR(90MHz, CDCl_3) δ ppm:

20 2.68(3H, s), 2.55(6H, s)

EXAMPLE 66

4,6-bis(hexylthio)-2-methyl-5-nitropyrimidine

25

Yield: 19%

Melting point: 28.4-31.5 °C

IR(KBr) ν cm^{-1} :

2930, 1534, 1498, 1322, 823

30 NMR(90MHz, CDCl_3) δ ppm:

3.17(4H, t, J = 7.1Hz), 2.64(3H, s), 1.98-1.08(16H, m), 0.90(6H, t, J = 5.8Hz)

EXAMPLE 67

35 Preparation of 4-mercapto-2-methyl-5-nitro-6-propylthiopyrimidine

To a solution of the product obtained in EXAMPLE 51 (4.87g) in DMF (100ml), sodium hydride (60% NaH dispersion in mineral oil; 1.13g) was added under ice-cooling and under nitrogen atmosphere. After stirring for 20 minutes, a solution of n-propyl bromide (2.35ml) in DMF (10ml) was added dropwise to the mixture and the resulting mixture was stirred for 1 hour under ice-cooling and for 1.5 hour at room temperature.

40

The reaction mixture was diluted with water, acidified to pH 3 with concentrated hydrochloric acid and then extracted three times with ethyl acetate. The collected organic layer was washed with water and saturated sodium chloride and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate : hexane = 1:2 - 1:1) to give 1.31g (23%) of the objective compound.

45

Melting point: 161.5-163.7 °C

IR(KBr) ν cm^{-1} :

2965, 1560, 1534, 1527, 1420, 1357, 858

50 NMR(90MHz, CDCl_3) δ ppm:

3.19(2H, t, J = 7.3Hz), 2.55(3H, s), 1.73(2H, q, J = 7.3Hz), 1.03(3H, t, J = 7.3Hz)

EXAMPLE 68

55 Preparation of 5-amino-2-methyl-4-mercapto-6-(N-phenyl-N-propylamino)pyrimidine

To a solution of the product obtained in EXAMPLE 34 (96.6g) in acetic acid (1000ml), zinc powder (103.7g) was added portionwise under ice-cooling. After stirring for 17 hours at room temperature, the

insoluble materials were filtered off and washed with ethyl acetate. The filtrate was concentrated under reduced pressure and the residue was dissolved in ethyl acetate. The solution was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was crystallized from methylene chloride-hexane and washed with hexane to give

31.8g (37%) of the objective compound.

Melting point: 183.7-185.0 °C

IR(KBr) ν cm^{-1} :

1596, 1565, 1561, 1496, 1451, 1423, 1119

NMR(90MHz, CDCl_3) δ ppm:

7.46-6.81(5H, m), 4.03- 3.56(4H, m), 2.50(3H, s), 1.88-1.42(2H, m), 0.91(3H, t, J = 7.6Hz)

The following compounds were prepared in a similar manner as EXAMPLE 68.

EXAMPLE 69

5-amino-4-(N,N-dimethylamino)-6-mercapto-2-methylpyrimidine

Yield: 68%

Melting point: 193.4 °C (decomposition)

IR(KBr) ν cm^{-1} :

1568, 1523, 1393, 1382, 1145, 923

NMR(90MHz, $\text{DMSO}-d_6$) δ ppm:

13.09(1H, s), 4.62(2H, s), 2.96(6H, s), 2.28(3H, s)

EXAMPLE 70

5-amino-4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidine

Yield: 83%

Melting point: 172.1-173.2 °C

IR(KBr) ν cm^{-1} :

3305, 1577, 1506, 1429

NMR(90MHz, CDCl_3) δ ppm:

12.81(1H, s), 4.12(2H, s), 3.51(4H, q, J = 7.0Hz), 2.44(3H, s), 1.16(6H, t, J = 7.0Hz)

EXAMPLE 71

5-amino-4-(N,N-dipropylamino)-6-mercapto-2-methylpyrimidine

Yield: 83%

Melting point: 144.1-144.7 °C

IR(KBr) ν cm^{-1} :

2960, 2873, 1570, 1500, 1419, 1358, 1142

NMR(90MHz, CDCl_3) δ ppm:

12.48(1H, br.s), 4.11(2H, br.s), 3.42(4H, t, J = 7.4Hz), 2.43(3H, s), 1.80-1.32(4H, m), 0.87(6H, t, J = 7.1Hz)

EXAMPLE 72

5-amino-4-(N,N-dibutylamino)-6-mercapto-2-methylpyrimidine

Yield: 76%

Melting point: 140.6-141.8 °C

IR(KBr) ν cm^{-1} :

3310, 3012, 2958, 2931, 2873, 1571, 1499

NMR(90MHz, CDCl_3) δ ppm:

3.45(4H, t, J = 7.1Hz), 2.41(3H, s), 1.74- 1.02(8H, m), 0.92(6H, t, J = 6.6Hz)

EXAMPLE 73

5-amino-4-(N,N-dihexylamino)-6-mercapto-2-methylpyrimidine

5 Yield: 75%

Melting point: 112.2-113.0 °C

IR(KBr) ν cm^{-1} :

3308, 3016, 2929, 1572, 1498, 1422, 1144

NMR(90MHz, CDCl_3) δ ppm:

10 12.57(1H, s), 4.10(2H, br.s), 3.45(4H, t, J = 7.3Hz), 2.43(3H, s), 1.71- 1.05(16H, m), 0.87(6H, t, J = 5.4Hz)

EXAMPLE 74

5-amino-4-(N,N-diphenylamino)-6-mercapto-2-methylpyrimidine

15

Yield: 78%

Melting point: 239.4-242.5 °C

IR(KBr) ν cm^{-1} :

1577, 1559, 1491, 1396, 1376, 1229, 1121, 696

20 NMR(90MHz, $\text{DMSO}-d_6$) δ ppm:

13.75(1H, s), 7.38-6.88(10H, m), 4.20(2H, br.s), 2.24(3H, s)

EXAMPLE 75

25 5-amino-4-(N-benzyl-N-ethylamino)-6-mercapto-2-methylpyrimidine

Yield: 93%

Melting point: 148.9-149.7 °C

IR(KBr) ν cm^{-1} :

30 3005, 2881, 1560, 1498, 1450, 1354

NMR(90MHz, $\text{DMSO}-d_6$) δ ppm:

13.20(1H, br.s), 7.40-7.04(5H, m), 4.65(2H, s), 3.40(2H, q, J = 7.1Hz), 2.26(3H, s), 1.05(3H, t, J = 7.1Hz)

EXAMPLE 76

35

5-amino-4-(N-benzyl-N-heptylamino)-6-mercapto-2-methylpyrimidine

Yield: 80%

Melting point: 138.9-140.3 °C

40 IR(KBr) ν cm^{-1} :

3324, 2928, 1559, 1527

NMR(90MHz, CDCl_3) δ ppm:

12.14(1H, s), 7.48-7.14(5H, m), 4.76(2H, s), 4.16(2H, br.s), 3.42(2H, t, J = 7.4Hz), 2.41(3H, s), 1.74- 1.02(10H, m), 0.87(3H, t, J = 5.9Hz)

45

EXAMPLE 77

5-amino-4-(N-butylamino)-6-mercapto-2-methylpyrimidine

50 Yield: 12%

Melting point: 216.8-231.9 °C

IR(KBr) ν cm^{-1} :

3330, 2953, 2929, 2871, 1630, 1588

NMR(90MHz, $\text{DMSO}-d_6$) δ ppm:

55 12.61(1H, s), 6.51(1H, t, J = 6.4Hz), 4.52(2H, br.s), 3.54-3.12(2H, m), 2.26(3H, s), 1.71- 1.11(4H, m), 0.90(3H, t, J = 6.3Hz)

EXAMPLE 78

5-amino-4-mercapto-2-methyl-6-morpholinopyrimidine

- 5 Yield: 87%
 Melting point: 203.1-205.8 °C
 IR(KBr) ν cm^{-1} :
 2892, 1575, 1439, 1344, 1109, 916
 NMR(90MHz, CDCl_3) δ ppm:
 10 12.84(1H, br.s), 3.87-3.36(8H, m), 2.47(3H, s)

EXAMPLE 79

5-amino-4-mercapto-2-methyl-6-(4-methylpiperazinyl)pyrimidine

- 15 Yield: 45%
 Melting point: 237.9-242.8 °C
 IR(KBr) ν cm^{-1} :
 3464, 3433, 1637, 1589, 1564, 1433
 20 NMR(90MHz, CDCl_3) δ ppm:
 4.59(2H, br.s), 3.45-3.24(4H, m), 2.52-2.34(4H, m), 2.28(3H, s), 2.19(3H, s)

EXAMPLE 80

- 25 5-amino-4-mercapto-6-(N-phenyl-N-propylamino)pyrimidine

- Yield: 58%
 Melting point: 176.4-178.9 °C
 IR(KBr) ν cm^{-1} :
 30 1579, 1550, 1450, 1422, 1118
 NMR(90MHz, CDCl_3) δ ppm:
 7.81(1H, s), 7.47-6.90(5H, m), 4.05(2H, br.s), 3.95(2H, t, J = 7.6Hz), 1.82-1.38(2H, m), 0.92(3H, t, J = 7.3Hz)

EXAMPLE 81

- 35 5-amino-4-(N,N-diethylamino)-6-mercaptopyrimidine

- Yield: 85%
 Melting point: 201.1-202.1 °C
 40 IR(KBr) ν cm^{-1} :
 2968, 2889, 1591, 1552, 1506, 1429, 1373, 1120
 NMR(90MHz, $\text{DMSO}-d_6$) δ ppm:
 13.32(1H, br.s), 7.76(1H, s), 3.40(4H, q, J = 6.9Hz), 1.06(6H, t, J = 6.9Hz)

- 45 EXAMPLE 82

5-amino-4-(N,N-dibutylamino)-6-mercaptopyrimidine

- Yield: 57%
 50 Melting point: 122.1-122.6 °C
 IR(KBr) ν cm^{-1} :
 2956, 2872, 1587, 1552, 1504, 1427, 1358
 NMR(90MHz, CDCl_3) δ ppm:
 7.74(1H, s), 4.30(2H, br.s), 3.42(4H, t, J = 7.3Hz), 1.77-1.08(8H, m), 0.91(6H, t, J = 6.3Hz)
 55

EXAMPLE 83

5-amino-4-(N,N-diethylamino)-2-(N,N-dimethylamino)-6-mercaptopyrimidine

5 Yield: 72%

Melting point: 161.0-162.1 °C

IR(KBr) ν cm^{-1} :

2962, 1591, 1564, 1516, 1348, 1325

NMR(90MHz, CDCl_3) δ ppm:

10 3.62(4H, q, J = 6.9Hz), 3.08(6H, s), 1.20(6H, t, J = 6.9Hz)

EXAMPLE 84

5-amino-4-(N,N-dibutylamino)-2-(N,N-dimethylamino)-6-mercaptopyrimidine

15

Yield: 74%

Melting point: 140.1-142.9 °C

IR(KBr) ν cm^{-1} :

2956, 2931, 1593, 1566, 1504, 1331

20 NMR(90MHz, DMSO-d_6) δ ppm:

11.0(1H, br.s), 4.02(2H, br.s), 3.50(4H, t, J = 6.9Hz), 3.00(6H, s), 1.80-0.96(8H, m), 0.88(6H, t, J = 5.9Hz)

EXAMPLE 85

25 5-amino-4-(N,N-diethylamino)-6-mercapto-2-methoxypyrimidine

Yield: 41%

Melting point: 147.4-151.9 °C

IR(KBr) ν cm^{-1} :

30 1618, 1570, 1514, 1425, 1340, 1026

NMR(90MHz, DMSO-d_6) δ ppm:

12.82(1H, br.s), 4.16(2H, br.s), 3.83(3H, s), 3.56(4H, q, J = 6.9Hz), 1.14(6H, t, J = 6.9Hz)

EXAMPLE 86

35

5-amino-4-(N,N-diethylamino)-6-mercapto-2-methylthiopyrimidine

Yield: 58%

Melting point: 166.6-172.1 °C

40 IR(KBr) ν cm^{-1} :

2868, 2850, 1549, 1512, 1423, 1344, 1313

NMR(90MHz, DMSO-d_6) δ ppm:

13.30(1H, br.s), 4.41(2H, br.s), 3.50(4H, q, J = 6.9Hz), 2.46(3H, s), 1.11(6H, t, J = 6.9Hz)

45 EXAMPLE 87

5-amino-4-methoxy-2-methyl-6-(N-phenyl-N-propylamino)pyrimidine

Yield: 56%

50 Melting point: 55.9-57.5 °C

IR(KBr) ν cm^{-1} :

1575, 1492, 1471, 1426, 1405, 1203

NMR(90MHz, CDCl_3) δ ppm:

7.39-6.71(5H, m), 3.99(3H, s), 3.91(2H, t, J = 7.6Hz), 3.04(2H, br.s), 2.49(3H, s), 1.92-1.44(2H, m), 0.92(3H, t, J = 7.3Hz)

EXAMPLE 88

5-amino-4-(N,N-diethylamino)-6-methoxy-2-methylpyrimidine

5 Yield: 62%

IR(neat) ν cm^{-1} :

3426, 3338, 1579, 1467, 1428, 1211

NMR(90MHz, CDCl_3) δ ppm:3.97(3H, s), 3.54- 3.06(2H, m), 3.27(4H, q, $J = 6.9\text{Hz}$), 2.44(3H, s), 1.07(6H, t, $J = 6.9\text{Hz}$)

10

EXAMPLE 89

5-amino-4-(N,N-dipropylamino)-6-methoxy-2-methylpyrimidine

15 Yield: 86%

IR(neat) ν cm^{-1} :

2960, 1579, 1470, 1427, 1203

NMR(90MHz, CDCl_3) δ ppm:3.96(3H, s), 3.30(2H, br.s), 3.18(4H, t, $J = 7.3\text{Hz}$), 2.43(3H, s), 1.74-1.26(4H, m), 0.86(6H, t, $J = 7.3\text{Hz}$)

20

EXAMPLE 90

5-amino-4-(N,N-dibutylamino)-6-methoxy-2-methylpyrimidine

25 Yield: 79%

IR(neat) ν cm^{-1} :

3433, 3342, 2958, 2870, 1579, 1470, 1427, 1196

NMR(90MHz, CDCl_3) δ ppm:3.96(3H, s), 3.27(2H, br.s), 3.21(4H, t, $J = 7.3\text{Hz}$), 2.43(3H, s), 1.67-1.03(8H, m), 0.89(6H, t, $J = 5.9\text{Hz}$)

30

EXAMPLE 91

5-amino-4-(N,N-dibutylamino)-6-ethoxy-2-methylpyrimidine

35 Yield: 82%

IR(neat) ν cm^{-1} :

2958, 2929, 2872, 1578, 1443, 1381, 1196, 1072

NMR(90MHz, CDCl_3) δ ppm:4.39(2H, q, $J = 7.1\text{Hz}$), 3.20(4H, t, $J = 7.3\text{Hz}$), 3.12(2H, br.s), 2.41(3H, s), 1.39(3H, t, $J = 7.1\text{Hz}$), 1.74- 1.02(8H,

40

m), 0.89(6H, t, $J = 5.6\text{Hz}$)

EXAMPLE 92

5-amino-4-(N,N-dibutylamino)-6-ethoxy-pyrimidine

45

Yield: 42%

IR(neat) ν cm^{-1} :

2956, 2929, 1578, 1450, 1383, 1194, 1053

NMR(90MHz, CDCl_3) δ ppm:50 8.05(1H, s), 4.43(2H, q, $J = 7.0\text{Hz}$), 3.49(2H, br.s), 3.22(4H, t, $J = 7.1\text{Hz}$), 1.89-1.05(8H, m), 1.42(3H, t, $J = 7.0\text{Hz}$), 0.89(6H, t, $J = 5.9\text{Hz}$)

EXAMPLE 93

55 5-amino-4-(N,N-diethylamino)-6-methoxy-2-methylthiopyrimidine

Yield: 90.5%

IR(neat) ν cm^{-1} :

1568, 1462, 1416, 1387, 1336, 1306, 1211

NMR(90MHz, CDCl₃) δ ppm:

3.96(3H, s), 3.33(4H, q, J = 7.0Hz), 2.50(3H, s), 1.10(6H, t, J = 7.0Hz)

5 EXAMPLE 94

5-amino-4-(N,N-diethylamino)-2,6-dimethoxypyrimidine

Yield: 91%

10 IR(neat) ν cm⁻¹:

2970, 1589, 1466, 1396, 1375, 1217, 1088

NMR(90MHz, CDCl₃) δ ppm:

3.97(3H, s), 3.87(3H, s), 3.40(4H, q, J = 7.1Hz), 1.13(6H, t, J = 7.1Hz)

15 EXAMPLE 95

5-amino-2-methyl-4-methylthio-6-(N-phenyl-N-propylamino)pyrimidine

Yield: 49%

20 Melting point: 66.5-67.4 °C

IR(KBr) ν cm⁻¹:

1598, 1541, 1487, 1425, 1401, 1216, 1116

NMR(90MHz, CDCl₃) δ ppm:

7.41-6.86(5H, m), 3.92(2H, t, J = 7.3Hz), 3.09(2H, br.s), 2.61(3H, s), 2.55(3H, s), 1.86-1.37(2H, m), 0.92(3H, t,

25 J = 7.3Hz)

EXAMPLE 96

5-amino-4,6-bis(N,N-diethylamino)-2-methylpyrimidine

30

Yield: 93%

IR(neat) ν cm⁻¹:

2967, 2931, 1570, 1459, 1432, 1421, 1224

NMR(90MHz, CDCl₃) δ ppm:

35 3.27(8H, q, J = 7.0Hz), 2.43(3H, s), 1.09(12H, t, J = 7.0Hz)

EXAMPLE 97

5-amino-4,6-bis(hexylamino)-2-methylpyrimidine

40

Yield: 52%

Melting point: 65.0-65.7 °C

IR(KBr) ν cm⁻¹:

3326, 2927, 2856, 1593, 1500, 1419, 1190

45 NMR(90MHz, CDCl₃) δ ppm:

4.77(2H, br.s), 3.40(4H, dt, J = 5.9 and 6.4Hz), 2.39(3H, s), 1.56-1.02(16H, m), 0.89(6H, t, J = 4.9Hz)

EXAMPLE 98

50 5-amino-4-hydroxy-2-methyl-6-(N-phenyl-N-propylamino)pyrimidine

Yield: 80%

Melting point: 93.8-96.7 °C

IR(KBr) ν cm⁻¹:

55 1654, 1648, 1490, 1405

NMR(90MHz, CDCl₃) δ ppm:

7.44-7.11(3H, m), 7.02-6.72(2H, m), 3.88(2H, t, J = 7.4Hz), 2.84(2H, br.s), 2.42(3H, s), 1.95-1.41(2H, m), 9.93-(3H, t, J = 7.4Hz)

EXAMPLE 99

5-amino-4-mercapto-2-methyl-6-propylthiopyrimidine

5 Yield: 91%

Melting point: 178.3-180.2 °C

IR(KBr) ν cm^{-1} :

3404, 3305, 2869, 1571, 1550, 1344, 1295, 1281, 1104

NMR(90MHz, CDCl_3) δ ppm:10 12.27(1H, s), 4.56(2H, br.s), 3.20(2H, t, $J = 7.1\text{Hz}$), 2.49(3H, s), 1.84-1.54(2H, m), 1.03(3H, t, $J = 7.3\text{Hz}$)

EXAMPLE 100

5-amino-4,6-bis(methylthio)-2-methylpyrimidine

15

Yield: 27%

Melting point: 123.3-124.0 °C

IR(KBr) ν cm^{-1} :

3363, 3282, 3196, 2920, 1532, 1418, 1363, 798

20 NMR(90MHz, CDCl_3) δ ppm:

3.61(2H, br.s), 2.61(6H, s), 2.55(3H, s)

EXAMPLE 101

25 5-amino-4,6-bis(hexylthio)-2-methylpyrimidine

Yield: 31%

IR(neat) ν cm^{-1} :

2930, 1526, 1523, 1419

30 NMR(90MHz, CDCl_3) δ ppm:3.64(2H, br.s), 3.24(4H, t, $J = 7.1\text{Hz}$), 2.52(3H, s), 2.04-1.08(16H, m), 0.89(6H, t, $J = 5.6\text{Hz}$)

EXAMPLE 102

35 5-amino-4,6-dimethoxy-2-methylpyrimidine

Yield: 26%

Melting point: 98.2-98.8 °C

IR(KBr) ν cm^{-1} :

40 1592, 1487, 1437, 1377, 1188, 1076

NMR(90MHz, CDCl_3) δ ppm:

3.97(6H, s), 3.34(2H, br.s), 2.45(3H, s)

EXAMPLE 103

45

5-amino-4-chloro-6-(N,N-dimethylamino)pyrimidine

Yield: 10%

Melting point: 117.8-118.0 °C

50 IR(KBr) ν cm^{-1} :

3370, 1627, 1557, 1531, 1403, 975

NMR(90MHz, CDCl_3) δ ppm:

8.11(1H, s), 3.82(2H, br.s), 2.96(6H, s)

55

EXAMPLE 104

Preparation of 5-amino-4-(N,N-dimethylamino)-6-hexylaminopyrimidine

5 A suspension of the product obtained in EXAMPLE 103 (280mg) and hexylamine (2ml) was refluxed for 7 hours. After cooling to room temperature, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:1) followed by crystallization from ether-hexane to give 220mg (57%) of the objective compound.

10 Melting point: 123.2-124.8 °C

IR(KBr) ν cm^{-1} :

3367, 3327, 2929, 1583, 1446, 1417, 1335

NMR(90MHz, CDCl_3) δ ppm:

15 8.14(1H, s), 4.41(1H, br.s), 3.54-3.24(2H, m), 2.80(6H, s), 1.80-1.05(8H, m), 1.05-0.72(3H, m)

EXAMPLE 105

Preparation of 5-amino-4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidine

20 Starting from the product obtained in EXAMPLE 70, the objective compound was prepared in a similar manner as EXAMPLE 64.

Yield: 98%

IR(neat) ν cm^{-1} :

25 2967, 2929, 1542, 1430, 1375, 1364

NMR(90MHz, CDCl_3) δ ppm:

3.50(2H, br.s), 3.27(4H, q, J = 7.0Hz), 2.60(3H, s), 2.48(3H, s), 1.09(6H, t, J = 7.0Hz)

EXAMPLE 106

30 Preparation of 4-hydroxy-6-isopropyl-2-methyl-5-phenylazopyrimidine

To a solution of aniline (17.66g) in 3N hydrochloric acid (210ml), a solution of sodium nitrite (13.1g) in water (40ml) was added dropwise under ice-cooling to give the solution of diazonium salt. To a solution of ethyl isobutyrylacetate (30g) in ethanol (190ml), a solution of sodium acetate (136g) in water (75ml) was added and then the solution of diazonium salt was added dropwise under ice-cooling. After stirring for 30 minutes under ice-cooling, the reaction mixture was diluted with water and extracted twice with ethyl acetate. The combined organic layer was washed with water, saturated sodium bicarbonate and saturated sodium chloride in order, dried over anhydrous sodium sulfate and then concentrated under reduced pressure to give the phenylazo- β -ketoester derivative. 28g (55%) of the objective compound was prepared from above obtained β -ketoester derivative in a similar manner as EXAMPLE 1.

40 Melting point: 171.3 °C (decomposition)

IR(KBr) ν cm^{-1} :

3473, 2966, 1654, 1581, 1545, 1457, 1431

45 NMR(90MHz, CDCl_3) δ ppm:

7.98-7.14(2H, m), 7.62-7.38(3H, m), 4.71(1H, s), 4.20-3.60(1H, m), 2.60(3H, s), 1.31(6H, d, J = 6.6Hz)

EXAMPLE 107

50 Preparation of 5-amino-4-hydroxy-6-isopropyl-2-methylpyrimidine

To a suspension of the product obtained in EXAMPLE 106 (5.0g) in 3N aqueous sodium hydroxide (10ml), sodium hydrosulfite (10g) was added and the mixture was stirred for 5 hours under reflux. After the addition of sodium hydrosulfite (5.0g), the mixture was stirred for another 2 hours under reflux. The reaction mixture was poured into ice-water and extracted three times with ethyl acetate. The combined organic layer was washed with saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:1 to ethyl acetate) followed by crystallization from ether-hexane to give 1.6g (49%) of the

objective compound.

Melting point: 170.9-171.6 °C

IR(KBr) ν cm^{-1} :

3368, 2965, 1670, 1606, 1588, 1309

5 NMR(90MHz, CDCl_3) δ ppm:

12.85(1H, br.s), 3.56(2H, br.s), 3.06-2.70(3H, s), 1.22(6H, d, $J = 6.9\text{Hz}$)

EXAMPLE 108

10 Preparation of ethyl 2-(N-phenyl-N-propylamino)acetate

To a solution of N-propylaniline (60g) and ethyl bromoacetate (83.6ml) in dioxane (60ml), diazabicycloundecene (DBU;113ml) was added dropwise under ice-cooling. After stirring for 1 hour at room temperature, the reaction mixture was diluted with water and extracted three times with ethyl acetate. The

15 combined organic layer was washed with successive, 1N hydrochloric acid, water and saturated sodium chloride in order. After drying over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure to give 87.9g (90%) of the objective compound.

IR(neat) ν cm^{-1} :

2963, 1751, 1600, 1508, 1186, 748

20 NMR(90MHz, CDCl_3) δ ppm:

7.32-7.05(2H, m), 6.81-6.51(3H, m), 4.18(2H, q, $J = 7.1\text{Hz}$), 4.02(2H, s), 3.34(2H, t, $J = 7.6\text{Hz}$), 1.81-1.44(2H, m), 1.25(3H, t, $J = 7.1\text{Hz}$), 0.94(3H, t, $J = 7.3\text{Hz}$)

EXAMPLE 109

25 Preparation of 2-(N-phenyl-N-propylamino)acetic acid

To a solution of the product obtained in EXAMPLE 108 (5.0g) in ethanol (30ml), 3N aqueous sodium hydroxide (30ml) was added and the mixture was stirred for 10 minutes under reflux. The aqueous solution

30 was concentrated under reduced pressure and washed with ether, acidified to pH 3 with 2N hydrochloric acid and extracted four times with ethyl acetate. The combined organic layer was washed with saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was crystallized from ethyl acetate-hexane to give 2.96g (68%) of the objective compound.

Yield: 89.8-91.4 °C

35 IR(KBr) ν cm^{-1} :

2955, 1709, 1599, 1508, 1236

NMR(90MHz, CDCl_3) δ ppm:

7.38-7.08(2H, m), 6.90-6.60(3H, m), 5.05(1H, br.s), 4.05(2H, s), 3.33(2H, t, $J = 7.6\text{Hz}$), 1.92-1.44(2H, m), 0.94-(3H, t, $J = 7.3\text{Hz}$)

40 EXAMPLE 110

Preparation of 3-(N-phenyl-N-propylamino)propionic acid

45 A mixture of N-propyl aniline (5.0g), acrylic acid (5.1ml) and water (7ml) was stirred for 2 hours under reflux. After cooling to room temperature, the aqueous solution was adjusted to pH 11 with 5N aqueous sodium hydroxide and washed four times with ether. The aqueous layer was acidified to pH 3 with concentrated hydrochloric acid and extracted three times with ethyl acetate. The combined organic layer

50 was washed with saturated sodium chloride, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 7.2g (94%) of the objective compound.

IR(neat) ν cm^{-1} :

2958, 1716, 1600, 1506, 1367

NMR(90MHz, CDCl_3) δ ppm:

7.38-7.08(2H, m), 6.90-6.63(3H, m), 3.61(2H, t, $J = 7.2\text{Hz}$), 3.23(2H, t, $J = 7.6\text{Hz}$), 2.61(2H, t, $J = 7.2\text{Hz}$), 1.86-

55 1.38(2H, m), 0.92(3H, t, $J = 7.3\text{Hz}$)

EXAMPLE 111

Preparation of 4-(N-methyl-N-phenylamino)butanoic acid

5 A mixture of N-methylaniline (10g), ethyl 4-bromobutyrate (13.2ml) and potassium carbonate (12.7g) was stirred for 1.5 hour at 110 °C. After cooling to room temperature, ethanol (100ml) and 3N aqueous sodium hydroxide (100ml) were added to the mixture, and the mixture was stirred for 30 minutes under reflux. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure and the residue was diluted with water and then washed with ether. The aqueous layer was acidified to pH 4 and the residue was collected and extracted three times with ethyl acetate. The organic layers were collected and extracted twice with 3N hydrochloric acid. The aqueous layers were collected, adjusted to pH 4 by using 20 % NaOH aqueous solution, and extracted five times with an ethyl acetate. The combined organic layer was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure to give 14.8g (84%) of the objective compound.

15 IR(neat) ν cm^{-1} :
2942, 1702, 1600, 1508, 1375, 1194
NMR(90MHz, CDCl_3) δ ppm:
10.74(1H, br.s), 7.32-7.08(2H, m), 6.81-6.57(3H, m), 3.36(2H, t, J = 7.1Hz), 2.91(3H, s), 2.40(2H, t, J = 7.3Hz), 2.07-1.74(2H, m)

20 The following compounds were prepared in a similar manner as EXAMPLE 111.

EXAMPLE 112

4-(N-phenyl-N-propylamino)butyric acid

25 Yield: 73%
IR(neat) ν cm^{-1} :
2962, 1716, 1599, 1506, 747
NMR(90MHz, CDCl_3) δ ppm:
30 7.34-7.10(2H, m), 6.76-6.54(3H, m), 3.30(2H, t, J = 7.3Hz), 3.26(2H, t, J = 7.6Hz), 2.41(2H, t, J = 7.6Hz), 2.22-1.32(4H, m), 0.91(3H, t, J = 7.3Hz)

EXAMPLE 113

35 3-(N-hexyl-N-phenylamino)propionic acid

Yield: 39%
IR(neat) ν cm^{-1} :
2929, 2858, 1713, 1599, 1506, 1367, 1194, 746
40 NMR(270MHz, CDCl_3) δ ppm:
7.32-7.22(2H, m), 6.89-6.78(3H, m), 3.57(2H, t, J = 7.0Hz), 3.23(2H, t, J = 7.6Hz), 2.60(2H, t, J = 7.0Hz), 1.60-1.46(2H, m), 1.38-1.21(6H, m), 0.88(3H, t, J = 6.6Hz)

EXAMPLE 114

45 4-(N-hexyl-N-phenylamino)butyric acid

Yield: 41%
IR(neat) ν cm^{-1} :
50 2927, 1708, 1598, 1507, 1370, 1192, 746, 694
NMR(90MHz, CDCl_3) δ ppm:
9.81(1H, br.s), 7.32-7.02(2H, m), 6.78-6.48(3H, m), 3.33(2H, t, J = 7.3Hz), 3.24(2H, t, J = 7.4Hz), 2.42(2H, t, J = 6.8Hz), 2.10-1.68(2H, m), 1.68-1.02(8H, m), 0.89(3H, t, J = 5.3Hz)

55

EXAMPLE 115

4-(N-cycloheptyl-N-phenylamino)butyric acid

5 Yield: 59%

IR(neat) ν cm^{-1} :

2927, 2858, 1732, 1711, 1597, 1502

NMR(270MHz, CDCl_3) δ ppm:

7.29(2H, dd, $J=8.3$ and 7.3Hz), 7.01(2H, d, $J=8.3\text{Hz}$), 6.92(1H, t, $J=7.3\text{Hz}$), 3.62-3.50(1H, m), 3.28(2H, t, $J=7.3\text{Hz}$), 2.47(2H, t, $J=6.7\text{Hz}$), 2.06-1.34(14H, m)

EXAMPLE 116

4-(N-decyl-N-phenylamino)butyric acid

15 Yield: 40%

IR(neat) ν cm^{-1} :

2921, 2856, 1702, 1598, 1508, 746

NMR(90MHz, CDCl_3) δ ppm:

20 7.32-7.08(2H, m), 6.78-6.54(3H, m), 3.33(2H, t, $J=7.3\text{Hz}$), 3.25(2H, t, $J=7.6\text{Hz}$), 2.43(2H, t, $J=6.8\text{Hz}$), 2.07-1.74(2H, m), 1.68-1.08(16H, m), 0.88(3H, t, $J=6.6\text{Hz}$)

EXAMPLE 117

25 4-[N-(4-butylphenyl)-N-propylamino]butyric acid

Yield: 37%

IR(neat) ν cm^{-1} :

2957, 2931, 1708, 1617, 1521, 1191, 1170

30 NMR(90MHz, CDCl_3) δ ppm:

9.78(1H, br.s), 7.05(2H, d, $J=8.9\text{Hz}$), 6.69(2H, d, $J=8.9\text{Hz}$), 3.31(2H, t, $J=7.1\text{Hz}$), 3.18(2H, t, $J=7.6\text{Hz}$), 2.51(2H, t, $J=7.3\text{Hz}$), 2.43(2H, t, $J=6.3\text{Hz}$), 2.04-1.08(8H, m), 0.92(3H, t, $J=7.3\text{Hz}$), 0.90(3H, t, $J=7.3\text{Hz}$)

EXAMPLE 118

35 4-[N-(4-methoxyphenyl)-N-propylamino]butyric acid

Yield: 29%

IR(neat) ν cm^{-1} :

40 2966, 1719, 1509, 1242, 1181, 1037

NMR(90MHz, CDCl_3) δ ppm:

10.81(1H, br.s), 6.87(4H, s), 3.77(3H, s), 3.36-2.94(4H, m), 2.96(2H, t, $J=6.8\text{Hz}$), 2.04-1.32(4H, m), 0.88(3H, t, $J=7.3\text{Hz}$)

45 EXAMPLE 119

4-[N-(3-methoxyphenyl)-N-propylamino]butyric acid

Yield: 77%

50 IR(neat) ν cm^{-1} :

2937, 1709, 1610, 1576, 1500, 1211, 1159

NMR(270MHz, CDCl_3) δ ppm:

7.12(1H, t, $J=8.6\text{Hz}$), 6.32(1H, dd, $J=8.2$ and 2.3Hz), 6.29-6.22(2H, m), 3.79(3H, s), 3.33(2H, t, $J=7.4\text{Hz}$), 3.21(2H, t, $J=7.8\text{Hz}$), 2.42(2H, t, $J=7.1\text{Hz}$), 1.99-1.86(2H, m), 1.69-1.51(2H, m), 0.91(3H, t, $J=7.4\text{Hz}$)

55

EXAMPLE 120

4-[N-(1,3-benzodioxol-5-yl)-N-propylamino]butyric acid

5 Yield: 83%

IR(neat) ν cm^{-1} :~~1713, 1504, 1491, 1244, 1217, 1038~~NMR(90MHz, CDCl_3) δ ppm:

9.05(1H, br.s), 6.71(1H, d, $J = 8.3\text{Hz}$), 6.46(1H, d, $J = 2.3\text{Hz}$), 6.27(1H, dd, $J = 8.3$ and 2.3Hz), 5.88(2H, s),
 10 3.22(2H, t, $J = 6.9\text{Hz}$), 3.10(2H, t, $J = 7.6\text{Hz}$), 2.43(2H, t, $J = 6.8\text{Hz}$), 2.07-1.14(4H, m), 0.89(3H, t, $J = 7.3\text{Hz}$)

EXAMPLE 121

4-[N-hexyl-N-(4-methoxyphenyl)amino]butyric acid

15

Yield: 82%

IR(neat) ν cm^{-1} :

2954, 2931, 1718, 1514, 1464, 1246, 1182

NMR(90MHz, CDCl_3) δ ppm:

20 7.58(1H, br.s), 7.02-6.72(4H, m), 3.77(3H, s), 3.33-2.94(4H, m), 2.49(2H, t, $J = 6.6\text{Hz}$), 2.01-1.62(2H, m), 1.62
 -1.08(8H, m), 0.86(3H, t, $J = 4.6\text{Hz}$)

EXAMPLE 122

25 4-[N-hexyl-N-(2-methoxyphenyl)amino]butyric acid

Yield: 65%

IR(neat) ν cm^{-1} :

2956, 2931, 1736, 1500, 1464, 1240

30 NMR(270MHz, CDCl_3) δ ppm:

7.27-7.15(2H, m), 6.98 - 6.91(2H, m), 3.87(3H, s), 3.22(2H, t, $J = 5.9\text{Hz}$), 3.12-3.04(2H, m), 2.58-2.51(2H, m),
 1.87-1.76(2H, m), 1.46-1.30(2H, m), 1.30-1.15(6H, m), 0.84(3H, t, $J = 6.6\text{Hz}$)

EXAMPLE 123

35

4-[N-(2,4-difluorophenyl)-N-propylamino]butyric acid

Yield: 48%

IR(neat) ν cm^{-1} :

40 2966, 2934, 1710, 1508, 1273, 1142

NMR(90MHz, CDCl_3) δ ppm:

7.14-6.60(3H, m), 3.24-2.82(4H, m), 2.43(2H, t, $J = 7.1\text{Hz}$), 1.92-1.62(2H, m), 1.62-1.20(2H, m), 0.86(3H, t,
 $J = 7.3\text{Hz}$)

45 EXAMPLE 124

4-(N-benzyl-N-propylamino)butyric acid

Yield: 42%

50 IR(neat) ν cm^{-1} :

2966, 1718, 1577, 1457, 1406, 742, 701

NMR(90MHz, CDCl_3) δ ppm:

11.41(1H, br.s), 7.62-7.20(5H, m), 4.02(2H, s), 3.06-2.52(4H, m), 2.52-2.16(2H, m), 2.10-1.44(4H, m), 0.90-
 (3H, t, $J = 7.1\text{Hz}$)

55

EXAMPLE 125

4-(N-benzyl-N-heptylamino)butyric acid

Yield: 10%

IR(neat) ν cm^{-1} :

2955, 2929, 2857, 1718, 1458

NMR(90MHz, CDCl_3) δ ppm:8.38(1H, br.s), 7.56-7.32(5H, m), 4.03(2H, s), 3.06-2.64(4H, m), 2.55-2.34(2H, m), 2.10-1.80(2H, m), 1.41-1.08(10H, m), 0.86(3H, t, $J = 5.4\text{Hz}$)

EXAMPLE 126

4-tetrahydroquinolinobutyric acid

Yield: 62%

IR(KBr neat) ν cm^{-1} :

1702, 1498, 1245, 754

NMR(90MHz, CDCl_3) δ ppm:10.67(1H, br.s), 7.20-6.78(2H, m), 6.72-6.36(2H, m), 3.42-3.06(4H, m), 2.74(2H, t, $J = 6.3\text{Hz}$), 2.42(2H, t, $J = 6.8\text{Hz}$), 2.10-1.50(4H, m)

EXAMPLE 127

4-(4-phenylpiperazinyl)butyric acid

Yield: 24%

IR(KBr) ν cm^{-1} :

3384, 1598, 1579, 1498, 1394, 771

NMR(90MHz, CDCl_3) δ ppm:

7.41-7.17(2H, m), 7.05-6.78(3H, m), 3.45-3.24(4H, m), 3.03-2.79(4H, m), 2.79-2.52(4H, m), 2.07-1.74(2H, m)

EXAMPLE 128

5-(N-phenyl-N-propylamino)pentanoic acid

Yield: 87%

IR(neat) ν cm^{-1} :

2956, 2875, 1716, 1710, 1599, 746

NMR(90MHz, CDCl_3) δ ppm:7.32-7.02(2H, m), 6.75-6.45(3H, m), 3.39-3.03(4H, m), 2.52-2.22(2H, m), 1.86-1.32(6H, m), 0.91(3H, t, $J = 7.3\text{Hz}$)

EXAMPLE 129

5-(N-hexyl-N-phenylamino)pentanoic acid

Yield: 72%

IR(neat) ν cm^{-1} :

2933, 2859, 1709, 1598, 1507, 746

NMR(90MHz, CDCl_3) δ ppm:7.32-7.08(2H, m), 6.72-6.51(3H, m), 3.36-3.12(4H, m), 2.49-2.25(2H, m), 1.80-1.14(12H, m), 0.89(3H, t, $J = 5.6\text{Hz}$)

EXAMPLE 130

5-(N-Cyclohexyl-N-propylamino)pentanoic acid

Yield: 40%

IR(neat) ν cm^{-1} :

3398, 2943, 1716, 1456

NMR(270MHz, DMSO- d_6) δ ppm:

3.04-2.88(1H m), 2.88- 2.70(4H, m), 2.25(2H, t, J = 6.90Hz), 1.98-1.86(2H, m), 1.82-1.71(2H, m), 1.69-1.00-
 10 (12H, m), 0.88(3H, t, J = 7.3Hz)

EXAMPLE 131

6-(N-phenyl-N-propylamino)hexanoic acid

Yield: 10%

IR(neat) ν cm^{-1} :

2939, 1718, 1598, 1507, 1244

NMR(90MHz, CDCl_3) δ ppm:

7.32-7.08(2H, m), 6.78-6.48(3H, m), 3.37-3.09(4H, m), 2.37(2H, t, J = 7.1Hz), 1.92-1.14(8H, m), 0.91(3H, t,
 20 J = 7.3Hz)

EXAMPLE 132

25 Preparation of N-[4-mercapto-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-2-(N-phenyl-N-propylamino)acetamide

To a solution of the product obtained in EXAMPLE 68 (137mg) and the product obtained in EXAMPLE 109 (116mg) in methylene chloride (5ml), N,N'-dicyclohexylcarbodiimide (134mg) was added under ice-cooling and the solution was stirred for 1 hour at room temperature. The formed insoluble material was filtered off and the filtrate was diluted with 50 ml of ethyl acetate. The organic solution was washed with saturated sodium bicarbonate and saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:4-2:3) and followed by washing with ether to give 164mg (73%) of the objective
 35 compound.

Melting point: 230.1-231.1 °C

IR(KBr) ν cm^{-1} :

2959, 1654, 1596, 1561, 1506, 1457, 1421, 1229

NMR(90MHz, DMSO- d_6) δ ppm:

40 13.17(1H, s), 8.21(1H, s), 7.44-6.90(7H, m), 6.68-6.32(3H, m), 4.02-3.78(2H, m), 3.17(2H, s), 3.12-2.88(2H, m), 2.37(3H, s), 1.86-1.32(4H, m), 0.85(6H, t, J = 6.9Hz)

The following compounds were prepared in a similar manner as EXAMPLE 132.

EXAMPLE 133

45 N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-2-(N-phenyl-N-propylamino)acetamide

Yield: 17%

Melting point: 200.0-201.2 °C

IR(KBr) ν cm^{-1} :

1655, 1601, 1561, 1542, 1527, 1508

NMR(90MHz, DMSO- d_6) δ ppm:

12.77(1H, s), 8.73(1H, s), 7.12(2H, t, J = 7.9Hz), 6.75-6.51(3H, m), 4.05(2H, s), 1.74-1.44(2H, m), 1.14-0.80-
 55 (6H, m)

EXAMPLE 134

N-[4-(N,N-diphenylamino)-6-mercapto-2-methylpyrimidin-5-yl]-2-(N-phenyl-N-propylamino)acetamide

5 Yield: 48%

Melting point: 194.1-195.7 °C

IR(KBr) ν cm^{-1} :

1686, 1535, 1521, 1492, 1465, 1451, 1240, 748, 696

NMR(90MHz, DMSO- d_6) δ ppm:

10 13.55(1H, s), 8.53(1H, s), 7.34-6.94(12H, m), 6.60-6.37(3H, m), 3.34(2H, s), 3.00(2H, t, J = 8.6Hz), 2.22(3H, s), 1.64-1.26(2H, m), 0.84(3H, t, J = 6.9Hz)

EXAMPLE 135

15 N-[4-methoxy-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-2-(N-phenyl-N-propylamino)acetamide

Yield: 16%

Melting-point: 152.8-153.4 °C

IR(KBr) ν cm^{-1} :

20 3201, 1666, 1555, 1496, 1415, 1376, 1127

NMR(90MHz, CDCl_3) δ ppm:

7.41-6.36(10H, m), 3.91(2H, t, J = 7.6Hz), 3.74(3H, s), 3.36(2H, s), 2.83(2H, t, J = 7.6Hz), 2.47(3H, s), 1.82-1.01(4H, m), 1.01-0.69(6H, m)

25 EXAMPLE 136

N-[4-hydroxy-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-2-(N-phenyl-N-propylamino)acetamide

Yield: 63%

30 Melting point: 197.3-198.4 °C

IR(KBr) ν cm^{-1} :

1654, 1618, 1560, 1507, 1496, 1458, 1414

NMR(90MHz, DMSO- d_6) δ ppm:

12.01(1H, s), 7.96(1H, s), 7.50-7.14(7H, m), 6.66-6.24(3H, m), 3.84(2H, t, J = 7.0Hz), 3.14(2H, s), 2.97(2H, t, J = 7.0Hz), 2.25(3H, s), 1.80-1.02(4H, m), 0.84(6H, t, J = 6.9Hz)

EXAMPLE 137

N-(4-mercapto-2-methyl-6-propylthiopyrimidin-5-yl)-2-(N-phenyl-N-propylamino)acetamide

40 Yield: 26%

Melting point: 184.7-186.8 °C

IR(KBr) ν cm^{-1} :

2964, 1684, 1591, 1577, 1554, 1521, 1507, 1492

45 NMR(90MHz, DMSO- d_6) δ ppm:

13.81(1H, s), 9.13(1H, s), 7.26-7.00(2H, m), 6.79-6.49(3H, m), 4.02(2H, s), 3.46-3.16(2H, m), 3.03(2H, t, J = 6.8Hz), 2.41(3H, s), 1.72-1.50(4H, m), 1.09-0.78(6H, m)

EXAMPLE 138

50 N-[4-mercapto-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-3-(N-phenyl-N-propylamino)-propionamide

Yield: 36%

55 Melting point: 130.6-132.4 °C

IR(KBr) ν cm^{-1} :

2957, 1595, 1560, 1506, 1459, 1423

NMR(90MHz, DMSO- d_6) δ ppm:

13.09(1H, s), 8.16(1H, s), 7.38-6.90(7H, m), 6.66-6.42(3H, m), 4.02-3.75(2H, m), 3.28-2.94(4H, m), 2.08(3H, s), 1.94-1.02(6H, m), 0.85(6H, t, J = 6.6Hz)

EXAMPLE 139

5

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-3-(N-phenyl-N-propylamino)propionamide

Yield: 25%

Melting point: 182.7-186.4 °C

10 IR(KBr) ν cm⁻¹:

2964, 2869, 1674, 1607, 1564, 1506, 1320

NMR(90MHz, DMSO-d₆) δ ppm:

12.73(1H, s), 8.90(1H, s), 7.26-6.93(2H, m), 6.72-6.48(3H, m), 4.02-3.06(8H, m), 2.67-2.37(2H, m), 2.28(3H, s), 1.74-1.32(2H, m), 1.07(6H, t, J = 7.1Hz), 0.89(3H, t, J = 7.6Hz)

15

EXAMPLE 140

N-[4-methoxy-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-3-(N-phenyl-N-propylamino)propionamide

20 Yield: 6%

Melting point: 124.4-125.2 °C

IR(KBr) ν cm⁻¹:

1660, 1578, 1550, 1506, 1495, 1372

NMR(90MHz, CDCl₃) δ ppm:

25 7.34-6.47(10H, m), 3.87(3H, s), 4.04-3.73(2H, m), 3.54-2.96(4H, m), 2.50(3H, s), 1.95-1.09(6H, m), 0.88(6H, t, J = 6.6Hz)

EXAMPLE 141

30 N-[4-hydroxy-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-3-(N-phenyl-N-propylamino)propionamide

Yield: 23%

Melting point: 90.5-91.4 °C

IR(KBr) ν cm⁻¹:

35 1654, 1617, 1596, 1560, 1507

NMR(90MHz, DMSO-d₆) δ ppm:

12.01(1H, s), 8.14(1H, s), 7.35-6.75(7H, m), 6.60-6.24 (3H, m), 4.00-3.60(2H, m), 3.24-2.88(4H, m), 2.25(3H, s), 1.92-1.30(6H, m), 1.02-0.72(6H, m)

40 EXAMPLE 142

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-3-(N-hexyl-N-phenylamino)propionamide

Yield: 50%

45 Melting point: 166.5-168.2 °C

IR(KBr) ν cm⁻¹:

2960, 2929, 1605, 1564, 1506, 1431, 1321

NMR(270MHz, DMSO-d₆) δ ppm:

50 12.76(1H, s), 8.92(1H, s), 7.15(2H, dd, J = 8.3 and 7.3Hz), 6.68(2H, d, J = 8.3Hz), 6.57(1H, t, J = 7.3Hz), 3.62-3.51 (2H, m), 3.44(4H, q, J = 6.9Hz), 3.28(2H, t, J = 7.4Hz), 2.56-2.44(2H, m), 2.28(3H, s), 1.58-1.43(2H, m), 1.35-1.20(6H, m), 1.06(6H, t, J = 6.9Hz), 0.87(3H, t, J = 6.8Hz)

EXAMPLE 143

55 N-[4-mercapto-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 41%

Melting point: 131.8-134.2 °C

IR(KBr) ν cm^{-1} :

2958, 1595, 1560, 1505, 1466, 1459, 1423,

NMR(90MHz, DMSO- d_6) δ ppm:

13.06(1H, s), 7.87(1H, s), 7.38-6.84(7H, m), 6.72-6.42(3H, m), 3.85(2H, t, $J = 6.9\text{Hz}$), 3.29-3.00(4H, m), 2.37-
5 (3H, s), 1.75-1.28(8H, m), 0.87(3H, t, $J = 6.9\text{Hz}$), 0.84(3H, t, $J = 7.3\text{Hz}$)

EXAMPLE 144

N-[4-(N,N-dimethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 24%

Melting point: 194.8-197.6 °C

IR(KBr) ν cm^{-1} :

1761, 1606, 1570, 1506, 1398

NMR(90MHz, DMSO- d_6) δ ppm:

12.75(1H, s), 8.75(1H, s), 7.26-6.93(2H, m), 6.78-6.36(3H, m), 3.36-2.84(4H, m), 3.04(6H, s), 2.28(3H, s),
15 2.04-1.20(6H, m), 0.88(3H, t, $J = 7.3\text{Hz}$)

EXAMPLE 145

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 60%

Melting point: 172.4-174.5 °C

IR(KBr) ν cm^{-1} :

3212, 1677, 1608, 1566, 1506

NMR(90MHz, DMSO- d_6) δ ppm:

12.71(1H, s), 8.79(1H, s), 7.26-6.90(2H, m), 6.78-6.36(3H, m), 3.66-2.82(8H, m), 2.27(3H, s), 2.04-1.20(6H,
20 m), 1.00(6H, t, $J = 6.9\text{Hz}$), 0.88(3H, t, $J = 7.1\text{Hz}$)

EXAMPLE 146

N-[4-(N,N-dibutylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 84%

Melting point: 170.8-171.9 °C

IR(KBr) ν cm^{-1} :

2957, 2930, 2870, 1608, 1562, 1506

NMR(90MHz, DMSO- d_6) δ ppm:

12.71(1H, s), 8.79(1H, s), 7.20-6.90(2H, m), 6.72-6.33(3H, m), 3.60-3.30(8H, m), 2.36-2.16(2H, m), 2.26(3H,
35 s), 1.98-0.98(12H, m), 0.87(9H, t, $J = 6.3\text{Hz}$)

EXAMPLE 147

N-[4-(N,N-dihexylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 45%

Melting point: 143.3-145.6 °C

IR(KBr) ν cm^{-1} :

2956, 2929, 1676, 1610, 1567, 1506

NMR(90MHz, DMSO- d_6) δ ppm:

12.70(1H, s), 8.76(1H, s), 7.20-6.93(2H, m), 6.72-6.36(3H, m), 3.60-3.00(8H, m), 2.26(3H, s), 1.98-1.65(2H,
40 m), 1.65-0.99(20H, m), 0.99-0.69(9H, m)

EXAMPLE 148

N-[4-(N-benzyl-N-heptylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

5 Yield: 52%

Melting point: 123.4-124.7 °C

IR(KBr) ν cm⁻¹:

3219, 2870, 2855, 1648, 1599, 1564, 1561

NMR(90MHz, DMSO-d₆) δ ppm:

10 12.89(1H, s), 8.80(1H, s), 7.44-6.84(7H, m), 6.72-6.30(3H, m), 4.98-4.50(2H, m), 3.48-2.76(6H, m), 2.27(3H, s), 2.34-1.98(2H, m), 1.92-0.96(14H, m), 0.96-0.66(6H, m)

EXAMPLE 149

15 N-[4-mercapto-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 39%

Melting point: 138.7-140.2 °C

IR(KBr) ν cm⁻¹:

20 1607, 1590, 1529, 1506, 1425

NMR(90MHz, DMSO-d₆) δ ppm:

13.26(1H, s), 8.08(1H, s), 8.03(1H, s), 7.38-6.80(7H, m), 6.70-6.36(3H, m), 3.87(2H, t, J = 6.6Hz), 3.36-2.82-(4H, m), 2.34-1.20(8H, m), 0.87(3H, t, J = 6.9Hz), 0.83(3H, t, J = 7.3Hz)

25 EXAMPLE 150

N-[4-(N,N-diethylamino)-6-mercapto-2-methoxypyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 21%

30 Melting point: 118.6-118.9 °C

IR(KBr) ν cm⁻¹:

2958, 1616, 1570, 1506, 1344, 1321, 1038

NMR(270MHz, DMSO-d₆) δ ppm:

35 12.69(1H, s), 8.72(1H, s), 7.10(2H, dd, J = 8.3 and 7.3Hz), 6.66(2H, d, J = 8.3Hz), 6.51(1H, t, J = 7.3Hz), 3.87-(3H, s), 3.56-3.10(8H, m), 2.45-2.18(2H, m), 1.88-1.72(2H, m), 1.62-1.45(2H, m), 1.17(6H, t, J = 6.8Hz), 0.88-(3H, t, J = 7.3Hz)

EXAMPLE 151

40 N-[4,6-bis(hexylamino)-2-methylpyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 22%

Melting point: 139.6-140.7 °C

IR(KBr) ν cm⁻¹:

45 3382, 3226, 2956, 2929, 2858, 1646, 1593, 1507

NMR(90MHz, DMSO-d₆) δ ppm:

8.36(1H, s), 7.20-6.81(2H, m), 6.81-6.30(3H, m), 5.54(2H, br.s), 3.45-2.61(8H, m), 2.61-2.22(2H, m), 2.19(3H, s), 1.98-1.02(20H, m), 1.02-0.66(9H, m)

50 EXAMPLE 152

N-[4-(N,N-dimethylamino)-6-hexylaminopyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 7%

55 Melting point: 81.0-81.9 °C

IR(KBr) ν cm⁻¹:

3427, 3246, 2958, 2873, 1647, 1593, 1506, 1411

NMR(90MHz, DMSO-d₆) δ ppm:

8.77(1H, s), 7.92(1H, s), 7.17-6.90(2H, m), 6.72-6.36(3H, m), 6.02(1H, t, J = 7.0Hz), 3.36-3.00(6H, m), 2.93-
(6H, s), 2.64-2.19(2H, m), 1.95-0.99(12H, m), 0.89(6H, t, J = 5.0Hz)

EXAMPLE 153

N-[4-(4-hydroxy-6-isopropyl-2-methylpyrimidin-5-yl)-4-(N-phenyl-N-propylamino)butanamide

Yield: 40%

Melting point: 201.0-202.2 °C

IR(KBr) ν cm⁻¹:

3235, 2964, 2931, 1675, 1659, 1606, 1506

NMR(90MHz, DMSO-d₆) δ ppm:

12.40(1H, s), 8.94(1H, s), 7.26-6.96(2H, m), 6.78-6.36(3H, m), 3.48-2.70(5H, m), 2.46-2.16(2H, m), 2.27(3H, s), 1.98-1.26(4H, m), 1.05(6H, d, J = 6.9Hz), 0.88(3H, t, J = 7.3Hz)

EXAMPLE 154

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-methyl-N-phenylamino)butanamide

Yield: 79%

Melting point: 169.6-171.8 °C

IR(KBr) ν cm⁻¹:

1663, 1605, 1596, 1523, 1508, 1431, 1322

NMR(90MHz, DMSO-d₆) δ ppm:

12.70(1H, s), 8.76(1H, s), 7.26-7.02(2H, m), 6.78-6.45(3H, m), 3.63-3.12(6H, m), 2.88(3H, s), 2.43-2.13(2H, m), 2.27(3H, s), 2.01-1.59(2H, m), 1.08(6H, t, J = 6.6Hz)

EXAMPLE 155

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 66%

Melting point: 143.3-145.6 °C

IR(KBr) ν cm⁻¹:

2956, 2929, 1607, 1561, 1508

NMR(90MHz, DMSO-d₆) δ ppm:

12.71(1H, s), 8.77(1H, s), 7.20-6.96(2H, m), 6.75-6.36(3H, m), 3.63-3.06(8H, m), 2.37-2.10(2H, m), 2.27(3H, s), 1.98-1.62(2H, m), 1.62-1.14(8H, m), 1.08(6H, t, J = 6.8Hz), 0.87(3H, t, J = 5.4Hz)

EXAMPLE 156

N-[4-(N,N-dipropylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 62%

Melting point: 148.0-149.3 °C

IR(KBr) ν cm⁻¹:

2960, 2929, 1606, 1564, 1506

NMR(270MHz, DMSO-d₆) δ ppm:

12.7(1H, s), 8.83(1H, s), 7.10(2H, dd, J = 7.9 and 7.3Hz), 6.67(2H, d, J = 7.9Hz), 6.52(1H, t, J = 7.3Hz), 3.57-3.12(8H, m), 2.45-2.18(2H, m), 2.27(3H, s), 1.89-1.72(2H, m), 1.62-1.38(6H, m), 1.37-1.21(6H, m), 0.86(3H, t, J = 6.6Hz), 0.80(6H, t, J = 7.3Hz)

EXAMPLE 157

N-[4-(N,N-dibutylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 33%

Melting point: 125.6-128.1 °C

IR(KBr) ν cm^{-1} :

3218, 3178, 1682, 1610, 1567, 1506, 1426, 1326

NMR(90MHz, DMSO- d_6) δ ppm:

12.73(1H, s), 8.79(1H, s), 7.20-6.96(2H, m), 6.72-6.36(3H, m), 3.60-2.88(8H, m), 2.26(3H, s), 2.40-2.04(2H, m), 1.98-0.96(18H, m), 0.87(9H, t, J = 5.9Hz)

EXAMPLE 158

N-[4-(N-benzyl-N-ethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 55%

Melting point: 161.7-162.0 °C

IR(KBr) ν cm^{-1} :

2929, 1647, 1599, 1564, 1504, 1439, 1429, 1319

NMR(270MHz, DMSO- d_6) δ ppm:

12.90(1H, s), 8.81(1H, s), 7.36-7.17(5H, m), 7.18(2H, dd, J = 8.2 and 7.3Hz), 6.63(2H, d, J = 8.2Hz), 6.54(1H, t, J = 7.3Hz), 4.95-4.62(2H, m), 3.48-3.08(4H, m), 2.30-1.92(2H, m), 2.28(3H, s), 1.79-1.63(2H, m), 1.51-1.39(2H, m), 1.34-1.28(6H, m), 1.06(3H, t, J = 6.9Hz), 0.86(3H, t, J = 6.6Hz)

EXAMPLE 159

N-[4-(N-benzyl-N-heptylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 70%

Melting point: 119.2-120.9 °C

IR(KBr) ν cm^{-1} :

3228, 1648, 1600, 1561, 1506

NMR(90MHz, DMSO- d_6) δ ppm:

12.87(1H, s), 8.79(1H, s), 7.32-6.90(7H, m), 6.72-6.36(3H, m), 4.98-4.56(2H, m), 3.48-2.94(6H, m), 2.34-2.04(2H, m), 2.26(3H, s), 1.92-1.02(20H, m), 0.96-0.66(6H, m)

EXAMPLE 160

N-[4-(N-butylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 63%

Melting point: 215.8-216.7 °C

IR(KBr) ν cm^{-1} :

3315, 2956, 2929, 2861, 1654, 1591, 1506

NMR(90MHz, DMSO- d_6) δ ppm:

12.62(1H, s), 8.56(1H, s), 7.23-6.96(2H, m), 6.84(1H, t, J = 5.4Hz), 6.72-6.36(3H, m), 3.45-3.03(6H, m), 2.40-2.19(2H, m), 2.29(3H, s), 1.98-1.62(2H, m), 1.62-1.08(12H, m), 0.87(6H, t, J = 5.6Hz)

EXAMPLE 161

4-(N-hexyl-N-phenylamino)-N-(4-mercapto-2-methyl-6-morpholinopyrimidin-5-yl)butanamide

Yield: 38%

Melting point: 199.1-201.0 °C

IR(KBr) ν cm^{-1} :

2956, 2926, 1605, 1567, 1507, 1308

NMR(90MHz, DMSO- d_6) δ ppm:

12.93(1H, s), 8.76(1H, s), 7.20-6.96(2H, m), 6.72-6.36(3H, m), 3.72-3.42(8H, m), 3.42-3.09(4H, m), 2.40-2.16(2H, m), 2.30(3H, s), 1.95-1.62(2H, m), 1.62-1.08(8H, m), 0.87(3H, t, J = 5.8Hz)

EXAMPLE 162

4-(N-hexyl-N-phenylamino)-N-[4-mercapto-2-methyl-6-(4-methylpiperazinyl)pyrimidin-5-yl]butanamide

5 Yield: 8%

Melting point: 192.7-194.9 °C

IR(KBr) ν cm^{-1} :

3435, 2929, 1680, 1608, 1570, 1508, 1309

NMR(270MHz, DMSO- d_6) δ ppm:

10 12.89(1H, s), 8.79(1H, s), 7.11(2H, dd, J = 8.6 and 7.3Hz), 6.66(2H, d, J = 8.6Hz), 6.52(1H, t, J = 7.3Hz), 3.70-3.55(4H, m), 3.39-3.20(4H, m), 2.39-2.21(9H, m), 2.13(3H, s), 1.86-1.72(2H, m), 1.58-1.41(2H, m), 1.36-1.22(6H, m), 0.92-0.83(3H, m)

EXAMPLE 163

15

N-[4-(N,N-diethylamino)-6-mercaptopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 64%

Melting point: 133.3-135.2 °C

20 IR(KBr) ν cm^{-1} :

1612, 1595, 1545, 1502, 1470, 1431, 1321

NMR(270MHz, DMSO- d_6) δ ppm:

12.91(1H, s), 8.89(1H, s), 7.90(1H, s), 7.11(2H, dd, J = 8.3 and 7.3Hz), 6.66(2H, d, J = 8.3Hz), 6.52(1H, t, J = 7.3Hz), 3.47(4H, q, J = 6.9Hz), 3.32-3.20(4H, m), 2.46-2.22(2H, m), 1.88-1.72(2H, m), 1.56-1.38(2H, m), 25 1.38-1.20(6H, m), 1.09(6H, t, J = 6.9Hz), 0.87(3H, t, J = 6.6Hz)

EXAMPLE 164

N-[4-(N,N-diethylamino)-6-mercapto-2-methoxypyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

30

Yield: 47%

Melting point: 95.9-97.2 °C

IR(KBr) ν cm^{-1} :

2926, 1682, 1610, 1572, 1508, 1348, 1317, 1038

35 NMR(270MHz, DMSO- d_6) δ ppm:

12.67(1H, s), 8.70(1H, s), 7.10(2H, dd, J = 8.6 and 7.3Hz), 6.65(2H, d, J = 8.6Hz), 6.51(1H, t, J = 7.3Hz), 3.87-(3H, s), 3.60-3.18(8H, m), 2.40-2.20(2H, m), 1.86-1.72(2H, m), 1.56-1.42(2H, m), 1.34-1.20(6H, m), 1.12(6H, t, J = 6.9Hz), 0.87(3H, t, J = 6.6Hz)

40 EXAMPLE 165

N-[4-(N,N-diethylamino)-6-mercapto-2-methylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 49%

45 Melting point: 137.3-138.3 °C

IR(KBr) ν cm^{-1} :

2924, 1682, 1552, 1504, 1427, 1321, 1269

NMR(270MHz, DMSO- d_6) δ ppm:

13.10(1H, s), 8.82(1H, s), 7.11(2H, dd, J = 8.6 and 7.3Hz), 6.66(2H, d, J = 8.6Hz), 6.52(1H, t, J = 7.3Hz), 3.62-3.13(8H, m), 2.48(3H, s), 2.43-2.17(2H, m), 1.88-1.70(2H, m), 1.57-1.37(2H, m), 1.35-1.18(6H, m), 1.11(6H, t, J = 6.9Hz), 0.87(3H, t, J = 6.4Hz)

EXAMPLE 166

55 N-[4-(N,N-diethylamino)-6-methoxy-2-methylpyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 39%

Melting point: 74.0-74.8 °C

IR(KBr) ν cm^{-1} :

2854, 1654, 1568, 1561, 1506, 1374

NMR(90MHz, DMSO-d₆) δ ppm:

8.88(1H, s), 7.32-6.96(2H, m), 6.84-6.36(3H, m), 3.73(3H, s), 3.60-2.94(8H, m), 2.32(3H, s), 2.40-2.10(2H, m), 1.98-1.14(10H, m), 1.08(6H, t, J = 6.8Hz), 0.87(3H, t, J = 5.6Hz)

5

EXAMPLE 167

N-[4-(N,N-dipropylamino)-6-methoxy-2-methylpyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

10 Yield: 25%

Melting point: 79.8-81.2 °C

IR(KBr) ν cm⁻¹:

1651, 1583, 1564, 1506, 1427, 1375, 1109

NMR(270MHz, DMSO-d₆) δ ppm:

15 8.91(1H, s), 7.11(2H, dd, J = 8.3 and 7.3Hz), 6.65(2H, d, J = 8.3Hz), 6.53(1H, t, J = 7.3Hz), 3.73(3H, s), 3.42-3.20(8H, m), 2.34-2.18(2H, m), 2.30(3H, s), 1.86-1.68(2H, m), 1.60-1.38(6H, m), 1.38-1.16(4H, m), 0.83(3H, t, J = 7.3Hz), 0.80(6H, t, J = 7.3Hz)

EXAMPLE 168

20

N-[4-(N,N-diethylamino)-6-methoxy-2-methylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 40%

Melting point: 73.6-74.7 °C

25 IR(KBr) ν cm⁻¹:

2926, 1653, 1552, 1504, 1377, 1321, 1097

NMR(270MHz, DMSO-d₆) δ ppm:

8.93(1H, s), 7.12(2H, dd, J = 8.3 and 7.3Hz), 6.66(2H, d, J = 8.3Hz), 6.53(1H, t, J = 7.3Hz), 3.73(3H, s), 3.60-3.13(8H, m), 2.43(3H, s), 2.38-2.17(2H, m), 1.87-1.67(2H, m), 1.58-1.40(2H, m), 1.40-1.16(6H, m), 1.09(6H, t, J = 6.9Hz), 0.87(3H, t, J = 6.6Hz)

30

EXAMPLE 169

N-(4,6-dimethoxy-2-methylpyrimidin-5-yl)-4-(N-hexyl-N-phenylamino)butanamide

35

Yield: 73%

Melting point: 85.5-87.1 °C

IR(KBr) ν cm⁻¹:

3236, 1659, 1579, 1533, 1506, 1362, 1134

40 NMR(270MHz, DMSO-d₆) δ ppm:

9.04(1H, s), 7.12(2H, dd, J = 7.9 and 7.3Hz), 6.65(2H, d, J = 7.9Hz), 6.53(1H, t, J = 7.3Hz), 3.86(6H, s), 3.44-3.12(4H, m), 2.47(3H, s), 2.36-2.20(2H, m), 1.86-1.67(2H, m), 1.58-1.41(2H, m), 1.37-1.18(6H, m), 0.86(3H, t, J = 6.4Hz)

45 EXAMPLE 170

4-(N-cycloheptyl-N-phenylamino)-N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]butanamide

Yield: 48%

50 Melting point: 195.0-199.0 °C

IR(KBr) ν cm⁻¹:

2929, 1608, 1564, 1504, 1429, 1319

NMR(270MHz, DMSO-d₆) δ ppm:

12.74(1H, s), 8.83(1H, s), 7.12(2H, dd, J = 8.3 and 7.3Hz), 6.73(2H, d, J = 8.3Hz), 6.55(1H, t, J = 7.3Hz), 3.75-3.62(1H, m), 3.45(4H, q, J = 6.9Hz), 3.33-3.15(2H, m), 2.42-2.20(2H, m), 2.28(3H, s), 1.86-1.38(14H, m), 1.08(6H, t, J = 6.9Hz)

55

EXAMPLE 171

4-(N-decyl-N-phenylamino)-N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]butanamide

5 Yield: 56%

Melting point: 131.3-134.2 °C

IR(KBr) ν cm^{-1} :

2925, 2854, 1678, 1609, 1565, 1507

NMR(90MHz, DMSO- d_6) δ ppm:

10 12.73(1H, s), 8.80(1H, s), 7.20-6.96(2H, m), 6.72-6.39(3H, m), 3.63-3.09(8H, m), 2.28(3H, s), 2.01-1.65(2H, m), 1.65-1.20(18H, m), 1.08(6H, t, J = 6.9Hz), 0.85(3H, t, J = 5.8Hz)

EXAMPLE 172

15 4-[N-(4-butylphenyl)-N-propylamino]-N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]butanamide

Yield: 48%

Melting point: 145.7-147.5 °C

IR(KBr) ν cm^{-1} :

20 3172, 1610, 1564, 1430, 1320

NMR(90MHz, DMSO- d_6) δ ppm:

12.71(1H, s), 8.76(1H, s), 6.93(2H, d, J = 8.4Hz), 6.58(2H, d, J = 8.4Hz), 3.66-2.82(8H, m), 2.46-2.04(4H, m), 2.27(3H, s), 2.04-1.20(8H, m), 1.08(6H, t, J = 6.9Hz), 0.87(6H, t, J = 6.9Hz)

25 EXAMPLE 173

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-[N-(4-Methoxyphenyl)-N-propylamino]-butanamide

30 Yield: 75%

Melting point: 142.2-144.6 °C

IR(KBr) ν cm^{-1} :

2963, 2958, 1610, 1564, 1513, 1430, 1321, 1240

NMR(90MHz, DMSO- d_6) δ ppm:

35 12.71(1H, s), 8.74(1H, s), 6.84-6.48(4H, m), 3.64(3H, s), 3.60-2.94(8H, m), 2.40-2.10(2H, m), 2.27(3H, s), 1.98-1.26(4H, m), 1.07(6H, t, J = 6.8Hz), 0.86(3H, t, J = 7.1Hz)

EXAMPLE 174

40 N-[4-(N,N-diethylamino)-6-mercapto-2-methoxypyrimidin-5-yl]-4-[N-(4-methoxyphenyl)-N-propylamino]-butanamide

Yield: 25%

Melting point: 156.2-158.4 °C

45 IR(KBr) ν cm^{-1} :

2958, 1682, 1622, 1570, 1516, 1342, 1321, 1034

NMR(270MHz, DMSO- d_6) δ ppm:

12.68(1H, s), 8.70(1H, s), 6.76(2H, d, J = 9.2Hz), 6.65(2H, d, J = 9.2Hz), 3.87(3H, s), 3.64(3H, s), 3.58-3.35(4H, m), 3.33-3.05(4H, m), 2.43-2.15(2H, m), 1.85-1.70(2H, m), 1.58-1.40(2H, m), 1.11(6H, t, J = 6.8Hz), 0.86(3H, t, J = 7.3Hz)

EXAMPLE 175

55 N-[4-(N,N-diethylamino)-2,6-dimethoxypyrimidin-5-yl]-4-[N-(4-methoxyphenyl)-N-propylamino]butanamide

Yield: 33%

IR(neat) ν cm^{-1} :

3259, 2956, 1593, 1514, 1464, 1375, 1240, 1105

NMR(270MHz, DMSO-d₆) δ ppm:

8.80(1H, s), 6.77(2H, d, J = 9.2Hz), 6.65(2H, d, J = 9.2Hz), 3.78(3H, s), 3.71(3H, s), 3.54-3.36(4H, m), 3.26-3.10(4H, m), 2.37-2.12(2H, m), 1.82-1.65(2H, m), 1.57-1.38(2H, m), 1.09(6H, t, J = 6.9Hz), 0.86(3H, t, J = 7.4Hz)

5

EXAMPLE 176

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-[N-(3-methoxyphenyl)-N-propylamino]-butanamide

10

Yield: 41%

Melting point: 136.9-139.3 °C

IR(KBr) ν cm⁻¹:

2960, 2935, 1610, 1566, 1500, 1429, 1321

15

NMR(270MHz, DMSO-d₆) δ ppm:

12.74(1H, s), 8.82(1H, s), 7.01(1H, t, J = 8.3Hz), 6.27(1H, d, J = 8.3Hz), 6.17(1H, s), 6.13(1H, d, J = 8.3Hz), 3.68(3H, s), 3.45(4H, q, J = 6.9Hz), 3.39-3.12(4H, m), 2.40-2.19(2H, m), 2.28(3H, s), 1.87-1.72(2H, m), 1.60-1.43(2H, m), 1.08(6H, t, J = 6.9Hz), 0.87(3H, t, J = 7.3Hz)

20

EXAMPLE 177

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-[N-(1,3-benzodioxol-5-yl)-N-propylamino]-butanamide

25

Yield: 76%

Melting point: 172.6-173.1 °C

IR(KBr) ν cm⁻¹:

2958, 1682, 1610, 1564, 1504, 1429, 1321, 1221

NMR(270MHz, DMSO-d₆) δ ppm:

30

12.74(1H, s), 8.81(1H, s), 6.69(1H, d, J = 8.4Hz), 6.42(1H, d, J = 2.3Hz), 6.08(1H, dd, J = 8.4 and 2.3Hz), 5.82(2H, s), 3.45(4H, q, J = 7.1Hz), 3.39-3.00(2H, m), 2.43-2.18(2H, m), 2.27(3H, s), 1.86-1.66(2H, m), 1.58-1.42(2H, m), 1.08(6H, t, J = 7.1Hz), 0.86(3H, t, J = 7.3Hz)

EXAMPLE 178

35

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-[N-hexyl-N-(4-methoxyphenyl)amino]-butanamide

Yield: 61%

40

Melting point: 131.1-135.2 °C

IR(KBr) ν cm⁻¹:

2931, 2868, 1566, 1516, 1431, 1319, 1244

NMR(90MHz, DMSO-d₆) δ ppm:

45

12.72(1H, s), 8.75(1H, s), 6.84-6.48(4H, m), 3.64(3H, s), 3.60-2.94(8H, m), 2.40-2.13(2H, m), 2.27(3H, s), 1.95-1.59(2H, m), 1.59-1.14(8H, m), 1.07(6H, t, J = 6.6Hz), 0.85(3H, t, J = 5.4Hz)

EXAMPLE 179

50

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-[N-hexyl-N-(2-methoxyphenyl)amino]-butanamide

Yield: 35%

Melting point: 69.6-72.0 °C

IR(KBr) ν cm⁻¹:

55

2929, 1610, 1564, 1500, 1429, 1319, 1236

NMR(270MHz, DMSO-d₆) δ ppm:

12.70(1H, s), 8.69(1H, s), 6.95-6.77(4H, m), 3.76(3H, s), 3.42(4H, q, J = 6.7Hz), 3.14-2.97(4H, m), 2.32-2.17(2H, m), 2.26(3H, s), 1.75-1.57(2H, m), 1.43-1.30(2H, m), 1.30-1.12(6H, m), 1.05(6H, t, J = 6.8Hz), 0.83(3H, t,

J = 6.4 Hz)

EXAMPLE 180

5 N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-[N-(2,4-difluorophenyl)-N-propylamino]-butanamide

Yield: 38%

Melting point: 133.6-135.5 °C

10 IR(KBr) ν cm⁻¹:

2966, 1610, 1565, 1561, 1508, 1430, 1322

NMR(90MHz, DMSO-d₆) δ ppm:

12.69(1H, s), 8.70(1H, s), 7.26-6.75(3H, m), 3.43(4H, q, J = 6.8Hz), 3.24-2.82(4H, m), 2.40-2.10(2H, m), 2.27-(3H, s), 1.86-1.23(4H, m), 1.06(6H, t, J = 6.8Hz), 0.82(3H, t, J = 7.1Hz)

75

EXAMPLE 181

4-(N-benzyl-N-propylamino)-N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]butanamide

20 Yield: 47%

Melting point: 117.8-119.3 °C

IR(KBr) ν cm⁻¹:

3227, 2956, 1685, 1611, 1561, 1509, 1320

NMR(90MHz, DMSO-d₆) δ ppm:

25 12.68(1H, s), 8.65(1H, s), 7.43-7.13(5H, m), 3.54-3.18(4H, m), 3.53(2H, s), 2.40-2.10(6H, m), 2.26(3H, s), 1.92-1.26(4H, m), 1.06(6H, t, J = 6.8Hz), 0.80(3H, t, J = 7.1Hz).

EXAMPLE 182

30 4-(N-benzyl-N-heptylamino)-N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]butanamide

Yield: 77%

Melting point: 93.6-96.9 °C

IR(KBr) ν cm⁻¹:

35 2954, 2928, 1611, 1567, 1514, 1498, 1319

NMR(90MHz, DMSO-d₆) δ ppm:

12.70(1H, s), 8.66(1H, s), 7.38-7.14(5H, m), 3.63-3.24 (4H, m), 3.52(2H, s), 2.52-2.04(6H, m), 2.27(3H, s), 1.90-1.08(14H, m), 1.07(6H, t, J = 6.9Hz), 0.89(3H, t, J = 4.9Hz)

EXAMPLE 183

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(tetrahydroquinolino)butanamide

Yield: 14%

45 Melting point: 202.6-203.4 °C

IR(KBr) ν cm⁻¹:

3256, 1655, 1603, 1569, 1508

NMR(90MHz, DMSO-d₆) δ ppm:

12.71(1H, s), 8.78(1H, s), 7.02-6.72(2H, m), 6.66-6.30(2H, m), 3.60-3.06(8H, m), 2.66(2H, t, J = 5.9Hz), 2.34-2.10(2H, m), 2.27(3H, s), 1.98-1.56(4H, m), 1.08(6H, t, J = 6.6Hz)

50

EXAMPLE 184

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-4-(4-phenylpiperazinyl)butanamide

55

Yield: 5%

Melting point: 199.0-201.7 °C

IR(KBr) ν cm⁻¹:

2969, 1683, 1602, 1565, 1497, 1320

NMR(90MHz, CDCl₃) δ ppm:

8.02(1H, s), 7.38-7.11(2H, m), 6.99-6.72(3H, m), 3.75-3.30(4H, m), 3.30-3.06(4H, m), 2.76-2.40(8H, m), 2.35-(3H, s), 2.16-1.62(2H, m), 1.16(6H, t, J = 6.9Hz)

5

EXAMPLE 185

N-[4-mercapto-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

10 Yield: 31%

Melting point: 122.1-123.6 °C

IR(KBr) ν cm⁻¹:

2959, 1594, 1560, 1505, 1422

NMR(90MHz, DMSO-d₆) δ ppm:

15 13.07(1H, s), 7.79(1H, s), 7.38-6.81(7H, m), 6.66-6.39(3H, m), 4.00-3.70(2H, m), 3.30-3.00(4H, m), 2.64-2.28-(2H, m), 2.36(3H, s), 1.74-1.14(8H, m), 0.87(3H, t, J = 7.1Hz), 0.84(3H, t, J = 6.9Hz)

EXAMPLE 186

20 N-[4-(N,N-dimethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

Yield: 31%

Melting point: 180.2-181.0 °C

IR(KBr) ν cm⁻¹:

25 1678, 1606, 1570, 1504, 1398, 1313

NMR(270MHz, DMSO-d₆) δ ppm:

12.76(1H, s), 8.69(1H, s), 7.11(2H, dd, J = 8.3 and 7.3Hz), 6.61(2H, d, J = 8.3Hz), 6.52(1H, t, J = 7.3Hz), 3.33-3.12(4H, m), 3.01(6H, m), 2.38-2.20(2H, m), 2.28(3H, s), 1.68-1.38(6H, m), 0.88(3H, t, J = 6.8Hz)

30 EXAMPLE 187

N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

Yield: 55%

35 Melting point: 138.7-140.4 °C

IR(KBr) ν cm⁻¹:

1607, 1561, 1507, 1431, 1320

NMR(90MHz, DMSO-d₆) δ ppm:

40 12.70(1H, s), 8.68(1H, s), 7.26-6.96(2H, m), 6.72-6.66(3H, m), 3.60-3.03(8H, m), 2.46-2.10(2H, m), 2.27(3H, s), 1.92-1.26(6H, m), 1.06(6H, t, J = 6.9Hz), 0.88(3H, t, J = 7.4Hz)

EXAMPLE 188

N-[4-(N,N-dipropylamino)-6-mercapto-2-methylpyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

45

Yield: 61%

Melting point: 145.9-146.9 °C

IR(KBr) ν cm⁻¹:

2958, 2931, 2872, 1674, 1608, 1566, 1506, 1425

50 NMR(270MHz, DMSO-d₆) δ ppm:

12.7(1H, s), 8.72(1H, s), 7.11(2H, dd, J = 8.2 and 7.3Hz), 6.61(2H, d, J = 8.2Hz), 6.52(1H, t, J = 7.3Hz), 3.62-3.08(8H, m), 2.42-2.18(2H, m), 2.26(3H, s), 1.72-1.32(10H, m), 0.88(3H, t, J = 7.4Hz), 0.80(6H, t, J = 7.3Hz)

55

EXAMPLE 189

N-[4-(N,N-dibutylamino)-6-mercapto-2-methylpyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

5 Yield: 43%

Melting point: 140.3-143.0 °C

IR(KBr) ν cm^{-1} :

2956, 2870, 1678, 1610, 1566, 1510

NMR(90MHz, DMSO- d_6) δ ppm:

10 12.70(1H, s), 8.69(1H, s), 7.20-6.90(2H, m), 6.72-6.36(3H, m), 3.72-2.76(8H, m), 2.40-2.04(2H, m), 2.25(3H, s), 1.80-1.02(14H, m), 0.86(9H, t, J = 6.3Hz)

EXAMPLE 190

15 N-[4-(N-benzyl-N-ethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

Yield: 39%

Melting point: 55.9-57.1 °C

IR(KBr) ν cm^{-1} :

20 2956, 1662, 1605, 1564, 1506, 1431, 1319, 1296

NMR(270MHz, DMSO- d_6) δ ppm:

12.89(1H, s), 8.71(1H, s), 7.32-7.18(5H, m), 7.10(2H, dd, J = 8.6 and 7.3Hz), 6.59(2H, d, J = 8.6Hz), 6.51(1H, t, J = 7.3Hz), 4.99-4.59(2H, m), 3.50-3.29(2H, m), 3.26-3.09(4H, m), 2.32-1.98(2H, m), 2.27(3H, s), 1.60-1.40(6H, m), 1.03(3H, t, J = 6.9Hz), 0.86(3H, t, J = 7.4Hz)

25

EXAMPLE 191

N-[4-(N-benzyl-N-heptylamino)-6-mercapto-2-methylpyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

30 Yield: 55%

Melting point: 90.4-92.6 °C

IR(KBr) ν cm^{-1} :

2954, 2929, 2854, 1601, 1561, 1506

NMR(90MHz, DMSO- d_6) δ ppm:

35 12.86(1H, s), 8.70(1H, s), 7.32-6.93(7H, m), 6.66-6.36(3H, m), 4.98-4.56(2H, m), 3.42-2.97(6H, m), 2.31-2.04(2H, m), 2.26(3H, s), 1.80-0.96(16H, m), 0.96-0.66(6H, m)

EXAMPLE 192

40 N-[4-(N,N-dibutylamino)-6-mercaptopyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

Yield: 59%

Melting point: 107.4-108.0 °C

IR(KBr) ν cm^{-1} :

45 2954, 2931, 1668, 1608, 1537, 1504, 1425, 1375

NMR(270MHz, DMSO- d_6) δ ppm:

12.90(1H, s), 8.82(1H, s), 7.89(1H, s), 7.11(2H, dd, J = 8.2 and 7.3Hz), 6.61(2H, d, J = 8.2Hz), 6.52(1H, t, J = 7.3Hz), 3.60-3.44(2H, m), 3.36-3.15(6H, m), 2.42-2.20(2H, m), 1.69-1.38(10H, m), 1.30-1.12(4H, m), 0.88(3H, t, J = 7.3Hz), 0.86(6H, t, J = 7.3Hz)

50

EXAMPLE 193

N-[4-(N,N-dibutylamino)-2-(N,N-dimethylamino)-6-mercaptopyrimidin-5-yl]-5-(N-phenyl-N-propylamino)-pentanamide

55

Yield: 30%

Melting point: 94.6-100.0 °C

IR(KBr) ν cm^{-1} :

2956, 2933, 1610, 1552, 1506, 1371

NMR(270MHz, DMSO- d_6) δ ppm:

10.77(1H, s), 8.50(1H, s), 7.11(2H, dd, $J=8.2$ and 7.3 Hz), 6.61(2H, d, $J=8.2$ Hz), 6.52(1H, t, $J=7.3$ Hz), 3.54-3.12(8H, m), 3.05(6H, s), 2.43-2.12(2H, m), 1.70-1.33(10H, m), 1.26-1.18(4H, m), 0.88(3H, t, $J=7.3$ Hz), 0.86-0.81(6H, t, $J=7.3$ Hz)

EXAMPLE 194

N-[4-(N,N-dipropylamino)-6-methoxy-2-methylpyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

Yield: 48%

Melting point: 98.1-98.8 °C

IR(KBr) ν cm^{-1} :

1649, 1578, 1564, 1504, 1423, 1371, 1109

NMR(270MHz, DMSO- d_6) δ ppm:

8.83(1H, s), 7.11(2H, dd, $J=8.2$ and 7.3 Hz), 6.62(2H, d, $J=8.2$ Hz), 6.52(1H, t, $J=7.3$ Hz), 3.67(3H, s), 3.40-3.10(8H, m), 2.36-2.16(2H, m), 2.29(3H, s), 1.68-1.38(10H, m), 0.88(3H, t, $J=7.3$ Hz), 0.79(6H, t, $J=7.3$ Hz)

EXAMPLE 195

N-[4-(N,N-dibutylamino)-6-methoxy-2-methylpyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

Yield: 50%

Melting point: 83.6-85.3 °C

IR(KBr) ν cm^{-1} :

3296, 2956, 1651, 1576, 1504, 1109, 746, 694

NMR(270MHz, DMSO- d_6) δ ppm:

8.82(1H, s), 7.12(2H, dd, $J=8.2$ and 7.3 Hz), 6.62(2H, d, $J=8.2$ Hz), 6.55(1H, t, $J=7.3$ Hz), 3.67(3H, s), 3.42-3.14(8H, m), 2.30-2.20(2H, m), 2.29(3H, s), 2.30-2.20(2H, m), 1.65-1.38(10H, m), 1.30-1.13(4H, m), 0.88(3H, t, $J=7.3$ Hz), 0.87(6H, t, $J=7.3$ Hz)

EXAMPLE 196

N-[4-(N,N-dibutylamino)-6-ethoxy-2-methylpyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

Yield: 71%

Melting point: 87.9-89.2 °C

IR(KBr) ν cm^{-1} :

3305, 2956, 2872, 1653, 1578, 1506, 1375, 1111

NMR(270MHz, DMSO- d_6) δ ppm:

8.81(1H, s), 7.11(2H, dd, $J=7.9$ and 7.3 Hz), 6.61(2H, d, $J=7.9$ Hz), 6.52 (1H, t, $J=7.3$ Hz), 4.15(2H, q, $J=7.0$ Hz), 3.42-3.10(8H, m), 2.34-2.14(2H, m), 2.27(3H, s), 1.67-1.32(10H, m), 1.30-1.08(4H, m), 1.15(3H, t, $J=7.0$ Hz), 0.88(3H, t, $J=7.4$ Hz), 0.87(6H, t, $J=7.3$ Hz)

EXAMPLE 197

N-[4-(N,N-dibutylamino)-6-ethoxypyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

Yield: 23%

Melting point: 80.8-83.3 °C

IR(KBr) ν cm^{-1} :

2956, 1655, 1585, 1508, 1431, 1377, 1099

NMR(270MHz, DMSO- d_6) δ ppm:

8.92(1H, s), 8.08(1H, s), 7.11(2H, dd, $J=8.2$ and 7.3 Hz), 6.62(2H, d, $J=8.2$ Hz), 6.52 (1H, t, $J=7.3$ Hz), 4.18-4.12(2H, q, $J=7.0$ Hz), 3.42-3.16(8H, m), 2.30-2.20(2H, m), 1.63-1.40(10H, m), 1.30-1.12(4H, m), 1.16(3H, t, $J=7.0$ Hz), 0.88(3H, t, $J=7.4$ Hz), 0.87(6H, t, $J=7.3$ Hz)

EXAMPLE 198

N-4,6-dimethoxy-2-methylpyrimidin-5-yl)-5-(N-phenyl-N-propylamino)pentanamide

5 Yield: 31%

Melting point: 126.6-129.2 °C

IR(KBr) ν cm^{-1} :

3263, 1660, 1579, 1522, 1506, 1360, 1134

NMR(270MHz, DMSO- d_6) δ ppm:

10 8.98(1H, s), 7.11(2H, dd, J=7.9 and 7.3Hz), 6.62(2H, d, J=7.9Hz), 6.52(1H, t, J=7.3Hz), 3.81(6H, s), 3.33-3.16(4H, m), 2.45(3H, s), 2.34-2.22(2H, m), 1.66-1.44(6H, m), 0.88(3H, t, J=7.3Hz)

EXAMPLE 199

15 N-[4-(N,N-diethylamino)-6-mercapto-2-methylpyrimidin-5-yl]-5-(N-hexyl-N-phenylamino)pentanamide

Yield: 40%

Melting point: 93.0-97.0 °C

IR(KBr) ν cm^{-1} :

20 2931, 2867, 1609, 1561, 1506

NMR(90MHz, DMSO- d_6) δ ppm:

12.70(1H, s), 8.67(1H, s), 7.20-6.96(2H, m), 6.66-6.36(3H, m), 3.48(4H, q, J=6.8Hz), 3.36-3.06(4H, m), 2.40-2.13(2H, m), 2.27(3H, s), 1.80-1.14(12H, m), 1.06(6H, t, J=6.9Hz), 0.86(3H, t, J=5.6Hz)

25 EXAMPLE 200

5-(N-cyclohexyl-N-propylamino)-N-[4-(N,N-dibutylamino)-6-mercapto-2-methylpyrimidin-5-yl]butanamide

Yield: 32%

30 IR(KBr) ν cm^{-1} :

2933, 2860, 1606, 1560, 1520, 1456, 1427

NMR(270MHz, DMSO- d_6) δ ppm:

12.76(1H, s), 8.87(1H, s), 3.62-2.80(9H, m), 2.42-2.14(2H, m), 2.26(3H, s), 2.10-1.02(24H, m), 0.88(9H, t, J=6.6Hz)

35 The structures of the compounds of examples 132-200 are shown in the following.

40















45

50

55















Example No.

Example No.



Example No.



Example No.





Example No.

Example No.



5





10





15





20



25





30



35

40










45

50

55














Example No.

Example No.



Example No.

Example No.



EXAMPLE 201

Preparation of N-(4,6-dimethoxy-2-methylpyrimidin-5-yl)-2-(N-phenyl-N-propylamino)acetamide

To a solution of the product obtained in EXAMPLE 109 (0.23g) in methylene chloride (5ml), 2-chloro-1-methylpyridinium iodide (0.47g) and triethylamine (0.49ml) were added under ice-cooling. After stirring for 40 minutes at room temperature, a solution of the product obtained in EXAMPLE 102 (0.20g) in methylene

chloride (1ml) was added dropwise to the mixture under ice-cooling. The reaction mixture was stirred at room temperature for 30 minutes and then refluxed for 1 hour. After cooling to room temperature, the mixture was diluted with water and extraction with ethyl acetate. The organic layers was washed with water and saturated sodium chloride in order and dried over anhydrous sodium sulfate and solvents were removed under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:1) and followed by crystallization from ether-petroleum ether to give 0.18g (44%) of the objective compound.

Melting point: 173.1-174.4 °C

IR(KBr) ν cm^{-1} :

3238, 1671, 1580, 1530, 1509, 1359, 1135

NMR(90MHz, DMSO- d_6) δ ppm:

9.04(1H, s), 7.32 - 7.02(2H, m), 6.78 - 6.48(3H, m), 3.98(2H, s), 3.84(6H, s), 3.50-3.18(2H, m), 2.51(3H, s), 1.77-1.32(2H, m), 0.90(3H, t, J = 7.2Hz)

The following compounds were prepared in a similar manner as EXAMPLE 201.

EXAMPLE 202

N-[4,6-bis(N,N-diethylamino)-2-methylpyrimidin-5-yl]-2-(N-phenyl-N-propylamino)acetamide

Yield: 6%

Melting point: 146.2-147.5 °C

IR(KBr) ν cm^{-1} :

2962, 1672, 1600, 1548, 1508, 1445, 1438, 1283

NMR(90MHz, DMSO- d_6) δ ppm:

7.60(1H, s), 7.37-6.34 (5H, m), 3.97(2H, s), 3.64-3.30(2H, m), 3.22(8H, q, J = 6.9Hz), 2.37(3H, s), 1.76-1.46(2H, m), 1.20(3H, t, J = 6.9Hz), 0.99(12H, t, J = 6.9Hz)

EXAMPLE 203

N-[4,6-bis(methylthio)-2-methylpyrimidin-5-yl]-2-(N-phenyl-N-propylamino)acetamide

Yield: 6%

Melting point: 195.1-196.3 °C

IR(KBr) ν cm^{-1} :

3246, 1676, 1521, 1507

NMR(90MHz, DMSO- d_6) δ ppm:

9.58(1H, s), 7.26-7.02(2H, m), 6.78-6.48(3H, m), 4.03(2H, s), 3.48-3.00(2H, m), 2.56(3H, s), 2.44(6H, s), 1.80-1.32(2H, m), 0.91(3H, t, J = 7.1Hz)

EXAMPLE 204

N-[4,6-bis(hexylthio)-2-methylpyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 26%

IR(KBr) ν cm^{-1} :

3228, 1655, 1598, 1506

NMR(90MHz, CDCl_3) δ ppm:

7.38-7.02(2H, m), 6.84-6.36(3H, m), 3.72-2.82(8H, m), 2.57(3H, s), 2.46-1.08(22H, m), 0.90(9H, t, J = 7.1Hz)

EXAMPLE 205

N-[4-mercapto-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-6-(N-phenyl-N-propylamino)hexanamide

Yield: 14%

Melting point: 121.9-125.9 °C

IR(KBr) ν cm^{-1} :

2957, 1602, 1594, 1560, 1506, 1459, 1422

NMR(90MHz, DMSO- d_6) δ ppm:

13.06(1H, s), 7.76(1H, s), 7.30-6.84(7H, m), 6.66-6.36(3H, m), 3.96-3.72(2H, m), 3.33-3.06(4H, m), 2.58-2.28-(2H, m), 2.36(3H, s), 1.68-1.08(10H, m), 0.98-0.72(6H, m)



The structures of the compounds of examples 201-205 are shown in the following.

5



Example No.

Example No.


10



15



20



25

30 EXAMPLE 206

Preparation of N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-3-(N-phenyl-N-propylamino)-propionamide

35 To a solution of the product obtained in EXAMPLE 110 (0.27g) and N-methylmorpholine (0.15ml) in methylene chloride (4ml), isobutyl chloroformate (0.17ml) was added dropwise under ice-salt-cooling. After stirring for 30 minutes, a solution of the product obtained in EXAMPLE 105 (0.27g) in methylene chloride (1ml) was added dropwise to the reaction mixture. After stirring for 3 hours at room temperature, N-methylmorpholine (0.15ml) and isobutyl chloroformate (0.17ml) were added to the mixture and the mixture
40 was stirred at room temperature for another 10 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The obtained organic layer was washed with water, saturated sodium bicarbonate and saturated sodium chloride in order. After drying over anhydrous sodium sulfate, the organic layer was concentrated under reduced pressure. The residue was crystallized from ether-hexane to give 0.26g (46%) of the objective compound.

45 Melting point: 147.1-148.8°C

IR(KBr) ν cm^{-1} :

3249, 2964, 2928, 1647, 1599, 1556, 1523, 1505

NMR(90MHz, DMSO- d_6) δ ppm:

9.33(1H, s), 7.29-7.03(2H, m), 6.77-6.43(3H, m), 3.73-3.00(8H, m), 2.64-2.28(2H, m), 2.35(6H, s), 1.71-1.37-
50 (2H, m), 1.06(6H, t, J = 6.9Hz), 0.88(3H, t, J = 7.3Hz)

The following compound was prepared in a similar manner as EXAMPLE 206.

EXAMPLE 207

55 N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 9%

Melting point: 97.3-98.8°C

IR(KBr) ν cm^{-1} :

2965, 1649, 1598, 1546, 1506, 1413

NMR(90MHz, DMSO- d_6) δ ppm:



9.28(1H, s), 7.26-7.00(2H, m), 6.78-6.42(3H, m), 3.63-3.03(8H, m), 2.46-2.22(2H, m), 2.35(3H, s), 2.34(3H, s),

2.04-1.32(4H, m), 1.08(6H, t, $J = 6.8\text{Hz}$), 0.88(3H, t, $J = 7.3\text{Hz}$)

The structures of the compounds of examples 206-207 are shown in the following.

Example No.

Example No.



EXAMPLE 208

Preparation of 2-bromo-N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]acetamide

To a solution of the product obtained in EXAMPLE 105 (16g) and triethylamine (13.8ml) in methylene chloride (240ml) was added dropwise, and then the solution of bromoacetyl bromide (7.4ml) in methylene chloride (10ml) was added dropwise under ice cooling. After stirring at room temperature for 1 hour, bromoacetyl bromide (0.6ml) was added to the solution and the mixture was stirred under reflux for 15 minutes. After cooling to room temperature, the mixture was poured into water and decanted and then the aqueous layer was extracted with methylene chloride. The organic layer was washed with saturated aqueous sodium bicarbonate, water and saturated aqueous sodium chloride in order, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:4-1:2) to give 13.2g (54%) of the objective compound.

Melting point: 173.1-174.1 °C

IR(KBr) ν cm^{-1} :

3228, 1662, 1552, 1536

NMR(90MHz, CDCl_3) δ ppm:

7.54(1H, s), 4.04(2H, s), 3.48(4H, q, $J = 7.1\text{Hz}$), 2.47(3H, s), 2.44(3H, s), 1.17(6H, t, $J = 7.1\text{Hz}$)

The following compound was prepared in a similar manner as EXAMPLE 208.

EXAMPLE 209

2-bromo-N-[4,6-bis(methylthio)-2-methylpyrimidin-5-yl]acetamide

Yield: 75%

Melting point: 223.8-225.5 °C

IR(KBr) ν cm^{-1} :

3421, 1669, 1542, 1509, 1408, 811

NMR(90MHz, CDCl_3) δ ppm:

7.50(1H, s), 4.06(2H, s), 2.61(3H, s), 2.52(6H, s)

EXAMPLE 210

Preparation of 2-(N-benzyl-N-propylamino)-N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]acetamide

A solution of the product obtained in EXAMPLE 208 (0.5g) and N-benzyl-N-propylamine (0.43g) in diethylaniline (5ml) was stirred at 100 °C for 1.5 hour. After cooling to room temperature, the reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water

and saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. the residue was crystallized from ether to give 0.5g (84%) of the objective compound.

Melting point: 161.3-164.1 °C

IR(KBr) ν cm^{-1} :

5 3226, 1671, 1549, 1463, 1426

NMR(90MHz, CDCl_3) δ ppm:

8.36(1H, s), 7.32(5H, s), 3.71(2H, s), 3.34(4H, q, J = 7.0Hz), 3.22(2H, s), 2.63(2H, t, J = 6.9Hz), 2.44(3H, s), 2.43(3H, s), 1.92-1.41(2H, m), 0.97(6H, t, J = 7.0Hz), 0.95(3H, t, J = 7.1Hz)

The following compounds were prepared in a similar manner as EXAMPLE 210.

10

EXAMPLE 211

N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-2-(N,N-dipropylamino)acetamide

15 Yield: 28%

Melting point: 66.2-69.8 °C

IR(KBr) ν cm^{-1} :

3261, 1666, 1558, 1414

NMR(90MHz, CDCl_3) δ ppm:

20 8.55(1H, s), 3.48(4H, q, J = 7.1Hz), 3.21(2H, s), 2.57(4H, t, J = 7.1Hz), 2.46(3H, s), 2.43(3H, s), 1.80-1.26(4H, m), 1.14(6H, t, J = 7.1Hz), 0.92(6H, t, J = 7.1Hz)

EXAMPLE 212

25 N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-2-(4-phenylpiperazinyl)acetamide

Yield: 55%

Melting point: 166.5-168.4 °C

IR(KBr) ν cm^{-1} :

30 3259, 1670, 1599, 1548, 1493, 1421, 1360, 1239

NMR(90MHz, CDCl_3) δ ppm:

8.52(1H, s), 7.41-7.14(2H, m), 7.05-6.72(3H, m), 3.87(4H, q, J = 7.1Hz), 3.36-3.09(4H, m), 3.23(2H, s), 3.00-2.70(4H, m), 2.47(3H, s), 2.44(3H, s), 1.17(6H, t, J = 7.1Hz)

35 EXAMPLE 213

N-[4,6-bis(methylthio)-2-methylpyrimidin-5-yl]-2-(N-phenyl-N-propylamino)acetamide

Yield: 60%

40 Melting point: 195.1-196.3 °C

IR(KBr) ν cm^{-1} :

3246, 1676, 1521, 1507

NMR(90MHz, DMSO-d_6) δ ppm:

9.58(1H, s), 7.26-7.02(2H, m), 6.78-6.48(3H, m), 4.03(2H, s), 3.48-3.00(2H, m), 2.56(3H, s), 2.44(6H, s), 1.80-1.32(2H, m), 0.91(3H, t, J = 7.1Hz)

45







The structures of the compounds of examples 208-213 are shown in the following.

50

55

Example No.

Example No.



EXAMPLE 214

Preparation of N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-2-(N-phenyl-N-propylamino)-acetamide

To a suspension of the product obtained in EXAMPLE 133 (1.2g) and triethylamine (0.63ml) in methylene chloride (12ml), methyl iodide (0.8ml) was added under ice-cooling. After stirring at room temperature for 1.5 hours, triethylamine (0.63ml) and methyl iodide (0.28ml) were added and the solution was stirred for another 1.5 hour. The mixture was poured into water and extracted twice with ethyl acetate. The combined organic layer was washed with water and saturated sodium chloride in order, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:3) and followed by crystallization from ether to give 1.08g (90%) of the objective compound.

Melting point: 173.2-175.2 °C

IR(KBr) ν cm⁻¹:

3226, 2960, 1668, 1549, 1519, 1507, 1426, 1416

NMR(90MHz, DMSO-d₆) δ ppm:

9.32(1H, s), 7.24-7.03(2H, m), 6.77-6.47(3H, m), 4.03(2H, s), 3.56-3.21(6H, m), 2.36(3H, s), 2.35(3H, s), 1.71-1.41(2H, m), 1.07(6H, t, J=6.9Hz), 0.89(3H, t, J=7.4Hz)

The following compounds were prepared in a similar manner as EXAMPLE 214.

EXAMPLE 215

N-[2-methyl-4-methylthio-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-3-(N-phenyl-N-propylamino)-propionamide

Yield: 79%

Melting point: 132.9-134.1 °C

IR(KBr) ν cm⁻¹:

2962, 1663, 1599, 1543, 1530, 1506, 1494, 1416

NMR(90MHz, DMSO-d₆) δ ppm:

8.42(1H, s), 7.37-6.90(7H, m), 6.64-6.43(3H, m), 3.81(2H, t, J=5.9Hz), 3.30-2.96(4H, m), 2.58-2.34(2H, m),

2.47(3H, s), 2.36(3H, s), 1.80-1.33(4H, m), 0.86(6H, t, J = 6.6Hz)

EXAMPLE 216

- 5 N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-3-(N-phenyl-N-propylamino)propionamide

Yield: 76%

Melting point: 147.1-148.8 °C

IR(KBr) ν cm⁻¹:

- 10 3249, 2964, 2928, 1647, 1599, 1556, 1523, 1505

NMR(90MHz, DMSO-d₆) δ ppm:

9.33(1H, s), 7.29-7.03(2H, m), 6.77-6.43(3H, m), 3.73-3.00(8H, m), 2.64-2.28(2H, m), 2.35(6H, s), 1.71-1.37-(2H, m), 1.06(6H, t, J = 6.9Hz, 0.88(3H, t, J = 7.3Hz)

- 15 EXAMPLE 217

N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-3-(N-hexyl-N-Phenylamino)propionamide

Yield: 74%

- 20 Melting point: 110.5-111.7 °C

IR(KBr) ν cm⁻¹:

3232, 2927, 1653, 1599, 1552, 1506, 1414, 1365

NMR(270MHz, DMSO-d₆) δ ppm:

- 25 9.37(1H, s), 7.16(2H, dd, J = 8.3 and 7.3Hz), 6.67(2H, d, J = 8.3Hz), 6.58(1H, t, J = 7.3Hz), 3.58(2H, t, J = 7.1Hz), 3.40(4H, q, J = 6.9Hz), 3.28(2H, t, J = 7.4Hz), 2.56-2.45(2H, m), 2.36(3H, s), 2.35(3H, s), 1.57-1.44-(2H, m), 1.34-1.21(6H, m), 1.06(6H, t, J = 6.9Hz), 0.87(3H, t, J = 6.6Hz)

EXAMPLE 218

- 30 N-[2-methyl-4-methylthio-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 73%

Melting point: 140.9-142.7 °C

IR(KBr) ν cm⁻¹:

- 35 3245, 1670, 1542, 1533, 1506, 1415

NMR(90MHz, CDCl₃) δ ppm:

7.62-6.84(7H, m), 6.75-6.42(3H, m), 5.39(1H, s), 3.88(2H, t, J = 7.6Hz), 3.33-2.88(4H, m), 2.54(3H, s), 2.45-(3H, s), 1.98-1.32(8H, m), 0.89(6H, t, J = 7.3Hz)

- 40 EXAMPLE 219

N-[4-(N,N-dimethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 85%

- 45 Melting point: 145.0-146.8 °C

IR(KBr) ν cm⁻¹:

1644, 1548, 1506, 1413, 1399

NMR(90MHz, DMSO-d₆) δ ppm:

- 50 9.25(1H, s), 7.22-6.98(2H, m), 6.75-6.36(3H, m), 3.42-3.00(4H, m), 3.03(6H, s), 2.36(3H, s), 2.34(3H, s), 2.16-1.30(6H, m), 0.88(3H, t, J = 7.1Hz)

EXAMPLE 220

N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

- 55

Yield: 62%

Melting point: 97.3-98.8 °C

IR(KBr) ν cm⁻¹:

2965, 1649, 1598, 1546, 1506, 1413

NMR(90MHz, DMSO- d_6) δ ppm:

9.28(1H, s), 7.26-7.00(2H, m), 6.78-6.42(3H, m), 3.63-3.03(8H, m), 2.46- 2.22(2H, m), 2.35(3H, s), 2.34(3H, s), 2.04-1.32(4H, m), 1.08(6H, t, J = 6.8Hz), 0.88(3H, t, J = 7.3Hz)

5

EXAMPLE 221

N-[4-(N,N-dibutylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

10 Yield: 58%

Melting point: 129.5-130.8 °C

IR(KBr) ν cm^{-1} :

3242, 2956, 2929, 1654, 1551, 1506, 1415, 1376

NMR(90MHz, DMSO- d_6) δ ppm:

15 9.28(1H, s), 7.17-6.87(2H, m), 6.72-6.64(3H, m), 3.48-3.00(8H, m), 2.40-2.06(2H, m), 2.34(6H, s), 1.98-1.02-(12H, m), 0.88(9H, t, J = 6.4Hz)

EXAMPLE 222

20 N-[4-(N,N-dihexylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 45%

Melting point: 114.6-117.8 °C

IR(KBr) ν cm^{-1} :

25 2957, 2930, 1654, 1551, 1507, 1415

NMR(90MHz, DMSO- d_6) δ ppm:

9.26(1H, s), 7.20-6.96(2H, m), 6.72-6.36(3H, m), 3.48-3.06(8H, m), 2.34(6H, s), 1.98-1.65(2H, m), 1.65-0.99-(20H, m), 0.99-0.69(9H, m)

30 EXAMPLE 223

N-[4-(N-benzyl-N-heptylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 64%

35 Melting point: 109.2-111.8 °C

IR(KBr) ν cm^{-1} :

3220, 2956, 2928, 1654, 1545, 1506

NMR(90MHz, $CDCl_3$) δ ppm:

7.44-7.02(7H, m), 6.72-6.48(3H, m), 6.09(1H, s), 4.65(2H, s), 3.60- 3.00(6H, m), 2.47(3H, s), 2.44(3H, s),
40 2.04-1.08(16H, m), 0.91(3H, t, J = 6.9Hz), 0.87(3H, t, J = 4.6Hz)

EXAMPLE 224

N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-methyl-N-phenylamino)butanamide

45

Yield: 47%

Melting point: 146.0-148.3 °C

IR(KBr) ν cm^{-1} :

3241, 1666, 1600, 1557, 1507, 1411

50 NMR(90MHz, DMSO- d_6) δ ppm:

9.25(1H, s), 7.26-6.99(2H, m), 6.78-6.45(3H, m), 3.57-3.18(6H, m), 2.88(3H, s), 2.40-2.16(2H, m), 2.34(6H, s),
1.98-1.62(2H, m), 1.08(6H, t, J = 6.8Hz)

55

EXAMPLE 225

N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

5 Yield: 85%

Melting point: 90.1-91.4 °C

IR(KBr) ν cm⁻¹:

3210, 2956, 2930, 1649, 1545, 1507

NMR(90MHz, DMSO-d₆) δ ppm:

10 9.25(1H, s), 7.23-6.93(2H, m), 6.75-6.36(3H, m), 3.60-2.94(8H, m), 2.40-2.13(2H, m), 2.35(3H, s), 2.34(3H, s),
1.95-1.62(2H, m), 1.62-1.17(8H, m), 1.08(6H, t, J = 6.8Hz), 0.86(3H, t, J = 4.6Hz)

EXAMPLE 226

15 N-[4-(N,N-dipropylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 74%

Melting point: 101.4-102.8 °C

IR(KBr) ν cm⁻¹:

20 2960, 2929, 1653, 1551, 1506, 1416, 1375

NMR(270MHz, DMSO-d₆) δ ppm:

9.31(1H, s), 7.12(2H, dd, J = 7.9 and 7.3Hz), 6.66(2H, d, J = 7.9Hz), 6.53(1H, t, J = 7.3Hz), 3.45- 3.18(8H, m),
2.43-2.18(2H, m), 2.35(3H, s), 2.34(3H, s), 1.90-1.72(2H, m), 1.65-1.37(6H, m), 1.37-1.18(6H, m), 0.86(3H, t,
J = 6.6Hz), 0.80(6H, t, J = 7.4Hz)

EXAMPLE 227

N-[4-(N,N-dibutylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

30 Yield: 41%

Melting point: 95.2-96.7 °C

IR(KBr) ν cm⁻¹:

3207, 1654, 1551, 1507, 1414

NMR(90MHz, DMSO-d₆) δ ppm:

35 9.28(1H, s), 7.26-6.96(2H, m), 6.78-6.36(3H, m), 3.54-2.82(8H, m), 2.40-2.10(2H, m), 2.34(6H, s), 2.04-0.96-
(18H, m), 0.87(9H, t, J = 5.9Hz)

EXAMPLE 228

40 N-[4-(N-benzyl-N-ethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 98%

Melting point: 153.9-154.6 °C

IR(KBr) ν cm⁻¹:

45 1655, 1599, 1547, 1504, 1444, 1412, 1369

NMR(270MHz, DMSO-d₆) δ ppm:

9.26(1H, s), 7.31- 7.15(5H, m), 7.11(2H, dd, J = 8.2 and 7.3Hz), 6.63(2H, d, J = 8.2Hz), 6.52(1H, t, J = 7.3Hz),
4.74(2H, s), 3.52-3.28(2H, m), 3.28-3.12(4H, m), 2.37(3H, s), 2.35(3H, s), 2.26-1.88(2H, m), 1.76-1.59(2H, m),
1.54 -1.39(2H, m), 1.33-1.19(6H, m), 1.08(3H, t, J = 6.8Hz), 0.86(3H, t, J = 6.4Hz)

EXAMPLE 229

N-[4-(N-benzyl-N-heptylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

55 Yield: 62%

Melting point: 93.8-94.6 °C

IR(KBr) ν cm⁻¹:

3257, 2929, 1656, 1549, 1506

NMR(90MHz, DMSO- d_6) δ ppm:

9.27(1H, s), 7.32-6.90(7H, m), 6.72-6.36(3H, m), 4.77(2H, s), 3.48-2.82(6H, m), 2.36(6H, s), 2.22-1.92(2H, m), 1.86-1.02(20H, m), 0.96-0.66(6H, m)

5 EXAMPLE 230

N-[4-(N-butylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 65%

10 Melting point: 111.7-114.8 °C

IR(KBr) ν cm^{-1} :

3303, 2954, 2929, 1648, 1590, 1560, 1505

NMR(90MHz, DMSO- d_6) δ ppm:

8.88(1H, s), 7.20-6.96(2H, m), 6.72-6.36(4H, m), 3.42-3.09(6H, m), 2.40-2.16(2H, m), 2.35(6H, s), 1.98-1.65-
15 (2H, m), 1.65-1.02(12H, m), 0.87(6H, t, J = 6.3Hz)

EXAMPLE 231

N-[2-methyl-4-methylthio-6-morpholinopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

20

Yield: 50%

Melting point: 100.5-103.4 °C

IR(KBr) ν cm^{-1} :

2957, 2927, 1652, 1542, 1506, 1414

25 NMR(90MHz, DMSO- d_6) δ ppm:

9.31(1H, s), 7.26-6.96(2H, m), 6.78-6.42(3H, m), 3.66-3.42(8H, m), 3.42-3.06(4H, m), 2.43-2.16(2H, m), 2.40-
(3H, s), 2.37(3H, s), 1.92-1.59(2H, m), 1.59-1.08(8H, m), 0.86(6H, t, J = 5.4Hz)

EXAMPLE 232

30

N-[4-(N,N-diethylamino)-6-methylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 76%

Melting point: 83.9-85.0 °C

35 IR(KBr) ν cm^{-1} :

2929, 1653, 1599, 1552, 1504, 1373

NMR(270MHz, DMSO- d_6) δ ppm:

9.42(1H, s), 8.27(1H, s), 7.12(2H, dd, J = 8.6 and 7.3Hz), 6.67(2H, d, J = 8.6Hz), 6.53(1H, t, J = 7.3Hz), 3.54-
3.38(4H, m), 3.38-3.20(4H, m), 2.42-2.22(2H, m), 2.36(3H, s), 1.90-1.76(2H, m), 1.56-1.42(2H, m), 1.36-1.20-
40 (6H, m), 1.10(6H, t, J = 6.9Hz), 0.87(3H, t, J = 6.6Hz)

EXAMPLE 233

N-[4-(N,N-diethylamino)-2-methoxy-6-methylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

45

Yield: 81%

Melting point: 74.0-75.7 °C

IR(KBr) ν cm^{-1} :

1651, 1599, 1552, 1506, 1464, 1443, 1375, 1333

50 NMR(270MHz, DMSO- d_6) δ ppm:

9.20(1H, s), 7.12(2H, dd, J = 8.3 and 7.3Hz), 6.67(2H, d, J = 8.3Hz), 6.53(1H, t, J = 7.3Hz), 3.81(3H, s), 3.54-
3.22(8H, m), 2.40-2.18(2H, m), 2.33(3H, s), 1.92-1.74(2H, m), 1.58-1.42(2H, m), 1.38-1.20(6H, m), 1.10(6H, t,
J = 6.9Hz), 0.87(3H, t, J = 6.3Hz)

55

EXAMPLE 234

N-[4-(N,N-diethylamino)-2,6-bis(methylthio)pyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

5 Yield: 83%

Melting point: 86.3-87.4 °C

IR(KBr) ν cm⁻¹:

2926, 1651, 1597, 1537, 1506, 1348, 1037

NMR(270MHz, DMSO-d₆) δ ppm:

10 9:33(1H, s), 7.12(2H, dd, J = 8.3 and 7.3Hz), 6.67(2H, d, J = 8.3Hz), 6.53(1H, t, J = 7.3Hz), 3.56-3.18(8H, m),
 2.45(3H, s), 2.42-2.22(2H, m), 2.33(3H, s), 1.90-1.72(2H, m), 1.57-1.40(2H, m), 1.38-1.20(6H, m), 1.09(6H, t,
 J = 6.9Hz), 0.87(3H, t, J = 6.8Hz)

EXAMPLE 235

75

4-(N-cycloheptyl-N-phenylamino)-N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]butanamide

Yield: 75%

Melting point: 134.3-135.5 °C

20 IR(KBr) ν cm⁻¹:

2927, 1653, 1547, 1502, 1429, 1414, 1360

NMR(270MHz, DMSO-d₆) δ ppm:

9.30(1H, s), 7.13(2H, dd, J = 8.6 and 7.3Hz), 6.74(2H, d, J = 8.6Hz), 6.57(1H, t, J = 7.3Hz), 3.76-3.62(1H, m),
 3.52-3.34(4H, m), 3.25-3.10(2H, m), 2.40-2.25(2H, m), 2.36(3H, s), 2.34(3H, s), 1.88-1.38(14H, m), 1.08(6H, t,
 25 J = 6.9Hz)

EXAMPLE 236

4-(N-decyl-N-phenylamino)-N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]butanamide

30

Yield: 80%

Melting point: 81.9-83.6 °C

IR(KBr) ν cm⁻¹:

3255, 2925, 2853, 1651, 1546, 1508

35 NMR(90MHz, DMSO-d₆) δ ppm:

9.27(1H, s), 7.23-6.96(2H, m), 6.72-6.39(3H, m), 3.57-3.12(8H, m), 2.36(3H, s), 2.34(3H, s), 1.92-1.62(2H, m),
 1.62-1.14(18H, m), 1.09(6H, t, J = 6.8Hz), 0.85(3H, t, J = 5.6Hz)

EXAMPLE 237

40

4-[N-(4-butylphenyl)-N-propylamino]-N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-butanamide

Yield: 97%

45 IR(KBr) ν cm⁻¹:

3240, 1655, 1549, 1519, 1414

NMR(90MHz, DMSO-d₆) δ ppm:

9.27(1H, s), 6.94(2H, d, J = 8.1Hz), 6.59(2H, d, J = 8.1Hz), 3.60-2.88(8H, m), 2.46-2.04(4H, m), 2.34(6H, s),
 1.98-1.26(8H, m), 1.09(6H, t, J = 6.9Hz), 0.88(6H, t, J = 6.8Hz)

50

EXAMPLE 238

N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-[N-(4-methoxyphenyl)-N-propylamino]-butanamide

55 Yield: 14%

Melting point: 69.2-72.8 °C

IR(KBr) ν cm⁻¹:

3233, 2962, 2930, 1662, 1550, 1514, 1413, 1242

NMR(90MHz, DMSO-d₆) δ ppm:

9.24(1H, s), 6.87-6.54(4H, m), 3.64(3H, s), 3.57-2.94(8H, m), 2.40-2.13(2H, m), 2.35(3H, s), 2.33(3H, s), 1.92-1.29(4H, m), 1.08(6H, t, J = 6.8Hz), 0.86(3H, t, J = 7.1Hz)

5 EXAMPLE 239

N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-[N-hexyl-N-(4-methoxyphenyl)amino]-butanamide

10 Yield: 67%

Melting point: 41.2-44.2 °C

IR(KBr) ν cm⁻¹:

2956, 2929, 1655, 1549, 1514, 1429, 1246

NMR(270MHz, CDCl₃) δ ppm:

15 6.88-6.69(5H, m), 3.75(3H, s), 3.44(4H, q, J = 6.9Hz), 3.25-3.05(4H, m), 2.45(3H, s), 2.43(3H, s), 2.52-2.36-(2H, m), 2.08-1.98(2H, m), 1.58-1.40(2H, m), 1.37-1.20(6H, m), 1.13(6H, t, J = 6.9Hz), 0.88(3H, t, J = 6.6Hz)

EXAMPLE 240

20 N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-[N-hexyl-N-(2-methoxyphenyl)amino]-butanamide

Yield: 99%

IR(neat) ν cm⁻¹:

25 3238, 2929, 1659, 1552, 1500, 1414, 1238

NMR(270MHz, DMSO-d₆) δ ppm:

9.19(1H, s), 6.96-6.77(4H, m), 3.76(3H, s), 3.46-3.33(4H, m), 3.12-2.97(4H, m), 2.35(3H, s), 2.32(3H, s), 2.30-2.19(2H, m), 1.74-1.60(2H, m), 1.42-1.30(2H, m), 1.30-1.15(6H, m), 1.06(6H, t, J = 6.8Hz), 0.83(3H, t, J = 6.6Hz)

30

EXAMPLE 241

N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-[N-(2,4-difluorophenyl)-N-propylamino]-butanamide

35

Yield: 86%

Melting point: 87.5-89.0 °C

IR(KBr) ν cm⁻¹:

3232, 2967, 2931, 1655, 1559, 1511, 1429, 1419

40 NMR(90MHz, DMSO-d₆) δ ppm:

9.19(1H, s), 7.26-6.75(3H, m), 3.39(4H, q, J = 6.8Hz), 3.09(2H, t, J = 7.1Hz), 3.00(2H, t, J = 7.3Hz), 2.40-2.10-(2H, m), 2.34(3H, s), 2.32(3H, s), 1.86-1.20(4H, m), 1.06(6H, t, J = 6.8Hz), 0.82(3H, t, J = 7.1Hz)

EXAMPLE 242

45

4-(N-benzyl-N-propylamino)-N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]butanamide

Yield: 51%

Melting point: 74.6-77.1 °C

50 IR(KBr) ν cm⁻¹:

3228, 2958, 1656, 1550, 1416

NMR(90MHz, DMSO-d₆) δ ppm:

9.18(1H, s), 7.38-7.08(5H, m), 3.53(2H, s), 3.48-3.00(4H, m), 2.40-1.98(6H, m), 2.35(3H, s), 2.33(3H, s), 1.92-1.20(4H, m), 1.07(6H, t, J = 6.8Hz), 0.81(3H, t, J = 7.1Hz)

55

EXAMPLE 243

4-(N-benzyl-N-heptylamino)-N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]butanamide

5 Yield: 45%

IR(neat) ν cm^{-1} :

2956, 2930, 1654, 1559, 1542, 1414

NMR(90MHz, CDCl_3) δ ppm:

7.38-7.00(6H, m), 3.59(2H, s), 3.43(4H, q, J = 6.9Hz), 2.76-1.16(18H, m), 2.44(6H, s), 1.14(6H, t, J = 6.9Hz),

10 0.87(3H, t, J = 5.0Hz)

EXAMPLE 244

N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-(N-tetrahydroquinolino)butanamide

15 Yield: 64%

Melting point: 146.9-147.8°C

IR(KBr) ν cm^{-1} :

3254, 1656, 1551, 1507, 1416

20 NMR(90MHz, DMSO-d_6) δ ppm:

9.26(1H, s), 7.08-6.72(2H, m), 6.72-6.30(2H, m), 3.66-3.00(8H, m), 2.67(2H, t, J = 6.6Hz), 2.40-2.10(2H, m),

2.36(3H, s), 2.34(3H, s), 2.04-1.56(4H, m), 1.08(6H, t, J = 6.8Hz)

EXAMPLE 245

25 N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

Yield: 79%

Melting point: 132.1-135.2°C

30 IR(KBr) ν cm^{-1} :

1648, 1546, 1506, 1416, 1361

NMR(90MHz, DMSO-d_6) δ ppm:

9.20(1H, s), 7.26-6.90(2H, m), 6.72-6.39(3H, m), 3.63-2.84(8H, m), 2.46-2.04(2H, m), 2.35(3H, s), 2.32(3H, s),

1.80-1.26(6H, m), 1.07(6H, t, J = 6.9Hz), 0.88(3H, t, J = 7.2Hz)

35

EXAMPLE 246

N-[4-(N,N-dipropylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

40 Yield: 77%

Melting point: 115.3-116.2°C

IR(KBr) ν cm^{-1} :

2958, 1649, 1599, 1547, 1504, 1416, 1363, 750

NMR(270MHz, DMSO-d_6) δ ppm:

45 9.22(1H, s), 7.11(2H, dd, J = 8.6 and 7.3Hz), 6.61(2H, d, J = 8.6Hz), 6.52(1H, t, J = 7.3Hz), 3.46-3.10(8H, m),

2.42-2.14(2H, m), 2.34(3H, s), 2.31(3H, s), 1.72-1.32(10H, m), 0.88(3H, t, J = 7.4Hz), 0.80(6H, t, J = 7.3Hz)

EXAMPLE 247

50 N-[4-(N,N-dibutylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

Yield: 41%

Melting Point: 70.4-72.8°C

IR(KBr) ν cm^{-1} :

55 3213, 2957, 1653, 1551, 1506, 1417

NMR(90MHz, DMSO-d_6) δ ppm:

9.22(1H, s), 7.26-6.90(2H, m), 6.72-6.36(3H, m), 3.66-2.88(8H, m), 2.42-2.10(2H, m), 2.33(3H, s), 2.32(3H, s),

1.80-1.02(14H, m), 0.87(9H, t, J = 6.6Hz)

EXAMPLE 248

N-[4-(N-benzyl-N-ethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-5-(N-phenyl-N-propylamino)-
pentanamide

Yield: 77%

Melting point: 99.6-100.3 °C

IR(KBr) ν cm^{-1} :

1657, 1597, 1551, 1506, 1437, 1414, 1363

NMR(270MHz, DMSO- d_6) δ ppm:

9.19(1H, s), 7.33-7.17(5H, m), 7.11(2H, dd, J = 8.3 and 7.3Hz), 6.59(2H, d, J = 8.3Hz), 6.52(1H, t, J = 7.3Hz),
4.73(2H, s), 3.49-3.30(2H, m), 3.30-3.10(4H, m), 2.36(3H, s), 2.33(3H, s), 2.21-1.88(2H, m), 1.60-1.39(6H, m),
1.06(3H, t; J = 6.8Hz), 0.88(3H, t, J = 7.4Hz)

EXAMPLE 249

N-[4-(N-benzyl-N-heptylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-5-(N-phenyl-N-propylamino)-
pentanamide

Yield: 14%

IR(neat) ν cm^{-1} :

2956, 2928, 2856, 1654, 1598, 1541, 1506

NMR(90MHz, DMSO- d_6) δ ppm:

9.19(1H, s), 7.29-6.99(7H, m), 6.66-6.39(3H, m), 4.73(2H, s), 3.36-3.06(6H, m), 2.34(6H, s), 2.25-1.95(2H, m),
1.68-1.02(16H, m), 0.99-0.72(6H, m)

EXAMPLE 250

N-[4-(N,N-dibutylamino)-6-methylthiopyrimidin-5-yl]-5-(N-phenyl-N-propylamino)pentanamide

Yield: 78%

Melting point: 69.7-71.1 °C

IR(KBr) ν cm^{-1} :

2958, 2931, 1659, 1554, 1508, 1371

NMR(270MHz, DMSO- d_6) δ ppm:

9.35(1H, s), 8.26(1H, s), 7.12(2H, dd, J = 8.2 and 7.3Hz), 6.62(2H, d, J = 8.2Hz), 6.53(1H, t, J = 7.3Hz), 3.46-
3.15(8H, m), 2.40-2.20(2H, m), 2.33(3H, s), 1.69-1.38(10H, m), 1.30-1.14(4H, m), 0.88(3H, t, J = 7.4Hz), 0.87-
(6H, t, J = 7.3Hz)

EXAMPLE 251

N-[4-(N,N-dibutylamino)-2-(N,N-diethylamino)-6-methylthiopyrimidin-5-yl]-5-(N-phenyl-N-propylamino)-
pentanamide

Yield: 50%

Melting point: 90.1-91.3 °C

IR(KBr) ν cm^{-1} :

2956, 1657, 1560, 1541, 1506, 1398, 1375, 1350

NMR(270MHz, DMSO- d_6) δ ppm:

8.93(1H, s), 7.11(2H, dd, J = 8.6 and 7.3Hz), 6.61(2H, d, J = 8.6Hz), 6.52(1H, t, J = 7.3Hz), 3.43-3.12(8H, m),
3.06(6H, s), 2.40-2.06(2H, m), 2.28(3H, s), 1.70-1.30(10H, m), 1.22(4H, m), 0.88(3H, t, J = 7.3Hz), 0.87(6H, t,
J = 7.1Hz)

EXAMPLE 252

N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-5-(N-hexyl-N-phenylamino)pentanamide

5 Yield: 92%

Melting point: 135.9-138.3 °C

IR(KBr) ν cm^{-1} :

3215, 2929, 1651, 1548, 1505, 1415

NMR(90MHz, DMSO- d_6) δ ppm:

10 9.18(1H, s), 7.23-6.96(2H, m), 6.69-6.39(3H, m), 3.40(4H, q, J = 7.0Hz), 3.33-3.03(4H, m), 2.40-2.13(2H, m), 2.35(3H, s), 2.32(3H, s), 1.86-1.17(12H, m), 1.07(6H, t, J = 7.0Hz), 0.86(3H, t, J = 5.8Hz)

EXAMPLE 253

15 5-(N-cyclohexyl-N-propylamino)-N-[4-(N,N-dibutylamino)-2-methyl-6-methylthiopyrimidin-5-yl]pentanamide

Yield: 17%

Melting point: 93.6-94.7 °C

IR(KBr) ν cm^{-1} :

20 2933, 2860, 1659, 1549, 1454, 1414

NMR(270MHz, DMSO- d_6) δ ppm:

8.64(1H, s), 3.44-2.84(9H, m), 2.44-2.20(2H, m), 2.34(3H, s), 2.02-1.02(24H, m), 0.92(3H, t, J = 7.3Hz), 0.89(6H, t, J = 7.6Hz)

25 EXAMPLE 254

N-[4-isopropylthio-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-3-(N-phenyl-N-propylamino)-propionamide

30 Yield: 24%

Melting point: 66.2-69.8 °C

IR(KBr) ν cm^{-1} :

3235, 1661, 1528, 1496, 1411

NMR(90MHz, CDCl_3) δ ppm:

35 7.44-6.87(7H, m), 6.81-6.39(3H, m), 5.72(1H, s), 4.20-3.75(1H, m), 3.88(2H, t, J = 7.3Hz), 3.54-3.00(4H, m), 2.52(3H, s), 1.82(2H, t, J = 7.3Hz), 1.74-1.44(4H, m), 1.35(6H, d, J = 6.9Hz), 0.89(6H, t, J = 6.9Hz)

EXAMPLE 255

40 N-[4-benzylthio-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-3-(N-phenyl-N-propylamino)-propionamide

Yield: 78%

Melting point: 141.9-145.8 °C

45 IR(KBr) ν cm^{-1} :

3257, 1662, 1542, 1529, 1506, 1494, 1416

NMR(90MHz, CDCl_3) δ ppm:

7.68-6.40(15H, m), 5.73(1H, s), 4.37(2H, s), 3.88(2H, t, J = 7.4Hz), 3.32(2H, t, J = 7.3Hz), 3.13(2H, t, J = 7.3Hz), 2.56(3H, s), 1.79(2H, t, J = 6.9Hz), 1.74-1.14(4H, m), 0.89(3H, t, J = 7.3Hz), 0.83(3H, t, J = 6.9Hz)

50

EXAMPLE 256

N-[2-methyl-4-(N-phenyl-N-propylamino)-6-propylthiopyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

55 Yield: 55%

Melting point: 141.2-143.0 °C

IR(KBr) ν cm^{-1} :

2959, 1656, 1533, 1507, 1493, 1415

NMR(90MHz, CDCl₃) δ ppm:

7.38-6.84(7H, m), 6.72-6.48(3H, m), 5.39(1H, s), 3.88(2H, t, J = 7.4Hz), 3.30-2.84(6H, m), 2.51(3H, s), 2.36-1.84(10H, m), 1.10-0.72(9H, m)

5 EXAMPLE 257

N-[4-hexylthio-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 36%

10 Melting point: 95.8-97.5 °C

IR(KBr) ν cm⁻¹:

2958, 2931, 1540, 1533, 1506, 1493

NMR(90MHz, CDCl₃) δ ppm:

7.38-6.84(7H, m), 6.72-6.48(3H, m), 5.39(1H, s), 3.88(2H, t, J = 7.4Hz), 3.30-2.94(6H, m), 2.52(3H, s), 1.80-1.02(16H, m), 0.89(9H, t, J = 7.3Hz)

EXAMPLE 258

N-[4-benzylthio-2-methyl-6-(N-phenyl-N-propylamino)pyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

20

Yield: 56%

Melting point: 137.6-140.1 °C

IR(KBr) ν cm⁻¹:

3244, 1662, 1541, 1533, 1529, 1506, 1494, 1414

25 NMR(90MHz, CDCl₃) δ ppm:

7.80-6.36(15H, m), 5.36(1H, s), 4.37(2H, s), 3.89(2H, t, J = 7.3Hz), 3.30-2.94(4H, m), 2.56(3H, s), 1.98-1.08(8H, m), 0.89(3H, t, J = 7.3Hz), 0.86(3H, t, J = 7.3Hz)

EXAMPLE 259

30

N-[4-benzylthio-6-(N,N-diethylamino)-2-methylpyrimidin-5-yl]-4-(N-phenyl-N-propylamino)butanamide

Yield: 36%

Melting point: 66.3-69.1 °C

35 IR(KBr) ν cm⁻¹:

3234, 1654, 1550, 1506

NMR(90MHz, CDCl₃) δ ppm:

7.62-6.90(7H, m), 6.78-6.18(3H, m), 4.37(2H, s), 3.72-2.88(8H, m), 2.46(3H, s), 2.04-1.20(6H, m), 1.13(6H, t, J = 6.9Hz), 0.87(3H, t, J = 7.1Hz)

40

EXAMPLE 260

N-[4-(N,N-diethylamino)-6-ethylthio-2-methylpyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

45 Yield: 72%

Melting point: 80.2-82.4 °C

IR(KBr) ν cm⁻¹:

3224, 1651, 1545, 1518, 1506

NMR(270MHz, DMSO-d₆) δ ppm:

50 9.27(1H, s), 7.12(2H, dd, J = 8.6 and 7.3Hz), 6.67(2H, d, J = 8.6Hz), 6.53(1H, t, J = 7.3Hz), 3.52-3.20(8H, m), 3.08-2.88(2H, m), 2.42-2.22(2H, m), 2.35(3H, s), 1.88-1.72(2H, m), 1.58-1.42(2H, m), 1.36-1.22(6H, m), 1.21-(3H, t, J = 7.3Hz), 1.08(6H, t, J = 6.8Hz), 0.86(3H, t, J = 6.6Hz)

55

EXAMPLE 261

N-[4-(N,N-diethylamino)-2-methyl-6-propylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

5 Yield: 56%

Melting point: 77.8-78.9 °C

IR(KBr) ν cm^{-1} :

3226, 2960, 2929, 1655, 1554, 1504, 1414

NMR(270MHz, DMSO- d_6) δ ppm:

10 9.26(1H, s), 7.11(2H, dd, J=7.9 and 7.3Hz), 6.66(2H, d, J=7.9Hz), 6.53(1H, t, J=7.3Hz), 3.50-3.20(8H, m),
3.06-2.90(2H, m), 2.42-2.20(2H, m), 2.34(3H, s), 1.92-1.74(2H, m), 1.66-1.42(4H, m), 1.36-1.18(6H, m), 1.08-
(3H, t, J=6.8Hz), 0.92(3H, t, J=7.4Hz), 0.86(3H, t, J=6.9Hz)

EXAMPLE 262

15

N-[4-(N,N-diethylamino)-6-isopropylthio-2-methylpyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Yield: 70%

Melting point: 84.8-86.5 °C

20 IR(KBr) ν cm^{-1} :

2960, 2931, 1653, 1547, 1506, 1414

NMR(270MHz, DMSO- d_6) δ ppm:

25 9.21(1H, s), 7.11(2H, dd, J=7.6 and 6.9Hz), 6.66(2H, d, J=7.6Hz), 6.54(1H, t, J=6.9Hz), 3.94-3.78(1H, m),
3.50-3.20(8H, m), 2.40-2.22(2H, m), 2.34(3H, s), 1.88-1.72(2H, m), 1.56-1.40(2H, m), 1.36-1.20(12H, m), 1.07-
(6H, t, J=6.5Hz), 0.86(3H, t, J=5.9Hz)

EXAMPLE 263

N-(4-benzyloxy-6-isopropyl-2-methylpyrimidin-5-yl)-4-(N-phenyl-N-propylamino)butanamide

30

Yield: 31%

Melting point: 55.8-58.4 °C

IR(KBr) ν cm^{-1} :

3274, 2963, 1648, 1598, 1548, 1506

35 NMR(90MHz, CDCl_3) δ ppm:

7.50-6.48(11H, m), 5.24(2H, s), 3.48-2.64(5H, m), 2.58-1.32(6H, m), 2.45(3H, s), 1.19(6H, d, J=6.9Hz), 0.91-
(3H, t, J=7.3Hz)

EXAMPLE 264

40

Preparation of N-[4-(N,N-diethylamino)-2-(N,N-dimethylamino)-6-methylthiopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide

Starting from N-[4-(N,N-diethylamino)-2-(N,N-dimethylamino)-6-mercaptopyrimidin-5-yl]-4-(N-hexyl-N-phenylamino)butanamide (prepared in a similar manner as EXAMPLE 132 from the product obtained in EXAMPLE 9 and the product obtained in EXAMPLE 114), the objective compound was prepared in a similar manner as EXAMPLE 214.

Yield: 12%

Melting point: 114.3-115.3 °C

50 IR(KBr) ν cm^{-1} :

3230, 2931, 1653, 1558, 1506, 1400, 1367















NMR(270MHz, DMSO- d_6) δ ppm:

55 9.00(1H, s), 7.11(2H, dd, J=8.3 and 7.3Hz), 6.66(2H, d, J=8.3Hz), 6.53(1H, t, J=7.3Hz), 3.53-3.10(8H, m),
3.07(6H, s), 2.45-2.10(2H, m), 2.31(3H, s), 1.92-1.70(2H, m), 1.60-1.37(2H, m), 1.40-1.15(6H, m), 1.09(6H, t,
J=6.9Hz), 0.87(3H, t, J=6.9Hz)

The structures of the compounds of examples 214-264 are shown in the following.















Example No.

Example No.

















Example No.

Example No.












Example No.

Example No.



Example No.

Example No.



EXAMPLE 265

Preparation of N-(4-chloro-6-isopropyl-2-methylpyrimidin-5-yl)-4-(N-phenyl-N-propylamino)butanamide

A mixture of the product obtained in EXAMPLE 153 (12.0g) and phosphorus oxychloride(5ml) was stirred at room temperature for 1 hour. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:4) to give 300mg (29%) the objective compound.


IR(neat), cm^{-1} :

3246, 2966, 1661, 1599, 1568, 1506, 1417, 1369

NMR(90MHz, CDCl_3) δ ppm:7.38-7.02(2H, m), 6.90-6.48(4H, m), 3.54-2.76(5H, m), 2.68(3H, s), 2.50(2H, t, $J = 5.6\text{Hz}$), 2.26-1.80(2H, m), 1.80-1.38(2H, m), 1.22(6H, d, $J = 6.9\text{Hz}$), 0.92(3H, t, $J = 7.3\text{Hz}$)

The structure of the compound of Example 265 is shown in the following.

Example No.



EXAMPLE 266

Preparation of N-[4-(N,N-diethylamino)-6-isopropyl-2-methylpyrimidin-5-yl]-4-(N-phenyl-N-propylamino)-butanamide

A mixture of the product obtained in EXAMPLE 265 (100mg) and diethylamine (2ml) was stirred under reflux for 4 hours. After evaporation of excess diethylamine under reduced pressure, the residue was poured into water and extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 3:7) and followed by crystallization from ether to give 51mg (47%) of the objective compound.

Melting point: 129.4-130.8°C

IR(KBr) ν cm^{-1} :

3232, 2962, 1654, 1562, 1507, 1367, 751

NMR(90MHz, CDCl_3) δ ppm:

7.38-6.96(2H, m), 6.84-6.30(4H, m), 3.90-2.64(9H, m), 2.47(3H, s), 2.42(2H, t, $J = 7.3\text{Hz}$), 2.25-1.31(4H, m), 1.17(6H, d, $J = 6.6\text{Hz}$), 1.13(6H, t, $J = 6.6\text{Hz}$), 0.92(3H, t, $J = 7.1\text{Hz}$)

EXAMPLE 267

Preparation of N-(4-isopropyl-6-mercapto-2-methylpyrimidin-5-yl)-4-(N-phenyl-N-propylamino)butanamide

To a solution of the product obtained in EXAMPLE 265 (200mg) in ethanol (1ml), sodium hydrosulfide (100mg) was added and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 3:7) and followed by crystallization from ether to give 156mg (78%) of the objective compound.

Melting point: 144.1-145.2°C

IR(KBr) ν cm^{-1} :

3277, 2961, 1663, 1596, 1571, 1506, 1245, 746

NMR(90MHz, CDCl_3) δ ppm:

12.40(1H, s), 7.42(1H, s), 7.31-6.97(2H, m), 6.81-6.42(3H, m), 3.54-2.76(5H, m), 2.70-2.28(2H, m), 2.52(3H, s), 2.28-1.80(2H, m), 1.80-1.38(2H, m), 1.20(6H, d, $J = 6.6\text{Hz}$), 0.92(3H, t, $J = 7.3\text{Hz}$)

EXAMPLE 268

Preparation of N-(4-isopropyl-2-methyl-6-methylthiopyrimidin-5-yl)-4-(N-phenyl-N-propylamino)butanamide

Starting from the product obtained in EXAMPLE 267, the objective compound was prepared in a similar manner as EXAMPLE 214.

Yield: 96%

Melting point: 103.1-104.6°C

IR(KBr) ν cm^{-1} :

3215, 2966, 1648, 1598, 1542, 1505, 1409, 1368, 748

NMR(90MHz, CDCl_3) δ ppm:

7.35-6.99(2H, m), 6.84-6.30(4H, m), 3.60-2.79(5H, m), 2.64-2.28(2H, m), 2.63(3H, s), 2.50(3H, s), 2.22-1.80(2H, m), 1.80-1.35(2H, m), 1.19(6H, d, $J = 6.9\text{Hz}$), 0.92(3H, t, $J = 7.1\text{Hz}$)

EXAMPLE 269

Preparation of N-[4-(N,N-diethylamino)-2-methylpyrimidin-5-yl]-2-(N-phenyl-N-propylamino)acetamide

To a suspension of Raney Ni (4g) in methanol, the product obtained in EXAMPLE 133 (0.2g) was added. After stirring for 1 hour at room temperature, the reaction mixture was filtrated to remove the catalyst. The filtrate was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate. The organic solution was washed with water and saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was crystallized from hexane to give 67mg (37%) of the objective compound.

Melting point: 96.6-98.1 °C

IR(KBr) ν cm⁻¹:

3269, 1663, 1578, 1508

NMR(90MHz, DMSO-d₆) δ ppm:

9.37(1H, s), 7.71(1H, s), 7.32-7.02(2H, m), 6.78-6.48(3H, m), 4.03(2H, s), 3.66-3.12(6H, m), 2.34(3H, s), 1.86-1.32(2H, m), 1.05(6H, t, J = 6.9Hz), 0.90(3H, t, J = 7.6Hz)

The following compound was prepared in a similar manner as EXAMPLE 269.

EXAMPLE 270

N-[2-methyl-(4-N-phenyl-N-propylamino)pyrimidin-5-yl]-3-(N-phenyl-N-propylamino)propionamide

Yield: 61%

Melting point: 114.0-116.2 °C

IR(KBr) ν cm⁻¹:

3226, 2959, 1652, 1598, 1580, 1504, 1421






NMR(90MHz, DMSO-d₆) δ ppm:

8.59(1H, s), 7.91(1H, s), 7.40-6.93(7H, m), 6.65-6.40(3H, m), 3.88(2H, t, J = 7.4Hz), 3.34-2.95(4H, m), 2.48-(3H, s), 1.84-1.28(6H, m), 0.86(6H, t, J = 7.3Hz)

The structures of the compounds of the Examples 266-270 are shown in the following.

Example No.

Example No.



EXAMPLE 271

Preparation of N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]-4-[N-(4-hydroxyphenyl)-N-propylamino]butanamide

To a solution of the product obtained in EXAMPLE 238 (2.0g) in acetic acid (20ml), hydrobromic acid (48%; 3ml) and concentrated sulfuric acid (0.5ml) were added. After stirring under reflux for 12 hours, the mixture was poured into water (20ml). The aqueous solution was neutralized with 3N sodium hydroxide and extracted twice with ethyl acetate. The collected organic layer was washed with saturated sodium bicarbonate, water and saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:2) to give 0.74g (38%) of the objective compound.

IR(KBr) ν cm^{-1} :

3234, 1660, 1551, 1514, 1414

NMR(270MHz, DMSO- d_6) δ ppm:

9.26(1H, s), 8.52(1H, s), 6.59(4H, s), 3.53-3.26(4H, m), 3.22-3.01(4H, m), 2.42-2.18(2H, m), 2.36(3H, s), 2.33-(3H, s), 1.86-1.65(2H, m), 1.54-1.37(2H, m), 1.08(6H, t, J = 6.8Hz), 0.85(3H, t, J = 7.3Hz)

EXAMPLE 272

Preparation of 4-[N-(4-bromophenyl)-N-hexylamino]-N-[4-(N,N-diethylamino)-2-methyl-6-methylthiopyrimidin-5-yl]butanamide

To a solution of the product obtained in EXAMPLE 225 (100mg) in carbon tetrachloride (2ml) was added N-bromosuccinimide (4smg) and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was poured into water and extracted twice with ethyl acetate. The collected organic layer was washed with saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 1:3) to give 62mg (53%) of the objective compound.

Melting point: 89.8-93.0 °C

IR(KBr) ν cm^{-1} :

2927, 1653, 1547, 1500, 1414, 1049, 808



NMR(270MHz, DMSO- d_6) δ ppm:

9.30(1H, s), 7.23(2H, d, J = 8.9Hz), 6.63(2H, d, J = 8.9Hz), 3.53-3.19(8H, m), 2.43-2.22(2H, m), 2.36(3H, s), 2.34(3H, s), 1.88-1.71(2H, m), 1.56-1.41(2H, m), 1.35-1.19(6H, m), 1.08(6H, t, J = 6.9Hz), 0.86(3H, t, J = 6.6Hz)

The structures of the compounds of examples 271-272 are shown in the following.

Example No.

Example No.



Now, typical but non-limiting examples of formulations of the compound of the present invention will be shown below.

Formulations A (Capsules)

The compound of the example 159(500 g of weight), 485 g of lactose and 15 g of magnesium stearate were weighed and mixed until the mixture became homogeneous. The mixture was then filled in No.1 hard gelatin capsule at 300 mg each to obtain capsule preparations.

Formulations B (Tablets)

The compound of the example 187(500 g of weight), 350 g of lactose, 120 g of potato starch, 15 g of polyvinyl alcohol and 15 g of magnesium stearate were weighed. The weighed amount of compound 187, lactose and potato starch were mixed until accomplishing homogeneity. Then aqueous solution of polyvinylalcohol was added to the mixture and granulated by wet process. The granules were then dried, mixed with the weighed magnesium stearate and pressed into tablets, each weighing 300 mg.

Formulations C (Powders)


The compound of the example 245(200 g of weight), 790 g of lactose and 10 g of magnesium stearate were weighed and mixed until the mixture became homogeneous to obtain 20 % powder preparation.

Formulations D (Rectal suppositories)

The compound of the example 148(100 g of weight), 180 g of polyethyleneglycol 1500 and 720 g of polyethyleneglycol 4000 were ground well in a mortar and formulated into suppository by melting and casting into 1 g of appropriate mold.

Claims

1. A pyrimidine derivative represented by the formula (I), a salt, a solvate or a solvate of the salt thereof:



wherein R^1 represents hydrogen atom, an alkyl group of straight or branched chain having 1 to 4 carbon atoms, NR^6R^7 , SR^8 or OR^8 ,

R^2 represents hydrogen atom, NR^9R^{10} , SR^{11} , OR^{11} , an alkyl group of straight or branched chain having 1 to 6 carbon atoms, or a halogen atom,

R^3 represents hydrogen atom, $\text{NR}^{12}\text{R}^{13}$, SR^{14} , OR^{14} , an alkyl group of straight or branched chain having 1 to 6 carbon atoms, or a halogen atom,

R^4 and R^5 are identical or different and each represents a group selected from the group consisting of hydrogen atom, an alkyl group of straight or branched chain having 1 to 12 carbon atoms, a benzyl group, a cycloalkyl group having 3 to 10 carbon atoms and a phenyl group which may be substituted with 1 to 5 substituents selected optionally from the group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxyl group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxy group and an alkylenedioxy group having 1 or 2 carbon atoms; or

R^4 and R^5 , together with the nitrogen atom to which they are bonded, form a piperazine ring substituted with a phenyl group, or a tetrahydroquinoline ring,

R^6 , R^7 and R^8 are identical or different and each represents a group selected from the group consisting of hydrogen atom, and an alkyl group of straight or branched chain having 1 to 4 carbon atoms,

R^9 , R^{10} , R^{11} , R^{12} , R^{13} and R^{14} are identical or different and each represents a group selected from the group consisting of, hydrogen atom, a phenyl group, a benzyl group, and an alkyl group of straight or branched chain having 1 to 10 carbon atoms, or


R^9 and R^{10} , or R^{12} and R^{13} , together with the nitrogen atom to which they are bonded, each form a morpholine ring, or a piperazine ring which may be substituted with an alkyl group of straight or branched chain having 1 to 4 carbon atoms, and

n represents an integer from 1 to 6, provided that when n represents an integer of 1 and R^2 and R^3 represent methyl groups, R^1 does not represent a methyl group or an amino group.

2. The pyrimidine derivative, a salt, a solvate or a solvate of the salt thereof as claimed in claim 1, wherein R^2 represents NR^9R^{10} or an alkyl group of straight or branched chain having 1 to 6 carbon atoms, R^3 represents SR^{14} , OR^{14} or an alkyl group of straight or branched chain having 1 to 6 carbon atoms, R^4 and R^5 are identical or different and each represents a group selected from the group consisting of an alkyl group of straight or branched chain having 1 to 12 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms, a benzyl group and a phenyl group which may be substituted with 1 or 2 substituents selected optionally from the group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxy group and an alkylenedioxy group having 1 or 2 carbon atoms; or R^4 and R^5 together with the nitrogen atom to which they are bonded, form a piperazine ring substituted with a phenyl group, or a tetrahydroquinoline ring.
3. The pyrimidine derivative, a salt, a solvate or a solvate of the salt thereof as claimed in claim 2, wherein R^3 represents SR^{14} , R^4 represents an alkyl group of straight or branched chain having 3 to 10 carbon atoms or a cycloalkyl group having 3 to 10 carbon atoms, R^5 represents a benzyl group, or a phenyl group which may be substituted with 1 or 2 substituents selected optionally from the group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxy group and an alkylenedioxy group having 1 or 2 carbon atoms; R^9 and R^{10} are identical or different and each represents a group selected from the group consisting of an alkyl group of straight chain having 1 to 7 carbon atoms, a phenyl group, a benzyl group, or R^9 and R^{10} , together with the nitrogen atom to which they are bonded, form a morpholine ring, R^{14} represents hydrogen atom, an alkyl group of straight or branched chain having 1 to 6 carbon atoms or a benzyl group, n represents an integer of 3 or 4.
4. The pyrimidine derivative, a salt, a solvate or a solvate of the salt thereof as claimed in claim 3, wherein R^5 represents a phenyl group which may be substituted with 1 or 2 substituents selected optionally from the group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxy group and an alkylenedioxy group having 1 or 2 carbon atoms, R^9 and R^{10} identically represent ethyl groups, propyl groups or butyl groups, or R^9 represents a heptyl group and R^{10} represents a benzyl group, or R^9 represents a phenyl group and R^{10} represents a propyl group, or R^9 and R^{10} , together with the nitrogen atom to which they are bonded, form a morpholine ring.
5. The pyrimidine derivative, a salt, a solvate or a solvate of the salt thereof as claimed in claim 2, wherein R^2 represents NR^9R^{10} , R^3 represents OR^{14} , R^4 represents an alkyl group of straight or branched chain having 3 to 10 carbon atoms, R^5 represents a phenyl group which may be substituted with 1 or 2 substituents selected optionally from the group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxy group and an alkylenedioxy group having 1 or 2 carbon atoms; R^9 , R^{10} and R^{14} are identical or different and each represents an alkyl group of straight or branched chain having 1 to 4 carbon atoms, n represents an integer of 3 or 4.
6. The pyrimidine derivative, a salt, a solvate or a solvate of the salt thereof as claimed in claim 1, wherein R^1 represents NR^6R^7 , SR^8 or OR^8 , R^2 represents NR^9R^{10} or an alkyl group of straight or branched chain having 1 to 6 carbon atoms, R^3 represents SR^{14} , OR^{14} or an alkyl group of straight or branched chain having 1 to 6 carbon atoms, R^4 and R^5 are identical or different and each represents a group selected from the group consisting of an alkyl group of straight or branched chain having 1 to 12 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms, a benzyl group and a phenyl group which may be substituted with 1 or 2 substituents selected optionally from the group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxy group and an alkylenedioxy group having 1 or 2 carbon atoms; or R^4 and R^5 , together with the nitrogen atom to which they are bonded, form a piperazine ring substituted with a phenyl group, or a tetrahydroquinoline ring.
7. The pyrimidine derivative, a salt, a solvate or a solvate of the salt thereof as claimed in claim 6, wherein R^2 represents NR^9R^{10} , R^3 represents SR^{14} or OR^{14} , R^4 represents an alkyl group of straight or branched chain having 3 to 10 carbon atoms, R^5 represents a phenyl group which may be substituted with 1 or 2 substituents selected optionally from the group consisting of: an alkyl group of straight or

branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms; a halogen atom, hydroxy group and an alkylendioxy group having 1 or 2 carbon atoms, R^6 , R^7 , R^8 , R^9 , R^{10} and R^{14} are identical or different and each represents an alkyl group of straight or branched chain having 1 to 4 carbon atoms, n represents an integer of 3 or 4.

8. A process for producing a pyrimidine derivative represented by the formula (I), a salt, a solvate or a solvate of the salt thereof:



wherein R^1 represents hydrogen atom, an alkyl group of straight or branched chain having 1 to 4 carbon atoms, NR^6R^7 , SR^8 or OR^8 ,

R^2 represents hydrogen atom, NR^9R^{10} , SR^{11} , OR^{11} , an alkyl group of straight or branched chain having 1 to 6 carbon atoms or a halogen atom,

R^3 represents hydrogen atom, $NR^{12}R^{13}$, SR^{14} , OR^{14} , an alkyl group of straight or branched chain having 1 to 6 carbon atoms, or a halogen atom,

R^4 and R^5 are identical or different and each represents a group selected from the group consisting of hydrogen atom, an alkyl group of straight or branched chain having 1 to 12 carbon atoms, a benzyl group, a cycloalkyl group having 3 to 10 carbon atoms and a phenyl group which may be substituted with 1 to 5 substituents selected optionally from the group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxy group and an alkylendioxy group having 1 or 2 carbon atoms; or


R^4 and R^5 , together with the nitrogen atom to which they are bonded, form a piperazine ring substituted with a phenyl group, or a tetrahydroquinoline ring,

R^6 , R^7 and R^8 are identical or different and each represents a group selected from the group consisting of hydrogen atom, and an alkyl group of straight or branched chain having 1 to 4 carbon atoms,

R^9 , R^{10} , R^{11} , R^{12} , R^{13} and R^{14} are identical or different and each represents a group selected from the group consisting of hydrogen atom, a phenyl group, a benzyl group, and an alkyl group of straight or branched chain having 1 to 10 carbon atoms, or


R^9 and R^{10} , or R^{12} and R^{13} , together with the nitrogen atom to which they are bonded, each form a morpholine ring, or a piperazine ring which may be substituted with an alkyl group of straight or branched chain having 1 to 4 carbon atoms, and

n represents an integer from 1 to 6, provided that when n represents an integer of 1 and R^2 and R^3 represent methyl groups, R^1 does not represent a methyl group or an amino group, comprising reacting a 5-aminopyrimidine derivative or a salt thereof represented by the formula (II):



wherein R^1 represents hydrogen atom, an alkyl group of straight or branched chain having 1 to 4 carbon atoms, NR^6R^7 , SR^8 , OR^8 , a conventionally protected amino group, a conventionally protected mercapto group or a conventionally protected hydroxyl group, R^2 represents hydrogen atom, NR^9R^{10} ,


SR¹¹, OR¹¹, an alkyl group of straight or branched chain having 1 to 6 carbon atoms, a halogen atom, a conventionally protected amino group, a conventionally protected mercapto group or a conventionally protected hydroxyl group, R³ represents hydrogen atom, NR¹²R¹³, SR¹⁴, OR¹⁴, an alkyl group of straight or branched chain having 1 to 6 carbon atoms, a halogen atom, a conventionally protected amino group, a conventionally protected mercapto group or a conventionally protected hydroxyl group, with a carboxylic acid derivative or a salt thereof represented by the formula (III):



wherein R⁴, R⁵ and n have the same significance as defined in formula (I), and

if necessary and desired further removing the conventional amino-, mercapto- and/or hydroxyl-protecting groups.

9. A process for producing a pyrimidine derivative represented by the formula (I), a salt, a solvate or a solvate of the salt thereof:



wherein R¹ represents hydrogen atom, an alkyl group of straight or branched chain having 1 to 4 carbon atoms, NR⁶R⁷, SR⁸ or OR⁸,

R² represents hydrogen atom, NR⁹R¹⁰, SR¹¹, OR¹¹, an alkyl group of straight or branched chain having 1 to 6 carbon atoms or a halogen atom,

R³ represents hydrogen atom, NR¹²R¹³, SR¹⁴, OR¹⁴, an alkyl group of straight or branched chain having 1 to 6 carbon atoms, or a halogen atom,

R⁴ and R⁵ are identical or different and each represents a group selected from the group consisting of hydrogen atom, an alkyl group of straight or branched chain having 1 to 12 carbon atoms, a benzyl group, a cycloalkyl group having 3 to 10 carbon atoms and a phenyl group which may be substituted with 1 to 5 substituents selected optionally from the group consisting of: an alkyl group of straight or branched chain having 1 to 6 carbon atoms, an alkoxy group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxy group and an alkylenedioxy group having 1 or 2 carbon atoms; or

R⁴ and R⁵, together with the nitrogen atom to which they are bonded, form a piperazine ring substituted with a phenyl group, or a tetrahydroquinoline ring,


R⁶, R⁷ and R⁸ are identical or different and each represents a group selected from the group consisting of hydrogen atom, and an alkyl group of straight or branched chain having 1 to 4 carbon atoms,

R⁹, R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ are identical or different and each represents a group selected from the group consisting of hydrogen atom, a phenyl group, a benzyl group, and an alkyl group of straight or branched chain having 1 to 10 carbon atoms, or

R⁹ and R¹⁰, or R¹² and R¹³, together with the nitrogen atom to which they are bonded, each form a morpholine ring, or a piperazine ring which may be substituted with an alkyl group of straight or branched chain having 1 to 4 carbon atoms, and


n represents an integer from 1 to 6, provided that when n represents an integer of 1 and R² and R³ represent methyl groups, R¹ does not represent a methyl group or an amino group,

comprising reacting a 5-aminopyrimidine derivative or a salt thereof represented by the formula (II):




5

10 wherein R^1 , R^2 and R^3 have the same significance as defined in claim 8, with a carboxylic acid derivative or a salt represented by the formula (IV):



15

wherein Z represents a halogen atom, n has the same significance as defined in formula (I), to obtain a pyrimidine derivative or a salt thereof represented by the formula (V):



20

25

wherein Z represents a halogen atom, R^1 , R^2 , R^3 and n have the same significance as defined in formula (I) of claim 8, and then

reacting with an amine derivative represented by the formula (VI):

30




35

wherein R^4 and R^5 have the same significance as defined in formula (I), and

if necessary and desired, further removing the conventional amino-, mercapto- and/or hydroxyl-protecting groups.

10. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of at least one selected from a pyrimidine derivative represented by the formula (I), a salt, a solvate or a solvate of the salt thereof:

40



45

50 wherein R^1 represents hydrogen atom, an alkyl group of straight or branched chain having 1 to 4 carbon atoms, NR^6R^7 , SR^8 or OR^8 ,

R^2 represents hydrogen atom, NR^9R^{10} , SR^{11} , OR^{11} , an alkyl group of straight or branched chain having 1 to 6 carbon atoms, or a halogen atom,

R^3 represents hydrogen atom, $\text{NR}^{12}\text{R}^{13}$, SR^{14} , OR^{14} , an alkyl group of straight or branched chain having 1 to 6 carbon atoms, or a halogen atom,

55

R^4 and R^5 are identical or different and each represents a group selected from the group consisting of hydrogen atom, an alkyl group of straight or branched chain having 1 to 12 carbon atoms, a benzyl group, a cycloalkyl group having 3 to 10 carbon atoms and a phenyl group which may be substituted with 1 to 5 substituents selected optionally from the group consisting of: an alkyl group of

straight or branched chain having 1 to 6 carbon atoms, an alkoxyl group of straight or branched chain having 1 to 4 carbon atoms, a halogen atom, hydroxy group and an alkylenedioxy group having 1 or 2 carbon atoms; or

R⁴ and R⁵, together with the nitrogen atom to which they are bonded, form a piperazine ring substituted with a phenyl group, or a tetrahydroquinoline ring,

R⁶, R⁷ and R⁸ are identical or different and each represents a group selected from the group consisting of hydrogen atom, and an alkyl group of straight or branched chain having 1 to 4 carbon atoms,

R⁹, R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ are identical or different and each represents a group selected from the group consisting of hydrogen atom, a phenyl group, a benzyl group, and an alkyl group of straight or branched chain having 1 to 10 carbon atoms, or

R⁹ and R¹⁰, or R¹² and R¹³, together with the nitrogen atom to which they are bonded, each form a morpholine ring, or a piperazine ring which may be substituted with an alkyl group of straight or branched chain having 1 to 4 carbon atoms, and

n represents an integer from 1 to 6, provided that when n represents an integer of 1 and R² and R³ represent methyl groups, R¹ does not represent a methyl group or an amino group.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 93 10 2668

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D,A	EP-A-0 245 687 (WARNER-LAMBERT) * the whole document *	1,8,10	C07D239/48 C07D239/58 C07D239/46
A	--- JOURNAL OF ORGANIC CHEMISTRY vol. 26, 1961, WASHINGTON D.C. pages 3534 - 3535 S. BELL ET AL. 'THE SYNTHESIS OF PYRIMIDINE ANALOGS OF XYLOCAINE' * page 3534 - page 3535 *	1,8,10	C07D239/50 C07D239/52 C07D239/56 C07D239/42 C07D401/14 A61K31/505
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			C07D
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 06 APRIL 1993	Examiner FRANCOIS J.C.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document	